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Abstract 
The signaling cascades that direct the morphological differentiation of the 
vascular system during early embryogenesis are not well defined. Several signaling 
pathways, including Notch and VEGF signaling, are critical for the formation of the 
vasculature in the mouse. However, the relationship between the molecular signals and 
transcriptional networks directing this process are still not well defined.   To further 
understand the role of Notch signaling during endothelial differentiation and the genes 
regulated by this pathway, both loss-of-function and gain-of-function approaches were 
analyzed in vivo and in vitro.  Conditional transgenic models were used to expand and 
ablate Notch signaling in the early embryonic endothelium.  Embryos with activated 
Notch1 in the vasculature displayed a variety of defects, particularly in the yolk sac, and 
die soon after E10.5.  These phenotypes were distinct from endothelial loss-of-function of 
Rbpj, a transcriptional regulator of Notch activity. Gene expression analysis of RNA 
isolated from the yolk sac of transgenic embryos indicated aberrant expression in a 
variety of genes in these models.  In particular, a variety of secreted factors, including the 
VEGF family member, Pgf, displayed coordinate expression defects in the loss-of-
function and gain-of-function models.  These data indicate that Notch signaling may have 
potential nonautonomous roles in the remodeling of the yolk sac capillary plexus. To 
further understand the role of placental growth factor during endothelial differentiation, 
an in vivo gain-of-function transgenic model was developed.  Embryos with expanded 
expression of Pgf in the vasculature display two distinct phenotypes, which were 
classified moderate and severe.  Most notably, in both classes, the extraembryonic 
vasculature of the yolk sac displayed remodeling differentiation defects, with few 
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matured vessels.  Gene expression analysis of RNA isolated from the yolk sac of 
transgenic embryos indicated aberrant expression in a variety of genes.  In particular, 
Notch family members showed increased expression in the gain-of-function model.  The 
data from this model demonstrates regulatory connections between the VEGF and Notch 
signaling pathways during endothelial differentiation. We propose a role for Notch 
signaling in elaborating the microenvironment of the nascent arteriole, and suggest that 
novel regulatory connections exist between Notch signaling and other signaling 
pathways, particularly the VEGF family, during endothelial differentiation. 
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Chapter 1 
Introduction 
 The formation of a vascular system is essential for the growth and development of 
the early embryo, as it functions to transport nutrients and waste throughout the 
developing embryo.  In the mouse, a linear heart tube forms from cardiac progenitors and 
begins to beat by E8 (Ji et al. 2003; Lucitti et al. 2007). Concurrent with heart formation, 
the vascular system initially forms in two distinct regions, intraembryonic and 
extraembryonic, through the process of vasculogenesis (Risau and Flamme 1995; Drake 
and Fleming 2000).  This early vascular plexus is remodeled and refined in the presence 
of flow between E8.5 and E9.5 - through proliferation, sprouting, pruning, and vessel 
enlargement - to form the more complex vascular system found in the adult (Risau 1997; 
Djonov et al. 2000; Lucitti et al 2007).  Mural cells (smooth muscle cells and pericytes) 
are recruited to and surround the remodeled vessels and extracellular matrix is generated 
to provide support and contractility.  Vascular smooth muscle cells surround the larger 
blood vessels (arteries and veins) while the pericytes are associated with small caliber 
vessels (arterioles, capillaries, and venules) (Li et al. 2003; Hellstrom et al. 1999). These 
processes also occur in the adult, during wound healing, reproductive cycling, and tumor 
progression.  A greater understanding of these processes in vivo will provide insights into 
heart disease and the control of tumor progression (Jain 2003). 
 Several signaling cascades are required for the morphological differentiation of 
the embryonic vasculature, including vascular endothelial growth factor (VEGF) 
signaling, Notch signaling, and TGFβ signaling (Carmeliet et al. 1996; Tallquist et al. 
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1999; Krebs et al. 2000).  However, the relationship between the molecular signals and 
transcriptional networks directing endothelial differentiation are still not well defined. In 
this chapter, I summarize the current understanding of several signaling pathways 
relevant to my work and address outstanding questions that remain. 
1.1 Vasculogenesis 
 During the early stages of embryonic development, the extraembryonic yolk sac 
vasculature, primitive endocardium, and embryonic dorsal aorta all form through the 
process of vasculogenesis (Risau and Flamme 1995; Patan 2000).  This process is 
described as the formation of a network of simple endothelial tubes via the aggregation of 
angioblasts (Rossant and Howard 2002). Angioblasts are precursors to endothelial cells 
that express only a subset of endothelial cell markers and have yet to form a lumen (Risau 
and Flamme 1995).  In the extraembryonic region a subset of the primitive mesodermal 
cells from the splanchnopleuric mesoderm differentiate into the angioblast cells and 
aggregate into blood islands by approximately E7.0. The peripheral cells of the blood 
islands will differentiate to form the endothelial cells lining the vasculature, whereas the 
inner cells will become hematopoietic stem cells, the precursors of blood cells (Risau and 
Flamme 1995; Patan 2000).  It was initially believed that the angioblasts and the blood 
cells of the blood islands were derived from a common precursor, the hemangioblast, 
based on the observations that CD34 and PECAM1 are expressed on both endothelial 
cells and hematopoietic cells in the mouse (Risau and Flamme 1995; Choi et al. 1998). 
However, direct clonal analysis of blood island formation has shown that each island 
consists of multiple progenitors (Ueno and Weissman 2006). To analyze the origins of 
 3 
the hematopoietic and endothelial progenitors in the blood islands, three separate ES 
clones expressing the fluorescent markers EGFP, ECFP, and mRFP1 in the Rosa26 locus 
were injected into E3.5 blastocysts to generate tetrachimera mice.  Fluorescence imaging 
of embryos at E8 indicated that the origin of the blood islands is polyclonal; the 
endothelial and hematopoietic progenitors arise from distinct lineages (Ueno and 
Weissman 2006). By E8.5 the blood islands form lumenized vessels composed of 
endothelial cells, which fuse, forming the primitive polygon—shaped vascular plexus of 
the yolk sac, and blood flow commences (Patan 2000; Lucitti 2007; Figure 1.1). 
 Concurrent with the formation of the yolk sac vasculature, in the embryo proper 
the linear heart tube is formed form mesoderm-derived cardiac precursors and begins to 
beat by early E8.0 (Ji et al. 2003; Lucitti et al. 2007).  Also within the embryo, 
angioblasts derived from the splanchnic mesoderm at approximately E7.5 migrate and 
establish cell-cell contacts with other angioblasts to develop blood vessels, initially in the 
formation of the two ventral and dorsal aortae.  These vessels will later fuse to form the 
single, lumenized aorta seen in the adult (Patan 2000; Drake and Fleming 2000).  In 
contrast to extraembryonic vascular development, the initial intraembryonic vasculature 
is formed in the absence of hematopoiesis; blood cells from the yolk sac and other areas 
of hematopoiesis in the embryo will later populate the lumen of these vessels (Risau and 
Flamme 1995).  The distal portions of the dorsal aortae give rise to the vitelline arteries, 
which fuse with the yolk sac vessels to form the circulatory loop between the intra- and 
extraembryonic regions (Patan 2000). 
 Vasculogenesis also occurs in other regions of the embryo.  In the allantois, 
endothelial cell precursors are seen at approximately E7.0-7.5 and a vascular plexus  
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forms by E8.3.  This primitive vasculature gives rise to the umbilical vessels (Patan 2000; 
Drake and Fleming 2000).  It has also been shown that the vascularization of the kidney 
and liver occurs by vasculogenesis and that the development of the lung also involves   
vasculogenesis (Drake 2003). 
1.2 Angiogenesis 
 For many years the belief was that the vasculature formed initially through the 
process of vasculogenesis followed directly by angiogenesis, which is described as the 
formation of blood vessels from pre-existing ones (Risau 1997).  It has more recently 
been shown that this process is context dependent and not quite so straightforward 
particularly in the yolk sac. Early in vascular development, while the primary plexus is 
still forming, this plexus undergoes a remodeling or rearrangement without a network 
expansion.  This occurs through the fusion of vascular segments and migration of 
endothelial cells to form larger vessels, resulting in a more completely structured 
secondary plexus with different types and calibers of vessels, including arteries, veins and 
capillaries (Patan 2000; Rossant and Howard 2002).  The vasculature is also remodeled 
via the sprouting of endothelial cells from existing vessels, which migrate and proliferate 
to form other vessels (Risau 1997; Patan 2000). Based on these early findings, along with 
others, it is now widely accepted that angiogenesis is split into two broad processes, 
sprouting angiogenesis (SA) and intussusceptive angiogenesis (IA) (Risau 1997; Patan 
2000; Djonov et al. 2000).  
 
 
 6 
1.2.1 Sprouting angiogenesis 
 Sprouting angiogenesis was first described during second century Greece by the 
physician Galen (Galen, De foetuum formatione) and later during the beginning of the 
20th century in vivo in the sprouting capillaries in the chicken chorioallantoic membrane 
(CAM) (Patan 2000).  It is described as the expansion of the vasculature via the 
formation of new vessels composed of endothelial cells derived from an existing vessel.  
This process is the primary mode of angiogenesis and occurs simultaneously with IA 
early in development, in the yolk sac and embryo, and later during organogenesis (Risau 
1997; Patan 2000). Sprouting angiogenesis consists of a number of steps including the 
degradation of the basement membrane of an existing vessel, followed by the invasion of 
the endothelial cells into the surrounding matrix.  These endothelial cells proliferate and 
then migrate, forming ‘sprouts’ which join with other sprouts and lumenize to form an 
immature blood vessel. Mural cells and extracellular matrix stabilize the vessel and blood 
flow commences in the sprout (Patan 2000; Hillen and Griffioen 2007).  Sprouting 
angiogenesis occurs in a number of physiological conditions, including embryonic 
vascular development, wound healing, and the female reproductive system.  It also occurs 
in many pathological conditions, such as rheumatoid arthritis, diabetes, and tumor 
progression among others (Patan 2000; Jain 2003; Hillen and Griffioen 2007).   
1.2.2 Intussusceptive angiogenesis 
  Intussusceptive angiogenesis is simply defined as the internal division of the 
primary capillary plexus without sprouting. Observations of vessel remodeling in the yolk 
sac, particularly in the chick embryo, suggest that the formation of large diameter vessels 
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from pre-existing capillary-derived endothelial cells occurs via the process of 
intussusceptive angiogenesis (Patan 2000; Djonov et al. 2000).  This process is readily 
perceived by examination of the avascular space (‘pillars’), in which adjacent pillars 
‘fuse’ during this remodeling process.  This process involves the collapse of capillary 
microvessels, and the endothelial cells from the capillary are then recruited into the 
nascent vessels to result in a larger diameter vessel (Djonov et al. 2000).  New vascular 
segments are formed when endothelial cells on opposing capillary walls protrude into the 
lumen and contact one another.  Once this contact has been made, the cells are perforated 
centrally and a ‘pillar’ is formed.  The endothelial cells retract and the pillar is increased 
by the invasion of fibroblasts, collagen, and pericytes.  The pillars are continuously 
formed and joined together to expand and remodel the capillary plexus (Djonov et al. 
2003). 
   The process of intussusceptive angiogenesis is divided into three phases, 
intussusceptive microvascular growth (IMG), intussusceptive arborization (IAR), and 
intussusceptive branching remodeling (IBR). Each phase involves the formation of 
pillars; however they differ in the direction and arrangement of the pillars, which results 
in different vascular arrangements (Makanya et al. 2009). Intussusceptive microvascular 
growth greatly expands the primary capillary plexus through the delineation of new 
vascular segments resulting in organ-specific angioarchitecture. Intussusceptive 
arborization also expands the capillary plexus through the insertion of new pillars, 
remodeling the plexus into the vascular tree pattern. Intussusceptive branching 
remodeling further remodels the vascular tree to meet the perfusion demands of the local 
environment (Figure 1.2; Makanya et al. 2009). 
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Figure 1.2. Intussusceptive Angiogenesis
A schematic drawing showing the phases and phenotypes of intussusceptive angiogenesis 
(not drawn to scale). (A) The initial capillary plexus is a disorganized meshwork without 
a definite phenotype. The development of this meshwork proceeds through insertion of 
new pillars (arrows), which result in rapid expansion of the capillary plexus. Arrowheads 
indicate intraluminal appearance of the pillars. (B-C) From the disorganized capillary 
meshwork, IAR segregates the various vessel generations by formation of ‘vertical’ pillars 
in rows (arrows in B) and narrow tissue septa formed by pillar reshaping and pillar fusions 
segregate the new vascular entities. Subsequently, the formation of ‘horizontal pillars’ and 
folds (arrowheads in C) separates the new vessels from the capillary plexus. (D-F) The 
vasculature is finally adapted by IBR to suit the local perfusion demands. This entails 
modification of the branching angles and the diameters of the vessels by insertion of trans-
luminal pillars at branching points (arrows). Expansion and fusion of such pillars relocate 
the branching angle proximally with a concomitant change in blood flow properties. Part 
of the vascular remodeling by IBR involves severance of putative superfluous vessels, a 
process known as vascular pruning, which entails formation of eccentric pillars across the 
target branch (arrowheads in E, F), their subsequent augmentation and fusion resulting in 
ablation of the vessel. (G-I) Demonstration of intussusceptive microvascular growth 
(IMG) in the kidney glomerulus. Regardless of the organ, IMG proceeds through pillar 
initiation (arrowheads in G), pillar expansion (arrowheads in H), and ultimate fusion 
(arrowheads in I). In this way, the primordial simple capillary network is greatly expanded 
with delineation of new vascular segments and, depending on the pillar fusion pattern, the 
organ-specific angioarchitecture is formed (From Makanya et al. 2009).
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 IA only occurs in areas of pre-existing vasculature formed through either 
vasculogenesis or sprouting angiogenesis and is important for vasculature remodeling of 
a number of tissues (Makanya et al. 2009).  In the CAM, during the first phase of 
development (E5-E7) the blood vessels grow via SA, while in the second (E8-E12) and 
final phase the vasculature is expanded and remodeled by IA (Schlatter et al. 1997; Burri 
et al. 2004). IA is established following initial growth by sprouting angiogenesis in the rat 
mammary vasculature (Djonov et al. 2001).  IA is suspected to play a role in a number of 
pathological conditions, including psoriasis, rheumatic disease, and retinopathy, but has 
to date only been characterized in tumor angiogenesis (Makanya et al. 2009).   
 Sprouting angiogenesis and intussusceptive angiogenesis act in parallel and are 
similar processes which both result in the remodeling and maturation of the primary 
capillary plexus.  The main difference is that sprouting angiogenesis results in new 
vessels via migration of endothelial cells, while intussusceptive angiogenesis is the 
expansion of the vasculature through the splitting of existing vessel lumens.     
1.2.3 Tumor angiogenesis 
 The tumor microenvironment is a complex mixture of cell types and molecules 
such as ECM, endothelial cells, tumor cells, and immune cells among others (Nyberg et 
al. 2008).  Initial tumor growth is limited due to a lack of oxygen and nutrients.  Further 
outgrowth of the tumor requires the formation of new vessels from the pre-existing 
vasculature of the surrounding stroma and the remodeling of these vessels to form the 
tumor vascular network.  This progression from an avascular phase to a vascular phase is 
termed the “angiogenic switch” (Hillen and Griffioen 2007; Deshpande et al. 2010). 
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Tumor angiogenesis is a tightly controlled, complex process.  Similar to physiological 
angiogenesis, this process is dependent on a balance of promoters and inhibitors to 
regulate the growth of tumor blood vessels.  An increase in the positive regulators shifts 
the growth toward a pathological state (Patan 2000). The tumor vasculature is an 
unstable, evolving network of vessels, unlike normal vasculature, which is stable once 
formed (Jain 2003).   
 Several mechanisms have been implemented in the formation and remodeling of 
the tumor vasculature including both sprouting angiogenesis and intussusceptive 
arborization.  Sprouting angiogenesis is the initial growth of blood vessels from the 
existing vessels surrounding the tumor.  This process is important for both tumor growth 
and metastasis, as it is an unlimited process supplying oxygen and nutrients to the tumor 
cells.  Intussusceptive arborization is the rapid expansion of the vasculature via 
endothelial cell migration and vessel remodeling without endothelial cell proliferation 
(Hillen and Griffioen 2007; Deshpande et al. 2010). The process of IA in tumor 
angiogenesis is similar to that seen in the embryo, however there are differences.  In the 
tumor, the formation of pillars occurs more frequently and in shorter periods of time than 
in the embryo (Patan 2000). Following anti-angiogenic treatment or radiotherapy, as a 
mechanism for tumor recovery, vessel remodeling switches from SA to IA, restoring 
tumor vascularization and growth (Hlushchuk et al. 2008).  Based on recent knowledge 
of the pathways involved in tumor angiogenesis, promising anti-angiogenic therapies 
have been developed, although much work remains to fully understand the complex 
process of tumor development. 
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1.3 Signaling pathways in vascular development 
1.3.1 Notch signaling pathway  
Notch signaling is an evolutionarily conserved pathway originally discovered in 
Drosophila over 90 years ago.  Haploinsufficiency of the gene resulted in notches in the 
wing, hence the name (Mohr 1919).  It has since been shown to influence a broad 
spectrum of cell fate and developmental processes, including proliferation, 
differentiation, and apoptosis (Artavanis-Tsakonas et al. 1999).  Notch has been shown to 
suppress undifferentiated precursors from differentiating in neurogenesis, myogenesis, 
and hematopoiesis, among others, and can also determine cell fate and tissue patterning 
(Weinmaster 1998). 
 1.3.1.1 Notch family 
 The Notch family consists of four type1 transmembrane receptors, Notch 1 – 4 
and five type 1 cell surface ligands Delta-like (Dll) -1, -3, and -4 and Jagged (Jag) -1 and 
-2 (Mumm and Kopan 2000).  The receptors and ligands both consist of an extracellular 
domain, a transmembrane domain (TM), and an intracellular domain. In the receptors, the 
extracellular domain contains a signal sequence followed by 29 to 36 epidermal growth 
factor (EGF)-like repeats and 3 lin-12/Notch (LNR) motifs.  The C-terminal intracellular 
domain contains a RAM domain (~ 118 amino acids), 6 or 7 cdc10/ankyrin repeats, 1 or 
2 putative nuclear localization signals (NLS), a glutamine rich stretch, and a PEST 
domain (Figure 1.3).  In the trans-Golgi network the full-length receptor is processed by a 
furin-like convertase creating a heterodimeric receptor, which then localizes to the cell 
surface (Karsan 2005; Figure 1.4).  In the ligands, the extracellular domain contains an 
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N-terminal domain followed by a DSL domain and multiple tandem EGF-like repeats.  
The Jagged ligands contain approximately twice the number of EGF repeats than Delta 
and also contain a cysteine-rich region (CR).  The intracellular domain contains multiple 
lysine residues and a c-terminal PDZ (PSD-95/Dlg/ZO-1)-ligand motif (Figure 1.3; 
D’souza et al. 2008). 
 Upon ligand binding the receptor is further processed by a disintegrin-
metalloprotease in the extracellular region resulting in a product termed NEXT (Notch 
EXtracellular Truncation). A final cleavage within the TM domain by a γ-secretase-like 
protease, thought to be the Presenilins, releases the Notch IntraCellular Domain (NICD) 
(Mumm and Kopan 2000).  The NICD translocates to the nucleus mediated by the NLS, 
where it binds directly to the DNA-binding protein RBPJ, also termed CSL 
(CBF1/Rbpjk/KBF2 in mammals, Suppressor of hairless (Su[H]) in Drosophila and 
Xenopus, and Lag-1 in C. elegans), through the RAM domain (Weinmaster 1998) (Figure 
1.4).  In the absence of Notch, RBPJ acts as a transcriptional repressor at its DNA 
binding site GTGGGAA (Tun et al. 1994), forming a complex with the 
SMRT/NcoR/histone deacetylase 1 (HDAC1) or CIR/HDAC/SAP30 complexes, and Ski 
interacting protein (SKIP).  When the NICD translocates to the nucleus it displaces the 
SMRT or CIR/HDAC complex.  Mastermind, a transcriptional coactivator protein, then 
acts on the complex.  The conserved histone acetylase (HATs), PCAF, GCN5, and p300, 
are recruited to the corepressor complex, allowing for the activation of downstream genes 
(Mumm and Kopan 2000; Kovall 2007).  A number of Notch target genes have been 
identified to date, including members of the hairy/Enhancer of split-related genes, the 
HES (Jarriault et al. 1995; Kageyama and Ohtsuka 1999), HERP (Iso et al. 2003), and  
RBPJ
Activated
coA
N
-I
C
D
Hes/Hey/???
Signal-sending cell
Signal-receiving 
cell
Notch1-4
Dll1,3,4
   Jag1,2
γ secretase (S3)
???
N-ICD
???
RBPJ-independent
trans-Golgi
S1
S2
NEXT
Figure 1.4. Notch Signaling Pathway
(A) Schematic representation of the Notch signaling pathway.  The Notch ligand first 
undergoes a cleavage (S1) in the trans-Golgi network.  Then, upon ligand binding, the 
ligand is again cleaved (S2), resulting in the Notch ExtraCellular Truncation (NEXT).  
This product is then cleaved by a γ-secretase (S3), resulting in the Notch IntraCellular 
Domain (NICD).  This will translocate to the nucleus where it will interact with the bind-
ing factor RBPJ activating transcription of a subset of genes.
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HEY (Maier and Gessler 2000) families, which are basic helix-loop-helix (bHLH) 
transcription factors.  These genes are activated upon binding of the NICD-RBPJ 
complex and in turn act to repress the expression of other downstream target genes 
(Figure 1.4).  They act by binding to N- or E- box elements and recruiting corepressors to 
the binding site, acting as effectors of Notch signaling (Iso et al. 2003).  Thus, a number 
of different ligand, receptors, and effectors act in concert to direct Notch signaling in its 
many roles. 
1.3.1.2 Notch family expression 
 Embryonic expression of Notch family members, including ligands and receptors, 
as well as downstream targets, has been examined in some detail.   All Notch family 
members show expression at some point in the very early embryo, during preimplantation 
development.  Expression was analyzed in oocytes, zygotes, 2-cell embryos, morulae, 
blastocysts, and hatched blastocysts using nested PCR (Table 1.1).  Of the ligands, 
Notch1 and Notch2 are detected in oocytes and all throughout preimplantation 
development, Notch3 only in the 2-cell embryo and hatched blastocyst, and Notch4 from 
the 2-cell stage on.  The Notch ligands, Jag1, -2 and Dll3 are expressed in the oocytes 
through the late blastocyst stage, while Dll4 is not present until the 2-cell stage, and Dll1 
is expressed in the 2-cell embryo and weakly in the blastocyst and hatched blastocyst.  
The Notch transcription factor, Rbpj, is also expressed in the oocyte stage and all 
throughout preimplantation development.  All Notch family members showed expression 
in both embryonic stem (ES) cells and trophoblast stem (TS) cells (Cormier et al. 2004).  
 The vascular expression pattern of the Notch family members has also been  
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studied in depth in mouse embryos (Leimeister et al. 1999; Leimeister et al. 2000; Villa 
et al. 2001; Table 1.1).  Except for Notch2, which was not expressed in either arteries or 
veins, and Dll3 and Dll1, which were not detected at this early time point, all of the 
ligands and receptors exhibited arterial specific expression; none were detected at high 
levels in the veins of the early vasculature.  Interestingly, Notch3 is expressed in the 
smooth muscle cells of the dorsal aortae and not in the endothelial cells, Jag1 is 
expressed in smooth muscle cells in addition to the endothelia, and Notch4 and Dll4 are 
the only members to exhibit expression in the capillaries (Villa et al. 2001). The 
expression of the downstream targets of Notch, Hey1, Hey2, and HeyL has also been 
examined.  In the early embryo HeyL is expressed in a number of tissues, including the 
branchial arch mesenchyme, peripheral nervous system, and somites, while later in 
development it is also expressed in the smooth muscle cells of the digestive tract and the 
vasculature (Leimeister et al. 2000). In the early embryo, Hey1 and Hey2 are coexpressed 
in the somites and otic vessels.  Hey1 also exhibits expression in a number of tissues, 
including the dorsal aorta, allantois, and floor plate of the neural tube, among others.  
Hey2 is widely expressed as well, including in the spinal nerves and first branchial arch 
(Leimeister et al. 1999). 
This expression pattern indicates that the Notch signaling may play an important 
role during preimplantation development in the mouse and later in the formation of the 
vascular system, specifically in the specification of the arteries. 
1.3.1.3 Notch signaling in vascular development 
Mutations in both the ligands and receptors of the Notch family lead to defects in 
the vasculature, many of which are embryonic lethal (Table 1.2). Mutant mice lacking 
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Gene
Mutation
Lethality Vascular
Phenotype
Ligand
Dll4
overexpression
Dll4 deletion
Jag1 deletion
Receptor
Notch1
Notch1
conditional
Notch1
overexpression
Notch4
Notch4
overexpression
Notch1/Notch4
Rbpj
Effector
Hey1
Hey1/Hey2
E10.5
E11.5
E11.5
E11.5
E10.5
E10.5
Viable
E10
E9.5
E10.5
Viable
E11.5
Reduction in vascular sprouting, enlarged
vessels
Vascular remodeling defects, reduction in 
vessel diameter, arteriovenous malformations
Imapired remodeling in the yolk sac, 
reduction in vessel diameter
Vascular remodeling defects in embryo, 
yolk sac, and placenta
Vascular defects in the yolk sac, placenta, 
and embryo proper
Immature vasculature, impaired remodleing, 
arteriovenous malformations, cardiac defects
No vascular phenotype
Enlarged vessels, arterious malformations
More severe  phenotype than Notch1 deletion
Similar to defects in Notch mutation,vascular 
remodeling defects, reduction in vessel diameter
No vascular phenotype
Vascular remodeling defects, massive
 hemmorhage, lack of vessels in placenta
Table 1.2. Phenotype of Mice with Mutations in Notch Family Members
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Notch1 do not survive post E11.5 and harbor defects in vascular remodeling in the 
embryo, yolk sac, and placenta (Swiatek et al. 1994). Mice with a conditional deletion of 
Notch1 in the endothelial cells exhibited vascular defects in the yolk sac, placenta, and 
embryo proper, and died at approximately E10.5 (Limbourg et al. 2005). Deletion of 
Notch4 has no visible effect and embryos are viable; however, Notch1-/-Notch4-/- double 
mutants have more severe vascular phenotypes than the Notch1-/- and are embryonic 
lethal at E9.5 (Krebs et al. 2000; Iso et al. 2003). Mice lacking Jag1 (Xue et al. 1999) and 
mice with a heterozygous deletion of Dll4 (Krebs et al. 2004; Gale et al. 2004) exhibit 
growth retardation, defects in vascular remodeling, and lethality by E11.5. Activated 
expression of Notch family members also leads to vascular defects.  Mice with activated 
expression of Notch1 in the endothelia, under the control of Tie2, display an immature 
vasculature with impaired remodeling, arteriovenous malformations, and cardiac defects 
and are embryonic lethal at E10.5 (Venkatesh et al. 2008; Krebs et al. 2010).  Mice with 
an activated form of Notch4 in the endothelium also display enlarged vessels, 
arteriovenous malformations and embryonic lethality (Uyttendaele et al. 2001; Carlson et 
al. 2005).  Similarly, overexpression of the ligand Dll4 in the endothelium leads to a 
reduction in vascular sprouting, enlarged vessels and lethality by E10.5 (Trindade et al. 
2008). 
Other genes crucial to Notch signaling also display defects in vascular 
remodeling.  Mice with a conditional deletion of Rbpj in the endothelia display vascular 
defects similar to those seen in other Notch mutants, including an absence of vascular 
remodeling and a reduction in vessel diameter (Krebs et al. 2004).  Mice lacking Hey1 
have no apparent phenotype and are viable; however mice with a double knockout of 
Hey1 and Hey2 exhibit defects in growth and vascular remodeling and lethality by E11.5 
(Fischer et al. 2004). 
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In mouse studies, both loss-of-function and gain-of-function of members of the 
Notch families lead to abnormalities in the vasculature and embryonic lethality. These 
and other data indicate a definite role for Notch signaling in the control of endothelial 
differentiation in the early embryo.  However, the downstream targets of these signaling 
pathways remain largely undefined, particularly during early embryogenesis.  Much work 
remains to establish the complex hierarchy of signaling cascades involved in vascular 
differentiation. 
1.3.1.4 Notch signaling in pathological conditions 
Notch signaling has recently been found to play a role in tumor angiogenesis.  
The ligand Dll4 is strongly expressed in tumor vessels (Mailhos et al. 2001).  In tumors 
VEGF-A induces Dll4 expression in sprouting endothelial cells, which in turn signals 
through Notch acting as a negative regulator of growth.  Inhibition of Dll4/Notch 
signaling resulted in increased vessel density, but decreased vessel function.  Tumor 
hypoxia was increased and tumor growth retarded (Noguera-Troise et al. 2006).  High 
levels of Notch1 and Jag1 expression are found in breast cancer and prostate cancer 
(Santagata et al. 2004; Reedijk et al. 2005).  Based on these findings the inhibition of 
Notch signaling, via γ-secretase inhibitors or antibodies neutralizing DLL4, could be a 
strategy for cancer treatment. 
The importance of Notch signaling is also indicated by its role in congenital 
disorders.  Mutations in the Notch3 gene lead to cerebral autosomal dominant 
arteriopathy with subcortical infarct and leukoencephalopathy (CADASIL).  CADASIL 
is an autosomal dominant inherited disorder characterized by recurrent ischemic strokes, 
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cognitive impairment, and migraine.  Notch3 mutations in CADASIL patients are found 
in the cysteine residues of the EGF-like repeats, with over 100 different mutations 
reported (Tang et al. 2009).  In mice, Notch3 mutant embryos are viable, however adults 
exhibited arterial defects (Krebs et al. 2003).  How Notch3 mutations lead to CADASIL 
and possible treatments for the disorder remain unknown.  Mutations in Jag1 or in 
Notch2 lead to Alagille Syndrome (AGS).  AGS is an autosomal dominant disorder 
associated with abnormalities of the heart, eye, kidney, and skeleton and most commonly 
impaired development of the intrahepatic bile ducts (Niessen and Karsan 2007).  AGS is 
also characterized by vascular anomalies and abnormal intracranial vessel development 
(Kamath et al. 2004), which likely result due to the role of Jag1/Notch signaling in 
vasculogenesis.  There is no known cure for AGS. 
1.3.2 VEGF signaling pathway 
Another group of important, and one of the best characterized, signaling 
molecules involved in vascular differentiation is the vascular endothelial growth factor 
(VEGF) family.  VEGF was initially shown to be an endothelial cell-specific mitogen, an 
inducer of angiogenesis, and a mediator of vascular permeability (Park et al. 1994). The 
VEGF family is now known to play a crucial role in the formation of the vasculature in 
the early embryo as well as in the adult during wound healing and pathological 
angiogenesis.  The VEGF family is also an important component in lymphangiogenesis 
(Tjwa et al. 2003; Lohela et al. 2009).  
1.3.2.1 VEGF family 
The VEGF family includes VEGF-A (also referred to as VEGF), VEGF-B, 
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VEGF-C, VEGF-D, placental growth factor (PlGF), and the more recently identified 
ORF encoded VEGF-E and snake venom-isolated VEGF-F (Lohela et al. 2009). The 
VEGFs are dimeric glycoproteins belonging to the platelet-derived growth factor 
(PDGF)/VEGF superfamily, characterized by their cysteine-knot motif.  The monomers 
are oriented side-by-side and head-to-tail, held together by a single disulfide bond. (Tjwa 
et al. 2003; Lohela et al. 2009). VEGF-A, also known as vascular permeability factor has 
six isoforms generated by alternative splicing of the mRNA.  In the human they are 
VEGF121, VEGF145, VEGF165 (the most predominant), VEGF183, VEGF189, and VEGF206; 
the mouse and rat isoforms are one amino acid shorter. VEGF-A expression is tightly 
regulated by hypoxia at the transcriptional level via the hypoxia-inducible transcription 
factors (HIF-1 and -2), which bind the hypoxia-responsive element (HRE) in the VEGF-
A promoter (Tjwa et al. 2003). VEGF-B, also known as VEGF-related factor (VRF), 
consists of two isoforms generated by alternative splicing, VEGF-B167 and VEGF-B186, 
which differ only in the C-terminal sequence.  VEGF-B has a 44% sequence identity to 
VEGF-A. VEGF-C and VEGF-D are closely related; their amino acid sequence contains 
a central region with homology to VEGF-A, however they also consist of long N- and C-
terminal extensions, the C-terminal being rich in cysteine residues (Achen and Stacker 
1998). PlGF was discovered in human placenta shortly after the discovery of VEGF-A, in 
the early 1990s.  There are three isoforms in the human, formed via alternative splicing, 
PlGF-1 (PlGF131), PlGF-2 (PlGF152), and PlGF-3 (PlGF203).  PlGF-2 contains 21 basic 
amino acids in the C-terminus, which are lacking the PlGF-1 and -3, that allow for 
binding to heparin.  PlGF-2 is the only splice isoform found in mice.  PlGF has 
approximately 46% sequence identity to VEGF-A and can form homodimers and 
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heterodimers with VEGF-A (Achen and Stacker 1998; Tjwa et al. 2003). 
The VEGF family consists of three related tyrosine kinase receptors, FLT1 
(VEGFR1), KDR (VEGFR2, FLK1), and FLT4 (VEGFR3).  Each contains seven 
immunoglobulin (Ig)-like folds in the extracellular region, a split tyrosine kinase domain 
and one transmembrane domain.  All three are modified via N-linked glycosylation 
postranslationally (Matsumoto and Claesson-Welsh 2001).  There is also a soluble form 
of FLT1 (sFLT1), resulting from alternative splicing, which lacks the seventh Ig-like 
domain, the cytoplasmic domain, and the transmembrane domain (Kendall and Thomas, 
1993; Park et al. 1994).  Neuropilin-1 has also been identified as a relatively high affinity 
receptor for VEGF-A (Achen and Stacker 1998). 
VEGF-A binds to both FLT1 and KDR. Although VEGF-A binds with a higher 
affinity to FLT1, the angiogenic signal is thought to result from the binding of VEGF to 
KDR.  FLT1 and sFLT1 are believed to act as ‘sink’ receptors, regulating the binding of 
VEGF-A to KDR (Neufeld et al. 1999; Tjwa et al. 2003). VEGF-A binding induces the 
autophosphorylation of the receptor at four major sites and activates downstream 
signaling cascades, including the MAPK pathway and PI3K-AKT pathway among others.  
As a result VEGF signaling influences vascular permeability, proliferation, survival, 
migration, and cell mobilization (Rossant and Howard 2002; Kerbel 2008).  
The VEGF family homolog, PlGF, is also believed to be an inducer of vascular 
development.  PlGF binds with high affinity to FLT1 (Park et al. 1994).  PlGF is 
upregulated during pathological angiogenesis (Carmeliet et al. 2001) and stimulates 
vascular leakage (Park et al. 1994).  PlGF may stimulate vascular formation by signaling 
through FLT1 (Neufeld et al. 1999) or by acting as a ‘decoy’, limiting VEGF-A binding 
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to the ‘FLT1-sink’ and thereby increasing the amount of VEGF-A available to activate 
KDR (Park et al. 1994).  VEGF-B also binds with high affinity to FLT1. VEGF-B does 
not affect vascular development in the embryo, however it appears to be important in 
pathological settings, specifically in the regulation of lipid metabolism in cardiac muscle 
(Lohela et al. 2009). VEGF-C and VEGF-D bind both KDR and FLT4.  It has been 
shown that the binding of VEGF-C to FLT4 regulates the formation of lymphatic vessels, 
not blood vessels, in the early embryo.  Although VEGF-D does bind to with high 
affinity to FLT4 its role has not been elucidated (Lohela et al. 2009) (Figure 1.5). 
1.3.2.2 VEGF family expression 
The members of the VEGF family are broadly expressed in the developing 
embryo and in the adult.  Vegfa is expressed in the giant cells during early embryogenesis 
and is found in most organs in later stages.  Visualization via a LacZ knock-in reporter 
allele of Vegfa indicated strong expression in the extraembryonic visceral endoderm 
during early implantation and in the definitive endoderm at E8.0 (Miquerol et al. 1999). 
Vegfa also shows increased expression in regions of hypoxia.  Vegfb expression overlaps 
with that of Vegfa in most tissues; however it is not regulated by hypoxia.  It exhibits 
expression in the developing heart of the early embryo and, while widely expressed in the 
adult it is predominant in the adult cardiac and skeletal tissue.  Vegfc and Vegfd have 
similar expression profiles in many tissues of the embryo and adult, although Vegfc is 
particularly expressed in areas surrounding lymphatic vessels and Vegfd is predominant 
in the lung, heart, and skin tissues.  Pgf is expressed in the trophoblast cells and vascular 
endothelium of the placenta throughout the development of the embryo and in certain 
FLT-1
(VEGFR-1)
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(VEGFR-2) FLT-4
(VEGFR-2)
sFLT-1
VEGF-A
VEGF-C
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MAPK
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Figure 1.5. VEGF Signaling Pathway
Schematic representation of the VEGF signaling pathway.  The main angiogenic signal 
arises through the binding of VEGF-A to KDR.  Via the MAPK pathway and PI3K-AKT 
pathway, among others, VEGF-A mediates endothelial cell proliferation, migration, mobi-
lization, permeability, and survival.
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tumors (Vuorela et al. 1997; Achen and Stacker 1998; Matsumoto and Claesson-Welsh 
2001). 
The receptors, Flt1 and Kdr, are expressed in the endothelial cells of most tissues 
in the mouse and human.  Kdr is first found in the mesodermal precursors of the blood 
islands and then in the peripheral angioblast cells of the blood islands.  Flt1 appears in 
angioblasts at approximately E8.5.  Both are expressed in adult endothelial cells, however 
they are lacking in certain tissues, including the brain.  Flt1 and Kdr expression is 
increased in pathologies such as tumors and hyperthyroidism.  Flt4 is expressed in the 
developing vasculature of the embryo by E8.0; however it is restricted to the venous 
endothelium.  In the adult it is expressed in the lymphatic vasculature and vascular and 
nonendothelial tumors (Matsumoto and Claesson-Welsh 2001). 
1.3.2.3 VEGF signaling in vascular development 
In both heterozygous and homozygous Vegfa deficient embryos blood vessel 
formation was abnormal and the embryos died early in development (Carmeliet et al. 
1996; Ferrara et al. 1996).  Mice lacking Kdr lack endothelial cells and blood vessels, and 
die between E8.5 and E9.5, while Flt1 knockout mice, which also die at E8.5, have a 
normal level of endothelial cells but lack functional vessels (Shalaby et al. 1995; Fong et 
al. 1995). Mice lacking placental growth factor have impaired pathological angiogenesis, 
likely through the attenuation of the response to VEGF-A (Luttun et al., 2002), while 
mice overexpressing placental growth factor under the control of the keratin 14 promoter 
displayed increased vascularization and permeability in the vasculature of the skin 
(Odorisio et al., 2002).  Deletion of Vegfc in mice leads to embryonic lethality due to the 
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absence of lymph vessels; however no vascular defects have been identified (Karkkainen 
et al. 2004). 
It has long been established that the VEGF pathway is crucial for the development 
of the vascular system in the early embryo, specifically through the binding of VEGF-A 
to KDR.  However, evidence supports a role for other family members in this regulation.  
Work remains to determine the precise function of the VEGF pathway and its interaction 
with other signaling pathways. 
1.3.2.4 VEGF signaling in pathological conditions 
Members of the VEGF family have been implicated in many pathological 
conditions. VEGF-A and KDR are inducers of tumor angiogenesis (Kim et al. 1993; 
Carmeliet et al. 2001).  FLT1 is also important for tumor angiogenesis and is involved in 
rheumatoid arthritis and atherosclerosis (Zhao et al. 2004). VEGF-A induces vascular 
permeability via activation of KDR and subsequent signaling involving Src-kinases 
(Eliceiri et al. 1999). PlGF has been shown to stimulate vascular leakage, likely by 
attenuating the response to VEGF-A (Park et al. 1994; Luttun et al. 2002) and while it is 
minimally expressed in quiescent adult vasculature it is upregulated during tumor 
angiogenesis enhancing the angiogenic activity of VEGF-A (Carmeliet et al. 2001).  In 
Pgf-deficient mice, tumor angiogenesis and growth are reduced (Carmeliet et al. 2001), 
while mice overexpressing Pgf in the skin exhibit increased melanoma growth 
(Marcellini et al. 2006).  PlGF has also been shown to regulate inflammation and edema 
formation in adult mice (Oura et al. 2003). 
Vascularization in tumors has been diminished by the use of VEGF-A 
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neutralizing antibodies, a dominant negative mutant of KDR, and the expression of 
VEGF-A antisense RNA (Kim et al. 1993; Millauer et al. 1994; Saleh et al. 1996).  Based 
on this knowledge a number of therapies have been developed, including KDR inhibitors, 
and a VEGF-A neutralizing antibody (Wedge et al. 2000; Wood et al. 2000; Hurwitz et 
al. 2004).  Further study of the VEGF signaling pathway could lead to additional 
therapeutics to manipulate the vasculature in pathological conditions. 
1.3.3 TGFβ signaling pathway 
Compared to the signaling pathways discussed in the previous sections, the role of 
the TGFβ signaling family in vascular differentiation is less defined. There are almost 30 
members of the TGFβ family, including the TGFβs, bone morphogenic proteins (BMPs), 
activins, and inhibins.  There are two types of receptors, type I and type II.  Ligand 
binding to type II receptors leads to the phosphorylation and activation of type I 
receptors.  These in turn phosphorylate the Smads, which convey the signal to the nucleus 
thus activating the target genes. The members critical to vascular development appear to 
be the ligand TGFβ1 and the receptors TGFβRII (type II) and ACVRL1 (ALK1) (type I).  
Mice with a deletion of TGFβ1 have defective vascular development in the yolk sac and 
have 50% embryonic lethality by E10.5.  Knockout of TgfβRII or Acvrl1 also leads to 
vascular defects in the embryo and yolk sac as well as embryonic lethality.  It has been 
shown that TGFβ is important for the stabilization of the vasculature via the production 
of extracellular matrix (ECM) and the differentiation of vascular smooth muscle cells.  
Disruption of these processes may be the cause of the vascular defects seen in mutant 
mice (Jain 2003; Holderfield and Hughes 2008). 
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1.4 Interactions between the signaling pathways 
These and other data indicate a definite role for VEGF, Notch and TGFβ 
signaling in the control of endothelial differentiation in the early embryo, however the 
interactions and many of the downstream targets of these signaling systems remain 
unknown. VEGF was shown to upregulate the expression of Notch1 and Dll4 in human 
arterial endothelial cells in vitro (Liu et al. 2003) and the expression of Dll4 in vivo in the 
mouse retina (Lobov et al. 2007). VEGF has also been shown to act as an upstream 
component of Notch in the signaling cascade directing the differentiation of the zebrafish 
vasculature (Lawson et al. 2002).  During the process of sprouting angiogenesis, Notch 
and VEGF are thought to act in concert to control the migration and proliferation of the 
endothelial cells involved. VEGF-A upregulates the expression of Dll4 in the tip cell 
which is thought to activate Notch in the stalk cell and Notch in turn downregulates the 
expression of the VEGF receptors.  Thus the tip cell becomes migratory and the stalk cell 
remains connected to the blood vessel (Siekmann et al. 2008).  TGFβ has been shown to 
downregulate the transcription of KDR via a GATA site in the promoter.  In addition to 
other interactions, TGFβ/BMP signaling can either act with Notch to induce the 
expression of target genes or Notch can inhibit TGFβ/BMP signaling; it is all rather 
complex and context dependent (Holderfield and Hughes 2008). 
Taken together the data indicate specific and vital roles for both the Notch and 
VEGF signaling pathways in the formation of the vasculature in the early embryo and in 
pathological angiogenesis in the adult.  The process of vascular morphogenesis includes a 
number of processes involving many cell types.  It is a complex process involving 
multiple signaling pathways that must be tightly regulated both spatially and temporally. 
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While the morphological phenotypes of a number of mutations have been examined in 
detail, studies of the gene expression defects and, in turn, the genetic interactions between 
the pathways are lacking.  Crosstalk between the pathways is essential for the proper 
development of the vasculature in the early embryo, however the specific interactions 
remain unknown. These discrepancies prompt in-depth in vitro and in vivo studies to 
further examine the role of Notch signaling in the development of the vasculature and 
how this pathway interacts with other pathways central to this process.  
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Chapter 2 
Materials and Methods 
2.1 Standard solutions and reagents 
Doxycycline 
1 µg/ml in water, stored at -20°C 
InSolution gamma-secretase Inhibitor X (GSI-x) 
1 µM in Dimethyl sulfoxide (DMSO), stored at -20°C 
VEGF-A 
30 ng/µl in PBS, 0.1% BSA, stored at -20°C 
FGF-2 
20 ng/µl in PBS, 0.1% BSA, 1 mM DTT, stored at -20°C 
Endothelial Cell Differentiation Media (EC media) 
85 ml DMEM, 10 ml ES serum for endothelial cell differentiation (Stem Cell  
Technologies, Inc), 1 ml glutamine, 1 ml Pen/Strep, 1 ml BME stock, filter 
sterilized, stored at 4°C   
ECVF media 
EC Differentiation media, 90 ng/ml VEGF-A, 40 ng/ml FGF-2, stored at 4°C 
PBSMT 
Phosphate buffered saline, 3% nonfat dry milk, 0.1% Triton X-100, filter sterilized,  
stored at 4°C 
PBT 
Phosphate buffered saline, 0.2% BSA, 0.1% Triton X-100, filter sterilized, stored at  
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4°C 
Blocking Solution for Immunofluorescence 
Phosphate buffered saline, 3% BSA, 5% donkey serum (Jackson ImmunoResearch 
Laboratories, Inc), filter sterilized, stored at 4°C 
EC Collagen Prep Media (per 6 well plate) 
4.5 ml DMEM, 2.7 ml EC Differentiation Media, 190 µl Pen/Strep, 52 µl VEGF-A, 
37 µl FGF2 stock, stored at 4°C 
2.2 Animal husbandry 
2.2.1 Generation of the Z/EG-Pgf transgene 
 The Z/EG-Pgf construct was generated by inserting the Pgf CDS fragment into 
the Z/EG expression vector (Novak et al. 2000).  The resulting Z/EG-Pgf transgene 
contained a β-geo cassette flanked by loxP sites under the control of the β-actin 
promoter, followed by the Pgf cDNA and a GFP cassette.  The transgene was introduced 
into E14 embryonic stem (ES) cells via electroporation and clones were analyzed.  The 
B1 clone was used to generate chimeric mice by injection into C57Bl/6 host blastocysts.  
The resulting male chimeras were bred to wild type C57Bl/6 females and the resulting 
pups were assessed for germline transmission via coat color and genotyping. 
2.2.2 Breeding scheme to obtain mice and embryos 
The generation of RosaNotch mice (Murtaugh et al. 2003), loxP-flanked Rbpj 
(Tanigaki et al. 2002) and Tie2-Cre mice (Koni et al. 2001) has been described 
previously.  Tie2-Cre mice and loxP-flanked Rbpj mice were mated to obtain Tie2-Cre; 
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Rbpjf/+ males. Breeding pairs of Tie2-Cre males and RosaNotch females or Tie2-Cre; 
Rbpjf/+ males and Rbpjf/+ females, or Tie2-Cre males and ZEG-Pgf females were mated 
and the presence of a vaginal plug was taken as 0.5 dpc. Embryos were dissected from 
the decidual tissue at E8.5, E9.5, or E10.5 and treated according to the intended protocol. 
Placentas were separated from the embryos along with the mesometrial portion of the 
decidua and prepared for histology. 
2.2.3 Genotyping of progeny 
 The genotypes of all offspring were analyzed by PCR on genomic DNA isolated 
from ear punches, yolk sac samples, or embryonic tissue depending on the intended 
protocol. Genomic DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen). 
The Tie2-Cre transgene presence was tested with the primers Cre-R3, 5’-AAT GCT TCT 
GTC CGT TTG-3’ and Cre-F3, 5’-GGA TTA ACA TTC TCC CAC C-3’, giving a 458-
bp band (Steenhard et al. 2010). PCR genotyping for RosaNotch mice was performed as 
described (Soriano 1999). The wild type, floxed, and deleted Rbpj alleles were genotyped 
as described (Souilhol et al. 2006). Z/EG-Pgf mice were genotyped with primers iZ/EG 
3’ UP, 5’-AAG GTG AAC TTC AAG ATC CGC C-3’ and iZ/EG 3’ LOW – 5’-ACC 
TTT GTT CAT GGC AGC CAG-3’, yielding a 469-bp band. 
2.2.4 Animal euthanasia 
 All mice used in this study were sacrificed by asphyxiation with carbon dioxide 
followed by cervical dislocation to confirm mortality or by cervical dislocation alone 
according to IACUC standard operating procedure (SOP). 
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2.3 Generation and embedding of embryoid bodies 
2.3.1 Embryoid body formation 
 ES cells were collected in EC differentiation media at 60 cells/µl.  Cells were 
plated in 20 µl drops (1200 cells/drop) onto the lid of a 10 cm bacterial dish.  PBS (10-20 
ml) was added to the bottom of the dish to prevent hanging drops from drying out.  Cells 
were grown in an incubator undisturbed for 4 days 
2.3.2 Collagen embedding of embryoid bodies 
 2.3.2.1 Preparation of wells 
 The following collagen solution was prepared on ice in the hood: 
 EC-CPM  3.3 ml 
 Collagen stock 1.2 ml (neutralize with ~60 µl 0.4M NaOH in 20 µl units) 
PBS   3.3 ml 
 Next, 1ml collagen solution was added to each well of a 6-well plate and 
incubated at 37°C for 1 hour to set.  After 1 hour any liquid remaining on the top of the 
collagen was aspirated. 
2.3.2.2 Embryoid body embedding 
The following collagen solution was prepared: 
EC-CPM  4.4 ml 
Collagen stock 1.6 ml (neutralized with ~80 µl 0.4M NaOH in 20 µl units) 
PBS   4.4 ml 
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 The collagen solution was aliquoted in 1.5 ml aliquots into six 15 ml conical 
tubes.  Embryoid bodies from hanging drops were collected onto a 10 cm dish.  Then, 10 
embryoid bodies were picked with a P1000 and placed into each tube.  The volume of 
each tube was added onto a well with preset collagen and incubated for 1 hour at 37°C to 
set the collagen.  After 1 hour 4 ml of ECVF media was added to each well.  Embryoid 
bodies were incubated depending on the intended treatment. 
2.4 DNA manipulations 
2.4.1 Genomic DNA isolation 
 Genomic DNA was isolated from mouse and embryonic tissues using the DNeasy 
Blood and Tissue Kit (Qiagen).  Following the protocol mouse ear clips and embryonic 
tissues were incubated overnight in 180 µl Buffer ATL and 20 µl proteinase K.  The 
following morning the samples were vortexed and 200 µl Buffer AL and 200 µl ethanol 
(96-100%) was added to the samples and mixed thoroughly.  The entire sample was 
pipetted into the DNeasy Mini spin column and centrifuged at 6000 x g for 1 minute.  
Next, 200 µl Buffer AW1 was added to the column and again centrifuged for 1 minute at 
6000 x g.  Then 500 µl Buffer AW2 was added and the sample was centrifuged for 3 
minutes at 20,000 x g.  The column was placed in a clean 1.5 ml microcentrifuge tube 
and then 80 µl or 60 µl (respectively) Buffer AE was added directly onto the column 
membrane.  The sample was incubated at room temperature for 1 minute and then 
centrifuged for 1 minute at 6000 x g to elute.  Samples were stored at -20°C until needed. 
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2.4.2 Polymerase Chain Reaction (PCR) 
 PCR primers (Integrated DNA Tecnologies, Inc) were dissolved in TE buffer to a 
stock concentration of 1 µg/µl; primers were stored at -20°C.  PCR reactions were done 
with GoTaq Polymerase (Promega) on a DNA Engine Dyad Thermal Cycler (MJ 
Research (now Bio-Rad)).  PCR reactions were analyzed in 1% agarose gels. 
A typical PCR cocktail: 
5X GoTaq Flexi PCR Buffer  5.0 µl 
 25 mM magnesium chloride  2.0 µl 
 dNTPs     0.2 µl 
primer (forward)   0.1 µl 
primer (reverse)   0.1 µl 
GoTaq Polymerase   0.1 µl 
water     16.5 µl 
template    1 µl 
total volume    25 µl 
Typical conditions for PCR (annealing temp and cycle number varied): 
95°C    5 mins 
95°C    30 secs 
58°C    30 secs  30 cycles 
72°C    30 secs 
72°C    5 mins 
4°C    hold 
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2.5 RNA manipulations 
2.5.1 RNA isolation 
For RNA isolation of embryonic tissues, embryos were dissected at E9.5.  The 
uterus and decidua were carefully removed and discarded. The yolk sac and the placenta 
were separated from the embryo for RNA isolation and the embryo was used for 
genotyping. RNA was also isolated from ES cells, EBs, and differentiated endothelial 
cells.  Total RNA was isolated using an RNeasy mini kit (Qiagen).  Following the 
protocol, Buffer RLT was added to the sample (350 µl for embryonic tissues and 600 µl 
for cells).  Samples were vortexed and heated for a short amount of time to lyse the RNA.  
One volume of 70% ethanol was added to the lysate and mixed immediately by pipetting.  
Up to 700 µl of the sample was transferred to an RNeasy spin column and centrifuged for 
30 seconds at 8000 x g and the flow was discarded (repeated for samples larger than 
700µL).  Next, 700 µl Buffer RW1 was added and again the sample was centrifuged for 
30 seconds at 8000 x g and the flow was discarded.  Then 500 µl Buffer RPE was added 
and centrifuged for 30 seconds at 8000 x g, followed by another 500 µl Buffer RPE and 
centrifuged for 2 minutes at 8000 x g.  The spin column was placed in a new 1.5 ml 
collection tube and 30 µl RNase-free water was added directly to the spin column 
membrane and centrifuged for 1 minute at 8000 x g.  Samples were stored at -20°C until 
needed. 
2.5.2 Reverse Transcriptase (RT)-PCR  
 cDNA was generated using SuperScript III reverse transcriptase (Invitrogen). 
Semiquantitative RT-PCR was performed using a number of primers from IDT 
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(Integrated DNA Technologies, Inc) (Table 2.1), with ribosomal protein L7 (5’-GAA 
GCT CAT CTA TGA GAA GGC-3’ and 5’-AAG ACG AAG GAG CTG CAG AAC-3’) 
as a control. The above protocol for PCR was followed with the annealing temperature 
and number of PCR cycles optimized for each reaction. 
2.5.3 Real-time PCR  
 RNA was isolated from ES cells, EBs, differentiated endothelial cells, yolk sac 
tissues, or placentas using an RNeasy mini kit (Qiagen). cDNA from endothelial cells 
was generated using SuperScript III reverse transcriptase (Invitrogen) and quantitative 
real-time PCR analysis was performed using Taqman primer sets (Table 2.2) with the 
7500 Real Time PCR system (Applied Biosystems). Gene expression was normalized to 
GAPDH. 
2.5.4 Microarray analysis 
 RNA was isolated from ES cells, EBs, differentiated endothelial cells, yolk sac 
tissues, or placentas using an RNeasy mini kit (Qiagen). RNA was initially analyzed with 
the Mouse Genome 430 A Array from Affymetrix. EC-N1ICD and EC-Rbpj-KO 
microarray data were deposited to the Gene Expression Omnibus (GSE22418).  
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Gene Assay ID AmpliconLength
Ankrd1
Cdh5
CD34
Dll4
Flk1
Gapdh
Hey1
Heyl
Jag1
Notch1
Notch4
Nrarp
PECAM1
Pgf
Rhox5
Tgfb2
Vegfc
ZEG-Pgf
Mm00496512_m1
Mm00486938_m1
Mm00519283_m1
Mm00444619_m1
Mm01222419_m1
Mm99999915_g1
Mm00468865_m1
Mm00516555_m1
Mm00496902_m1
Mm00435245_m1
Mm00440536_g1
Mm00482529_s1
Mm01242584_m1
Mm00435613_m1
Mm00476718_m1
Mm00436952_m1
Mm00437313_m1
Mm00435611_m1
63
69
61
71
81
107
80
83
61
96
63
74
71
75
59
101
137
91
Table 2.2. Primers for Real Time-PCR
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2.6 Histology 
 Untreated whole-mount embryos, whole-mount PECAM stained embryos, and 
placentas were fixed in 4% paraformaldehyde overnight, dehydrated into 70% ethanol 
and embedded in paraffin wax. Embryos were then sectioned on the transverse generally 
in 8-10 µM sections. For histological observation, Hematoxylin & Eosin or Nuclear Fast 
Red staining was conducted on the paraffin sections and sections were observed or 
immunofluorescence was performed. 
2.7 Immunochemistry 
2.7.1 Embryo and yolk sac immunochemistry 
 Embryos with or without the surrounding yolk sac were fixed in 4% 
paraformaldehyde/PBS overnight at 4oC. The following day they were rinsed in PBS, 
dehydrated in methanol, and bleached in 1 ml of 1.5% H2O2 in methanol for 4-5 hours at 
room temperature. Embryos were then rehydrated through methanol into PBS, blocked in 
PBSMT for 2 hours at room temperature and incubated with PECAM1 (1:50; catalog no. 
557355; BD Pharmingen) overnight at 4oC. Embryos were washed 5 times for 1 hour 
each with PBSMT and incubated with HRP-coupled anti-rat IgG (1:100; catalog no. 14-
16-12; KPL, Inc) overnight at 4oC. Embryos were again washed 5 times in PBSMT with 
a final wash in PBT.  Then embryos were incubated in developing solution (0.3 mg/ml 
DAB, 0.5% NiCl2 in PBT) for 20 minutes at room temperature followed by the addition 
of H2O2 at a 0.03% final concentration. Once the color developed (approximately 10 
minutes), the embryos were rinsed in PBT and then PBS and fixed overnight in 2% 
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paraformaldehyde/0.1% gluteraldehyde/PBS at 4oC. Embryos were then rinsed in PBS 
and either equilibrated into 70% glycerol for imaging or dehydrated in ethanol for 
paraffin embedding. 
2.7.2 Embryoid body immunochemistry 
 EBs embedded in collagen were allowed to differentiate for 6 days in the 
appropriate media and then removed using a Pasteur pipette and treated in the same 
manner as the yolk sacs for immunochemical staining.   
2.8 Immunofluorescence  
2.8.1 Yolk sac immunofluorescence 
 Embryos were dissected at E9.5 in PBS. The uterus and decidua were carefully 
removed and discarded. The yolk sac was separated from the embryo by severing the 
vitelline arteries and the embryo was used for genotyping. The yolk sacs were collected 
in separate wells of a 24 well plate and then fixed in 1 ml of 3% paraformaldehyde/PBS 
for 15 minutes on ice. Then the yolk sacs were permeabilized in 1 m of PBS containing 
0.02% Triton X-100 for 30 minutes. Yolk sacs were transferred to separate 1.5 ml 
Eppendorf tubes containing 500 µl of blocking solution (5% donkey serum in PBS) for 2 
hours at room temperature. Blocking solution was changed once at 1 hour. Yolk sacs 
were then incubated with PECAM1 (1:33; catolog no. 557355, BD Pharmingen) 
overnight at 4oC. Embryos were washed 5 times for 1 hour each with blocking solution 
and incubated with FITC-conjugated AffiniPure Anti-Rat IgG (1:75; catalog no. 712-
095-153, Jackson ImmunoResearch Laboratories, Inc) overnight at 4oC. Embryos were 
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again washed 5 times in blocking solution with a final 20-minute wash in PBS. The yolk 
sacs were transferred via Pasteur pipette to a drop of SlowFade Gold antifade reagent 
(Invitrogen) on a glass slide and covered with a cover slip. 
2.8.2 Fluorescence histology 
 Embryos were prepared following the above protocol for histology.  Tissues were 
deparrafinized via the following:  
1. Incubate slides in xylene for 10 min 
2. Repeat 10 min xylene incubation 
3. Incubate in each of the following for 2 min: 
a. 100% EtOH 
b. 100% EtOH 
c. 75% EtOH 
d. 50% EtOH 
e. 25% EtOH 
f. cold tap water 
Antigen retrieval was performed on appropriate sections by immersing the slides 
in 10 mM calcium citrate for 20 minutes in a steam chamber.  Sections were washed first 
with water and then 2 times with PBS.  Sections were then blocked with blocking 
solution for 2 hours at room temperature.  Sections were stained with α-smooth muscle 
actin (1:250 dilution; catalog no. A2547; Sigma-Aldrich, Inc), CD34 (no antigen retrieval 
step) (1:75; catalog no. 553731; BD Pharmingen), or GFP (1:100; catalog no. NB100-
1770; Novus Biologicals) for 1 hour or overnight at 4°C.  Sections were washed 3 times 
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with blocking solution and then stained with Alexa Fluor 546 goat anti-mouse IgG 
(1:250; catalog no. A11003; Invitrogen), FITC-conjugated AffiniPure Anti-Rat IgG 
(1:75; catolog no. 712-095-153; Jackson ImmunoResearch Laboratories, Inc), and Alexa 
Fluor 546 donkey anti-goat IgG (1:250; catalog no. A11056; Invitrogen) respectively for 
30 minutes at room temperature in the dark.  Sections were again washed 3 times with 
blocking solution.  A small amount of ProLong Gold antifade reagent with DAPI 
(Invitrogen) was applied and the samples were covered with a cover slip, allowed to set, 
and imaged.  Slides were stored at 4°C. 
2.8.3 Embryoid body immunofluorescence 
 EBs embedded in collagen were allowed to differentiate for 6 days in the 
appropriate media and then removed using a Pasteur pipette and treated in the same 
manner as the yolk sacs for immunofluorescence staining with CD34 (1:50; catalog no. 
553731; BD Pharmingen) and FITC-conjugated AffiniPure Anti-Rat IgG (1:75; catalog 
no. 712-095-153; Jackson ImmunoResearch Laboratories, Inc). The EBs were transferred 
to a grease lined glass slide, covered with a cover slip and imaged. 
2.8.4 Endothelial cell immunofluorescence 
 For immunofluorescence, differentiated endothelial cells were plated on Type I 
collagen chamber slides at a concentration of 5 x 104 and incubated for 24 hours.  The 
cells were then treated in the same manner as the yolk sacs for immunofluorescence 
staining with CD34 (1:20; catalog no. 553731; BD Pharmingen) and FITC-conjugated 
AffiniPure Anti-Rat IgG (1:75; catalog no. 712-095-153; Jackson ImmunoResearch 
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Laboratories, Inc).  Chambers were carefully removed, slides were grease-lined and cells 
were covered with a cover slip and imaged.  
2.9 X-gal staining 
 Untreated whole-mount E8.5 embryos with surrounding yolk sac and adult organs 
and tissues were fixed on ice for 10 min and 30 min respectively in the following solution 
per established procedures (Venuti et al. 1995): 
 25% glutaraldehyde    80 µl 
 10% paraformaldehyde in 1X PBS  2 ml 
 10X PBS pH 7.4    800 µl 
 water      7.1 ml 
 The samples were then washed 3 times in 1X PBS pH 7.4 and stained overnight at 
37°C in the following solution: 
 K ferricyanide 50mM    1.0 ml 
 K ferrocyanide 50mM   1.0 ml 
 10X PBS     1.0 ml 
 1M MgCl2     20 µl 
 X-Gal in DMF (20mg/ml)   0.5 ml 
 water      6.5 ml 
 Solution was mixed well and filter sterilized (0.22 µM) prior to addition of 
samples.  Samples were rinsed in PBS and fixed overnight in 3.7% paraformaldehyde.  
The following day, the samples were again rinsed, imaged and stored in 70% EtOH for 
paraffin embedding.  
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2.10 Yolk sac endothelial cell purification 
2.10.1 Preparation of single yolk sac cell suspension  
 Embryonic day 9.5 embryos were obtained from timed matings. Yolk sacs were 
incubated in 0.1% collagenase (Stem Cell Technologies, Inc)/PBS/20% FBS at 37°C for 
30 minutes. The digested yolk sacs were aspirated through a 27 gauge needle. 
Genotyping was performed on DNA isolated from corresponding embryo tissues. 
2.10.2 Cell sorting with PECAM  
 Single cell suspensions from yolk sacs were incubated for 30 minutes at 4°C with 
anti-PECAM1 antibody conjugated to PE Cy-7 (eBioscience, Inc.). The PECAM1+ cells 
were isolated by cell sorting using a BD FACSAria™ cell sorter (BD Biosciences, USA). 
Sorted cells were prepared for RNA isolation using the RNeasy mini kit (Qiagen) and 
genes were analyzed via real time PCR. 
2.11 Identification of TFBSs 
 The ECR browser (Ovcharenko et al. 2004) was used to determine the location of 
potential RBPJ binding sites.  The evolutionary conserved regions of the mouse, human, 
and rat were examined upstream and flanking the transcription start site of each gene for 
the presence of the RBPJ binding sequence (GTGGGAA) (Tun et al. 1994). 
2.12 Microscopy and image acquisition 
 Images were acquired with a Nikon SMZ800 dissecting microscope for whole 
embryos and a Nikon ECLIPSE 55i for embryonic sections using a Leica DFC480 
camera and Leica FireCam 3.0 software. Images for yolk sac and cell 
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immunofluorescence were acquired with an Olympus 1X71 microscope and Olympus 
DP71 camera using Olympus DP71 controller software. Adobe Photoshop CS2 was used 
for photograph editing. 
2.13 Statistical analysis 
 Data bars represent the means +/- standard error of the mean. RNA analyses of 
yolk sac tissues were performed with an n of 5. RNA analyses of differentiated ES cells 
were performed in triplicate. The statistical significance of the data was determined using 
a t-test with a p-value of < 0.05 considered statistically significant. 
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Chapter 3 
Notch signaling regulates remodeling and vessel diameter in the 
extraembryonic yolk sac 
3.1 Introduction 
 In mice, the vascular system, essential for nutrient and waste transport, initially 
forms in intraembryonic and extraembryonic regions. In the extraembryonic yolk sac at 
approximately embryonic day E7.0-7.5, angioblasts are formed from the differentiation 
of mesodermal cells. These angioblasts differentiate into endothelial cells, elaborate cell 
contacts, and lumenize into simple tubes; resulting in the formation of a capillary plexus 
network (Risau and Flamme 1995; Drake and Fleming 2000). The simple plexus of the 
yolk sac is remodeled and refined after E8.5 to form the larger diameter vessels. During 
this process, extensive movements of endothelial cells within the plexus occur through a 
process termed intussusceptive arborization (Djonov et al. 2000), reallocating cells from 
the capillaries to larger vessels, to assemble a more complex vasculature network (Risau 
1997; Patan 2000). This process forms the vitelline arteriole and venule, which 
participate in the contiguous blood flow with the embryonic vasculature, concomitant 
with the initiation of flow after E9.0 (Patan 2000, Ji et al. 2003).  More work needs to be 
done to define the shared and distinct regulatory paths that control vascular 
differentiation in the various sites of development and in the adult. 
Both vasculogenic and angiogenic processes are highly regulative, and under the 
control of a number of signaling pathways, including the vascular endothelial growth 
factor (VEGF) pathway, the Notch pathway, and the transforming growth factor-β 
(TGFβ) pathway, among others (Tallquist et al. 1999; Carmeliet 2000; Yancopoulos et al. 
2000; Krebs et al. 2000). The Notch signaling pathway is evolutionary conserved and a 
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determinant of cell fate (Artavanis-Tsakonas et al. 1999). The Notch receptors are 
activated upon ligand binding, which initiates the proteolysis of its intracellular domain 
(N-ICD). The N-ICD translocates to the nucleus where it interacts with a family of DNA-
binding proteins, termed recombination signal-binding protein for immunoglobulin kappa 
J region (RBPJ; also known as C-promoter binding factor 1, CBF1), forming a 
transcriptional activator complex at the regulatory elements of target genes, thereby 
directing changes in gene transcription (Mumm and Kopan 2000). 
Much work has been done to define the roles of the Notch signaling pathway 
during vascular differentiation. Notch1, Notch4, Dll4, Jagged1, and Jagged2 are all 
expressed in the arterial endothelium of vertebrates, Notch4 being solely expressed in the 
endothelia of mouse embryos (Uyttendaele et al. 1996; Villa et al. 2001). Mutations in 
Notch family receptors, ligands, and effectors lead to defects in the vasculature of the 
placenta, embryo and yolk sac, many of which are embryonic lethal (Swiatek et al. 1994; 
Krebs et al. 2000; Uyttendaele et al. 2001; Iso et al. 2003; Krebs et al. 2010).  Although 
Notch clearly plays important roles in the formation of the early embryonic vasculature, 
very little is known about the nature of the downstream targets in vivo, and how changes 
in Notch activity elicit the observed morphological processes. In vitro analysis has 
indicated novel Notch targets, including receptors of the VEGF family, FLT4 (VEGFR-
3) and FLT1 (VEGFR-1) (Shawber et al. 2007; Funahashi et al. 2010). Given that several 
signaling cascades are required for the morphological differentiation of the embryonic 
vasculature, it is likely that these pathways interact during vascular development. 
 To better define the activity of Notch signaling in vascular differentiation, a 
detailed morphological and molecular analysis was performed using developmental 
models in which the Notch signaling pathway is altered. A gain-of-function Notch1 
transgenic model showed that expanded Notch1 signaling in the early vasculature results 
in defects in embryo growth, defective differentiation during remodeling of the yolk sac 
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vasculature, altered patterns of gene expression, and ultimately embryonic lethality. 
These phenotypes were compared to embryos lacking Notch signaling in the endothelia, 
via a tissue-specific loss of RBPJ function. Embryos lacking endothelial Rbpj exhibited 
distinct growth, vascular, and gene expression defects compared to the Notch1 gain-of-
function model. Gene expression analysis in the yolk sacs of these models demonstrated 
altered patterns of expression of a distinct subset of Notch targets. Additionally, several 
secreted ligands, including the TGFβ ligand, TGFβ2 and the VEGF ligands, VEGFC and 
placental growth factor (PlGF), were altered in these models, suggesting a role for an 
altered VEGF signaling pathway in the observed phenotypes of these models. Our data 
suggest a model in which Notch signaling in the endothelia is critical for elaborating a 
specialized local environment of the developing arterial vasculature, by influencing the 
expression of secreted factors, which may be important in autocrine or paracrine 
signaling to direct further morphological differentiation of the vasculature during 
remodeling. 
3.2 Results 
3.2.1 Conditional transgenesis to modulate Notch signaling in the early 
endothelia 
 To further understand the functions of Notch signaling in early vascular 
development, genetic models were employed to modulate Notch activity in the 
embryonic endothelia. These models employ endothelial-specific Cre-mediated 
recombination in vivo. To activate and expand Notch1 signaling in the endothelia, a 
transgenic line RosaNotch (Murtaugh et al. 2003) was used, which harbors a NOTCH1 
intracellular domain (N1ICD) cDNA downstream of a floxed STOP fragment targeted to 
the Rosa26 locus. Removal of the STOP cassette through loxP-mediated recombination, 
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via an endothelial Cre expressing transgene, results in expression of N1ICD in 
endothelial cells (designated as EC-N1ICD embryos; Figure. 3.1A). To delete Notch 
signaling in the early endothelia, a mouse line was used which harbors a conditional 
allele of Rbpj (Rbpjf mice) (Tanigaki et al. 2002). Crossing these mice to an endothelial-
specific Cre transgenic mice results in the deletion of exons 6 and 7, which encode the 
DNA binding domain of Rbpj, abrogating the activity of RBPJ only in endothelial cells 
(designated as EC-Rbpj-KO embryos; Figure 3.1B). The conditional deletion would be 
predicted to disrupt both Notch1 and Notch4 signaling, which have known redundant 
functions in early embryonic vascular differentiation (Krebs et al. 2000). Ablation of 
Rbpj in the endothelia was used to assure a complete disruption of Notch signaling in the 
developing vasculature. 
Tie2-Cre (Koni et al. 2001) or Flk1-Cre (Motoike et al. 2003) transgenic mice 
were crossed to either RosaNotch or Rbpjf mice. Each of these transgenes expresses the Cre 
recombinase gene and directs expression principally to the vascular endothelium. 
Identical phenotypes were observed when the Flk1-Cre and Tie2-Cre transgenic lines 
were crossed to the RosaNotch and Rbpjf models (data not shown). Previous work has 
demonstrated that these Cre expressing transgenes exhibit restricted endothelial 
expression of Cre recombinase activity to the endothelial and hematopoietic lineages 
(Motoike et al. 2003). The early embryonic expression and recombinase activity of the 
Tie2-Cre and Flk1-Cre transgenes was confirmed by crossing of these transgenes to a 
conditional lacZ reporter (Soriano 1999). Both transgenes showed specific expression 
within the early endothelial and hematopoietic lineages at E8.5 (Figure 3.2). 
neo/STOP IRES nEGFP
polyA
Notch1-ICD
X CRE
loxPloxP
Rosa26 locus
IRES nEGFP polyANotch1-ICD
loxP
Rosa26 locus
A
5 76
X CRE
loxPloxP
Rbpjfl allele
RbpjC allele
8Neo
5
loxP
8
B
Figure 3.1. Conditional Mouse EC-N1ICD and EC-Rbpj-KO Transgene Constructs
(A) Upon crossing of mice that carry the RosaNotch transgene to a transgenic mouse that 
expresses CRE in the endothelia (Tie2-Cre), recombination removes the neomycin 
cassette and induces expression of the Notch1 intracellular domain only in endothelial 
cells. (B) Upon crossing of mice that carry the Rbpjf transgene to a transgenic mouse that 
expresses Cre in the endothelia, recombination will remove the neomycin cassette along 
with exons 6 and 7, which encode for the DNA binding domains of RBPJ, abrogating the 
promoter activity of RBPJ only in endothelial cells.
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Figure 3.2. Tie2-Cre and Flk1-Cre are Expressed in the Endothelia of the Early 
Embryo
(A-E) X-Gal staining of embryos from R26R cross with Tie2-Cre transgene.  (A-C) Whole 
mount E8.5 embryos. (D, E) Histological sections of E8.5 embryos. (F-I) X-Gal staining 
of embryos from R26R cross with Flk1-Cre transgene. (F) Whole mount E8.0 embryo 
with surrounding yolk sac. (G) Whole mount E8.5 embryo. (H) Yolk sac from a E8.5 
embryo. (I) Histological section of E8.5 embryo. Note expression in the endothelia of 
dorsal aorta (DA), heart (He), anterior cardinal vein (ACV), yolk sac (YS), allantois (Al), 
lateral plate (LP), and vitelline artery (VA).
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3.2.2 Regulated Notch signaling is essential for the growth and 
development of the early embryo 
 To activate Notch1 signaling throughout the embryonic endothelia, female mice 
heterozygous for the RosaNotch transgene were crossed with male mice hemizygous for the 
Tie2-Cre transgene, and the resulting embryos were analyzed. At E8.5 the EC-N1ICD 
mice were morphologically normal and identical to the wild type siblings (Figure 3.3) 
with open neural folds and a vascularized allantois characteristic of this time point. 
Compared to stage-matched wild type embryos at E9.5, EC-N1ICD embryos exhibited an 
enlarged heart and a reduction in overall size (Figure 3.4A-B). Growth defects were 
much more pronounced at E10.5 (data not shown), and no viable embryos were observed 
after E10.5. 
To ablate Notch signaling in the embryo, Tie2-Cre mice were used in a two- 
generation cross to generate Tie2-Cre; Rbpjf/f embryos (EC-Rbpj-KO), which lack RBPJ 
binding activity in the endothelia. The EC-Rbpj-KO embryos displayed severe growth 
retardation defects at E9.5 similar to those observed in the EC-N1ICD embryos (Figure 
3.4C). The morphological analysis of the gain-of-function and loss-of-function embryos 
were consistent with other models (Krebs et al. 2000; Uyttendaele et al. 2001; Krebs et al. 
2004; Krebs et al. 2010) and confirmed that the appropriate Notch signaling in the 
endothelia of the early embryo is critical for proper growth and development of the 
embryo. 
3.2.3 Vascular defects in EC-N1ICD and EC-Rbpj-KO embryos 
 A detailed comparison of the vasculature was performed to define the vascular 
defects in the embryonic and extraembryonic vasculature of EC-N1ICD and EC-Rbpj-
KO embryos. At E8.5, no overt defects were observed in the developing vasculature of 
either the EC-N1ICD or EC-Rbpj-KO. In particular, the vascular plexus of the EC-
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N1ICD yolk sac, visualized by histochemical staining of endothelial cells with an 
antibody to PECAM1 (CD31), appeared unaffected when compared to stage-matched 
wild type embryos (Figure 3.3; data not shown). The most severe defects were seen in the 
yolk sac of the developing embryo beginning at approximately E9.5. Gross 
morphological examination of the vasculature of the yolk sac by whole mount light 
microscopy showed that at E9.5 the EC-N1ICD yolk sac was the same size as the stage-
matched wild type control; however these embryos lacked large diameter vessels (Figure 
3.4D-E), indicating a failure in appropriate blood vessel remodeling occurring at this time 
point (Patan 2000). The EC-N1ICD yolk sac vessels did contain blood cells, although the 
blood tended to pool near the proximal end of the yolk sac adjacent to the chorioallantoic 
plate (Figure 3.4E). EC-Rbpj-KO embryos also lacked vascular remodeling in the yolk 
sac, failing to form the large vitelline blood vessels (Krebs et al. 2004; Figure 3.4F). 
Immunofluorescence of PECAM1 stained E9.5 yolk sac revealed the failure of 
this remodeling in both the EC-N1ICD and EC-Rbpj-KO embryos in greater detail. In the 
EC-N1ICD embryos, no distinction between large caliber vessels and capillaries was 
observed (Figure 3.4H); instead, the vasculature consisted of vessels with an enlarged 
surface area with greatly decreased avascular inter-vessel space compared to wild type 
controls, as assessed by lack of PECAM1 expression (‘pillars’; Figure 3.4G-H, arrows). 
In contrast to the EC-N1ICD vessel defects, the EC-Rbpj-KO embryos exhibited a 
qualitatively different vessel phenotype in the yolk sac. Although EC-Rbpj-KO embryos 
also exhibited a lack of vascular remodeling, the yolk sac of these embryos displayed 
numerous small avascular intervessel spaces (Figure 3.4I, arrow). These results indicated 
that the yolk sac vasculature of the EC-Rbpj-KO embryos failed to form the large 
vitelline blood vessels, reminiscent of the simple vascular plexus seen at E8.5. 
Histological sectioning of yolk sac tissue was performed to visualize the vessels 
in cross-section via PECAM1 immunochemistry and hematoxylin and eosin staining. In  
Figure 3.3. Embryonic Growth and Vascular Remodeling is Normal in Early EC-
N1ICD Embryos
(A, B) Whole mount E8.5 wild type (A) and EC-N1ICD littermate (B) embryos with 
surrounding yolk sac stained with an antibody to PECAM1. EC-N1ICD yolk sac vascula-
ture appeared normal. (C, D) Lateral view of E8.5 wild type embryo (C) and EC-N1ICD 
littermate (D) stained with an antibody to PECAM1. EC-N1ICD embryos appeared 
normal. Scale bars are 500 µm (A, B) and 250 µm (C, D).
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Figure 3.4. Defects in Growth and Yolk Sac Vasculature Remodeling in EC-N1ICD 
and EC-Rbpj-KO Embryos
(A-C) Lateral view of E9.5 wild type (A), EC-N1ICD (B), and EC-Rbpj-KO (C) embryos. 
EC-N1ICD and EC-Rbpj-KO embryos were smaller in size than the wild type and exhib-
ited cardiovascular defects. (D-F) Whole mount E9.5 wild type (D), EC-N1ICD (E), and 
EC-Rbpj-KO (F) embryos with surrounding yolk sac. The EC-N1ICD and EC-Rbpjk-KO 
yolk sac lacked the large, well-defined blood vessels seen in the wild type. The blood in 
the EC-N1ICD yolk sac collected near the attachment to the placenta. (G-I) Immunofluo-
rescence image of E9.5 wild type (G), EC-N1ICD (H) and EC-Rpbj-KO (I) yolk sac visu-
alized with an antibody to PECAM. Wild type embryos showed a remodeled yolk sac 
vasculature, with both large and small caliber vessels. The EC-N1ICD yolk sac did not 
exhibit branching; all vessels were of a large caliber. The EC-Rbpj-KO yolk sac also failed 
to show vascular remodeling, although all vessels were of a small caliber. Scale bars are 
500 µm (A-C), 1 mm (D-F) and 100 µm (G-I). Arrows (G-I), avascular inter-vessel space. 
Asterisk (G), capillary collapse. 
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the wild type yolk sac a distribution of large and small caliber vessels were present and 
were filled with blood cells; in striking contrast, the EC-N1ICD yolk sac contained 
primarily large caliber lumenized vessels that contained blood cells (Figure 3.5A-B). 
Both wild type and EC-N1ICD embryos had a range of yolk sac vessel diameter. 
However, in wild type yolk sac a majority of the vessels measured consisted of small 
capillaries, while in the EC-N1ICD yolk sac a larger proportion of vessels consisted of a 
larger cross-sectional area. In EC-N1ICD yolk sac, approximately 36% of vessels 
measured had an area of 16000µm2 or greater, while in wild type yolk sac only 5% 
measured this size (Figure 3.5E). This enlarged vessel phenotype in response to Notch 
activation was observed in other sites of the vessel differentiation in the developing 
embryo. The dorsal aortae (DA) of EC-N1ICD embryos were approximately twice the 
cross-sectional area of wild type embryos (Figure 3.5C-D, asterisks). The embryo-
derived vasculature of the placenta of EC-N1ICD embryos did invade into the labyrinth 
layer of the placenta (Figure 3.5G, arrowheads), but exhibited greatly enlarged vessel 
diameter (Figure 3.5G, arrows). The EC-Rbpj-KO embryos exhibited a decrease in vessel 
diameter, including the DA, and arteriovenous malformations (Krebs et al. 2004). EC-
Rbpj-KO embryo-derived vasculature of the placenta was also reduced in size and did not 
invade the labyrinth layer of the placenta (Figure 3.5H, arrow). Immunostaining of E9.5 
wild type and EC-N1ICD embryos using anti-SMA, indicated that the dorsal aortae of 
wild type are surrounded by smooth muscle cells, while the EC-N1ICD did not recruit 
any SMA-positive cells to the dorsal aorta (Venkatesh et al. 2008; Figure 3.5F-G). 
The morphological analyses of the models of altered Notch signaling were 
consistent with previous analysis of Notch function in the vasculature (Krebs et al. 2000; 
Uyttendaele et al. 2001; Krebs et al. 2004; Krebs et al. 2010). These results point to 
multiple roles for Notch signaling in the formation of both the intra- and extraembryonic 
vasculature, including the remodeling of the yolk sac vasculature, the regulation of vessel  
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Figure 3.5. Defects in Vessel Diameter in EC-N1ICD and EC-Rbpj-KO Embryos
Histological sections (lateral) of PECAM1 and NFR-stained E9.5 yolk sac (A-B) and 
embryos (C-D) at the level of the heart. The wild type yolk sac contained both large and 
small caliber vessels (A, arrowheads). The EC-N1ICD yolk sacs contained primarily large 
caliber vessels (B, arrowheads), however they were lumenized. The dorsal aortae of the 
EC-N1ICD embryos (D, asterisk) were approximately twice the area of wild type dorsal 
aortae (C, asterisk). (E) Distribution of vessel area in the yolk sac of wild type and EC-
N1ICD embryos. Both wild type and EC-N1ICD embryos had an array of differently 
sized vessels. However, wild type yolk sac had a majority of vessels with an area of 
0-4000μm2, while EC-N1ICD contained many vessels with an area of 30000μm2 or 
greater. (F-G) Histological sections of E9.5 dorsal aorta stained with an antibody to 
smooth muscle α-actin. The dorsal aortae of the wild type contain SMA-positive cells (F), 
while the EC-N1ICD dorsal aortae are SMA-negative. (H-J) Histological sections of the 
placental vasculature in wild type (H), EC-N1ICD (I), and EC-Rbpj-KO (J) embryos. 
Blood vessels containing nucleated erythrocytes in EC-N1ICD placenta (I, arrow) were of 
larger caliber than blood vessels in wild type placenta (H, arrow). In both, the fetal vascu-
lature invaded into the maternal portion of the placenta. The vessels of the EC-Rbpj-KO 
placenta (J, arrow) were small in size and had not invaded into the labyrinthine layer. 
Asterisk (H-J), maternal blood. Scale bars are 100 µm (A-D).
 62 
diameter, and the invasion of the embryo-derived vasculature into the labyrinth layer of 
the placenta. 
3.2.4 Identification of Notch regulated genes in EC-N1ICD yolk sacs 
and EC-Rbpj-KO yolk sacs 
 Gene expression defects in the Notch models were examined to determine 
potential molecular mechanisms of how altered Notch disrupts vascular differentiation, 
through altered expression of putative Notch targets. RNA from yolk sacs of E9.5 wild 
type, EC-N1ICD and EC-Rbpj-KO embryos (resulting from a cross with Tie2-Cre or 
Flk1-Cre mice) was isolated for gene expression analysis via microarray and 
semiquantitative RT-PCR. Whole genome microarray identified a large number of gene 
expression defects in these Notch models, many of which were confirmed with RT-PCR. 
To identify putative Notch targets, genes were categorized on the altered response in the 
gain-of-function and loss-of-function models (Figure 3.6). Only a relatively small set of 
genes displayed upregulation in the EC-N1ICD model and downregulation in the EC-
Rbpj-KO model, which would be suggestive of genes that are positively regulated by the 
Notch1-Rbpj axis. Interestingly, no genes were identified as being downregulated in the 
EC-N1ICD model and upregulated in EC-Rbpj-KO (Figure 3.6). 
The members of the Hairy/Enhancer of split-related (HES/HEY) family are well 
described Notch targets, many of which are directly regulated by Notch1 signaling via its 
binding to RBPJ (Maier and Gessler, 2000) to regulatory regions of these loci. The 
microarray datasets revealed that in yolk sacs of EC-N1ICD embryos, both Hey1 and 
Heyl were highly induced, and expression of these genes was reduced in the EC-Rbpj-
KO; these results were confirmed by semi-quantitative RT-PCR (Figure 3.7A). 
Expression of Hey1 and Heyl was increased 4.4-fold and 20.5-fold in the EC-N1ICD 
model respectively, and decreased to 35% and 46% of wild type levels in the EC-Rbpj- 
63
EC-N1ICD wt EC-Rbpj-KOEC-N1ICD wt EC-Rbpj-KO
F
F
F
EC-N1ICD wt EC-Rbpj-KO
Negative Regulation by 
Notch/Rbpj signaling
-none-
FFF
Not Regulated by 
Notch/Rbpj signaling
>99%
F
F
F
EC-N1ICD wt EC-Rbpj-KO
Possible Downregulation 
During Remodeling
Ch25h
Dhtkd1
Dkk1
Esm1
Ier3
Igfbp3
F
F
EC-N1ICD wt EC-Rbpj-KO
Positive Regulation by 
Notch/Rbpj signaling
F
F
F
F
EC-N1ICD wt EC-Rbpj-KO
Possible Upregulation 
During Remodeling
Adamts4
Calcrl
CalmI4
Ccdc57
Col13a1
CxcI7
Gja4
Klf2
Nudt4
Rnase4
Saa1
Tfrc
Zfpm1
F
FF
Ectopic Positive Regulation 
by Notch Signaling
Cdh6
Col8a1
Myl7
Wnt5a
F
EC-N1ICD wt EC-Rbpj-KO
F F
Positive Regulation by Rbpj
Do Not Require Notch Signaling
Cep164
efnb2
EphB4
Eva1
Fancm
Mixf
F
EC-N1ICD wt EC-Rbpj-KO
FF
Positive Regulation by Notch
Do Not Require Rbpj
Bmp2
Cd44
Cyr61
Fbn2
Flt1
Ifih1
Jun
Lhfp
Nrarp
Ntn4
Pgf
Tgfb2
Tm4sf1
Ankrd1
Apcdd1
Col14a1
Ctgf
Hey1
Heyl
Id4
Lmo1
Npr3
Sept4
Sfrp1
Sox11
TagIn
Tnfaip2
Vegfc
Vwf
Figure 3.6. Gene Expression in EC-N1ICD and EC-Rbpj-KO Yolk Sac Tissues
A graphical representation of possible outcomes of expression data and the corresponding 
genes that display this type of expression.
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KO yolk sac tissue, respectively. Interestingly, the expression of other HES family 
members, such as Hes1 and Hes6 was not affected in these Notch models (data not 
shown), consistent with a context-dependent regulation of Notch targets (Radtke and Raj 
2003; Bolos et al. 2007); i.e. Notch signaling invokes distinct downstream targets 
depending on both the cell type and the local environment. 
 The expression of the endogenous Notch ligands and receptors was also examined 
in detail. Previous work has suggested a potential autoregulatory loop for Notch signaling 
in the control of ligands and receptors (Ross and Kadesh 2004; Qian et al. 2009). 
Although expression of the Notch family receptors was not altered in either the EC-
N1ICD or EC-Rbpj-KO yolk sacs, the Notch ligands Delta-like 4 (Dll4) and Jagged 1 
(Jag1) showed higher expression in EC-N1ICD (2.5-fold and 2.0-fold, respectively) with 
little or no change in expression in EC-Rbpj-KO yolk sac. These findings point to 
specific Notch pathway targets in the extraembryonic yolk sac vasculature. 
3.2.5 Notch-Rbpj signaling regulates the vascular expression of key 
signaling molecules 
 Given the defects in vessel diameter and remodeling in response to altered Notch 
activity, we wished to focus on gene expression analysis of secreted factors. Genes 
encoding several known and putative secreted factors were differentially expressed in the 
Notch models (Table 3.1). Expression defects of a subset of these genes were confirmed 
via RT-PCR, with a focus on genes with putative roles in vascular differentiation and that 
display coordinate defects in expression in the EC-N1ICD and EC-Rbpj-KO models. 
Although the expression of some VEGF family members was not significantly different 
in yolk sac, the microarray datasets indicated that expression of the VEGF family 
members Vegfc, encoding VEGF-C, and Pgf, encoding placental growth factor (PlGF), 
were both increased in EC-N1ICD, and Vegfc was decreased in EC-Rbpj-KO (Table 3.1). 
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RT-PCR confirmed that Vegfc was upregulated 2.6-fold in the EC-N1ICD and decreased 
to 8% in the EC-Rbpj-KO compared to control yolk sac tissue; Pgf was upregulated 1.9-
fold in the EC-N1ICD and decreased to 74% in the EC-Rbpj-KO compared to control 
yolk sac tissue. The secreted cytokine Tgfb2 also exhibited increased expression in the 
yolk sacs of EC-N1ICD embryos (4.7-fold) and decreased expression in EC-Rbpj-KO 
(49% of wild type levels) (Figure 3.7B). 
 Given that the N1-ICD was activated specifically in the endothelia in this 
transgenic model, we wished to confirm that the gene expression defects in this model are 
confined to the endothelial lineage, to determine if the gene expression defects are 
intrinsic to the endothelium, or are associated with another cell type within the yolk sac. 
To these ends, gene expression of Notch regulated genes was examined in endothelial 
cells purified via flow cytometry. Via fluorescent activated cell sorting (Figure 3.8), 
N1ICD embryos (from a cross with Flk1-Cre mice) and RNA was isolated from the 
purified cells for gene expression analysis via real time PCR. To confirm the enrichment 
of sorted endothelial cells within the PECAM1+ population, expression of lineage 
markers were compared between RNA from purified PECAM1+ cells and from whole 
unsorted wild type yolk sac tissue. Endothelial specific genes such as Cdh5 (VE-
cadherin) and Pecam1 exhibited significant enrichment in PECAM1+ cells (5.7-fold and 
6.7-fold respectively). In contrast, the levels of the primitive visceral endodermal marker 
Rhox5 (Pem, Lin et al. 1994) were reduced to 10% in the sorted cells compared to whole 
wild type yolk sac tissue (Figure 3.9A), demonstrating a substantial reduction of visceral 
endoderm cells in the purified endothelial cells. These findings demonstrate a specific 
enrichment of yolk sac endothelial cells via flow sorting. 
 The Notch-responsive genes identified in the previous analysis of whole yolk sac 
tissues were then examined in the sorted yolk sac endothelial cells. The endothelial 
marker, Pecam1 exhibited statistically equivalent expression between the EC-N1CD and  
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Gene
Symbol
Gene Name Fold Change
EC-Rbpj-KO
Fold Change
EC-N1ICD
Bmp2
Col14a1
Col8a1
Ctgf
Cxcl12
Cyr61
Esm1
Flt1
Ier3
Igfbp3
Ntn4
Rdh5
Snn
Tgfb2
Vegfc
Vtn
Vwf
Wnt4
Wnt5a
Pgf
bone morphogenetic protein 2
collagen, type XIV, alpha 1
collagen, type VIII, alpha 1
connective tissue growth factor
chemokine (C-X-C motif) ligand 12
cysteine rich protein 61
endothelial cell-specific molecule 1
FMS-like tyrosine kinase 1
immediate early response 3
insulin-like growth factor binding protein 3
netrin 4
retinol dehydrogenase 5
stannin
transforming growth factor, beta 2
vascular endothelial growth factor C
vitronectin
Von Willebrand factor homolog
wingless-related MMTV integration site 4
wingless-related MMTV integration site 5A
placental growth factor
2.35
2.29
4.88
2.13
1.94
2.63
3.41
1.94
2.01
3.85
5.76
2.06
1.97
3.11
3.65
3.34
2.05
2.09
2.47
1.93
1.11
-1.96
1.07
1.18
1.29
1.66
3.51
1.07
2.10
4.05
1.39
1.39
1.63
1.32
-2.50
3.15
-3.33
2.45
-1.12
1.43
Adamts4
Cxcl4
Hhip
Oit3
Rnase4
Saa1
a disintegrin-like and metallopeptidase 
with thrombospondin type 1 motif, 4
chemokine (C-X-C motif) ligand 2
Hedgehog-interacting protein
oncoprotein induced transcript 3
ribonuclease, RNase A family 4
serum amyloid A1
-2.12
-4.22
-2.33
-3.70
-2.14
-2.39
Upregulated in EC-N1ICD
Downregulated in EC-N1ICD
Table 3.1. Microarray Expression of Genes Encoding Secreted Factors in 
EC-N1ICD and EC-Rbpj-KO Yolk Sac Tissues
-2.44
-1.11
-1.39
1.53
-2.04
-2.44
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Figure 3.8. Histograms Obtained from PECAM1-PE Cy7 Fluorescent Activated Cell 
Sorting
Representative histograms showing the distribution of dissociated yolk sac cells for the 
(A) isotype control and PECAM1 staining (B) wild type yolk sac and (C) EC-N1ICD yolk 
sac. The gating used to purify PECAM1 cells is indicated.
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wild type sorted cells, similar to that seen in whole yolk sac tissues (data not shown). 
However, expression of Hey1 and Heyl was increased 4.4-fold and 16.7-fold in the EC-
N1ICD sorted endothelial cells respectively. Similarly, the VEGF family members Vegfc 
and Pgf were upregulated 2.1-fold and 1.9-fold, respectively in sorted EC-N1ICD 
endothelial cells compared to wild type, while Tgfb2 was increased 6.9-fold (Figure 
3.9B). These results demonstrate that the expression of these genes is upregulated 
specifically in the endothelial lineages in EC-N1ICD yolk sac. Taken together, the gene 
expression defects demonstrate that Notch-Rbpj signaling acts to regulate many key 
genes specifically in the endothelia of the developing yolk sac. The misexpression of 
some of these factors may contribute to the vascular differentiation defects seen in the 
transgenic models. 
3.2.6 Putative Notch regulated genes contain potential RBPJ binding 
sites in the upstream regulatory region 
 The in vivo studies have identified a number of putative Notch regulated genes in 
the developing vasculature. Many of these genes are known Notch targets, including 
Hey1 and Heyl, with known RBPJ binding sites within regulatory elements (Maier and 
Gessler 2000). These studies however also identified altered expression of several genes, 
including Vegfc, Tgfβ2, and Pgf, for which their regulation by Notch signaling has not 
previously been described. Bioinformatic tools were used to determine if these genes are 
potentially direct targets of Notch signaling through RBPJ. Several RBPJ binding sites, 
with a core consensus binding sequence GTGGGAA (Tun et al. 1994), have been 
previously identified in known Notch targets such as the HES family members 
(Nishimura et al. 1998; Maier and Gessler 2000). The bioinformatic tool, ECR browser 
(Ovcharenko et al. 2004), was used to determine if canonical RBPJ binding sites were 
observed in the promoter proximal regions of loci encoding the secreted factors, Vegfc,  
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Figure 3.9. Gene Expression in Transgenic EC-N1ICD PECAM1+ Sorted Yolk Sac 
Tissues
Real time-PCR analysis was used to analyze gene expression differences seen in 
PECAM1+ sorted yolk sac cells. (A) Real time-PCR analysis of Cdh5, Pecam1 and Rhox5 
in wild type E9.5 whole yolk sac tissues and sorted yolk sac endothelial cells. (B) Real 
time-PCR analysis of select Notch responsive genes. * p< .05, ** p< .01, *** p< .001 
compared to wild type.
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Pgf, and Tgfb2. The mouse, human, and rat genomic sequences of each of the target 
genes were aligned and examined for the RBPJ conserved transcription factor binding 
sites (TFBS) within the evolutionary conserved regions (ECRs) upstream and 
downstream of the start site. In each of the genes a GTGGGAA consensus sequence was 
found, indicating a potential RBPJ sites (Figure 3.10). In Vegfc locus, an RBPJ binding 
site is apparent approximately 7.8kb upstream of the start site, while in Pgf locus harbors 
an RBPJ binding site 4.1kb upstream and one at 3.8kb downstream of the transcriptional 
start site. RBPJ sites were observed at approximately 2.5kb and 5.8kb upstream of the 
start site of the Tgfβ2 locus. The putative Notch binding sites in each gene suggests that 
these genes may be direct targets of Notch signaling. 
3.3 Discussion  
Numerous studies have indicated critical roles for Notch signaling in the proper 
formation and maintenance of the early vascular system in the mouse. However, the 
mechanisms by which Notch signaling regulates such diverse aspects of endothelial 
differentiation in its various contexts are active areas of research. Our analysis details the 
morphological and molecular defects associated with altered Notch signaling in vivo, 
with a focus on the extraembryonic vasculature of the yolk sac. This work has 
characterized distinct morphological defects in the early embryonic and extraembryonic 
vasculature associated with loss or gain of Notch activity. Substantial gene expression 
differences in these models point to putative Notch target genes, and suggest potential 
mechanisms by which Notch signaling directs endothelial cell differentiation.  
 Morphological analysis of both EC-N1ICD and EC-Rbpj-KO models confirmed 
that the regulation of Notch signaling is critical in the formation of the intra- and 
extraembryonic vasculature of the developing embryo. Detailed examination of the yolk 
sac vasculature, dorsal aortae, and fetal vasculature of the placenta revealed an enlarged  
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vessel phenotype in the EC-N1ICD, remarkably apparent within the yolk sac, in which 
the plexus is converted to a mass of large diameter vessels (Figure 3.11A). In contrast, 
small caliber non-remodeled vessels are present in the EC-Rbpj-KO yolk sac model 
(Figure 3.11A). Other Notch models have demonstrated malformations in vessel diameter 
resulting from altered Notch activity, including other models of activated Notch in vivo 
(Venkatesh et al. 2008; Krebs et al. 2010). Notch1 deficient mice (Swiatek et al. 1994), 
mice lacking Rbpj in the endothelia, and Dll4+/- embryos (Krebs et al. 2004) each exhibit 
collapsed dorsal aortae and a lack of vascular remodeling. In contrast, embryos 
overexpressing either Dll4 (Trindade et al. 2008) or Notch4 (Uyttendaele et al. 2001) 
have enlarged dorsal aorta. Data indicated that the enlargement of the dorsal aorta in mice 
overexpressing Dll4 was due not to a proliferation of endothelial cells, but to the 
improper migration of these cells (Krebs et al. 2004). These data point to an important 
role for Notch signaling to regulate vessel diameter. 
 The defects in vessel diameter and the remodeling failure in the Notch models 
used in this study indicate a possible defect in the reallocation of endothelial cells from 
capillaries into arterioles and suggest that Notch plays a significant role in this migration. 
The phenotype observed in the EC-N1ICD yolk sac vasculature is possibly due to 
increased mobilization and disorganized recruitment of capillary-derived endothelial 
cells, resulting in a field of enlarged vessels. Conversely the failure of the yolk sac 
remodeling in the EC-Rbpj-KO model is due to the abrogation of endothelial cell 
migration to form the larger caliber vessels. Live imaging of the behavior of endothelial 
yolk sac cells in the Notch models used in this study will be required to elaborate this 
model. 
 A detailed understanding of the downstream effectors of Notch signaling during 
vascular differentiation in vivo, particularly within the extraembryonic tissues, has been 
lacking. The molecular analysis of the Notch models presented here identified a variety 
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of gene expression defects associated with altered Notch activity. Both the gain- and loss-
of- function in vivo models suggest misregulation of a number of genes. Data indicated 
that two of the Notch family ligands, Dll4 and Jag1 were upregulated in EC-N1ICD yolk 
sac, indicating a possible positive feedback loop for Notch signaling to direct expression 
of its ligands. There is some precedence for a positive regulatory loop in which Notch 
regulates the expression of ligands, including Jag1 in NIH 3T3 cells (Ross and Kadesh 
2004) and Dll1 in glioma cells (Qian et al 2009). 
 Importantly, the gene expression analysis also identified a number of secreted 
factors whose expression within the endothelia is altered in the Notch models. These data 
suggest that the Notch signaling pathway regulates a number of secreted factors 
important in endothelial differentiation such as, Pgf, Vegfc, and Tgfβ2, either directly or 
indirectly. Targeted deletions of select TGFβ signaling components in mice result in the 
improper formation of the yolk sac vasculature, indicating the importance for TGFβ 
signaling in the formation of the early vascular system (Goumans and Mummery 2000). 
VEGF signaling has critical early roles in the formation of the blood vessels in the early 
embryo (Carmeliet et al. 1996; Ferrara and Davis-Smyth 1997). VEGF has also been 
shown to act as an upstream component of Notch in the signaling cascade directing the 
differentiation of the zebrafish vasculature (Lawson et al. 2002). PlGF has known roles in 
pathological angiogenesis (Carmeliet et al. 2001; Oura et al. 2003), and may act as a 
VEGF agonist by countering the effects of the VEGFA antagonist FLT1. In addition to 
the essential functions of VEGFC in the developmental origin of the lymphatic system 
(Karkkainen et al. 2004; Lohela et al. 2009), there is conflicting data to suggest it plays a 
broader role in angiogenesis. Although this factor has known angiogenic activities in 
certain assays (Cao et al. 1998), no vascular defects have been reported in mice lacking 
Vegfc (Karkkainen et al. 2004). The expression of VEGFC within the yolk sac however 
suggests a potential non-lymphatic function for this factor in this tissue. A putative role 
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for VEGFC in angiogenesis may involve the modulation of its receptors, KDR 
(VEGFR2) and FLT4 (VEGFR3), both of which play a critical role in early angiogenesis.  
Notch signaling is essential for vessel remodeling, as our data shows that Notch 
regulates the expression of a variety of secreted factors. Notch signaling may play 
potential nonautonomous roles in the remodeling of the yolk sac capillary plexus (Figure 
3.11B). Notch signaling is important for the regulation of select signaling molecules, 
including members of the VEGF family and TGF-β family, which would emanate from 
the developing arteriole where activity of Notch signaling is highest. These molecules 
then act in a paracrine and autocrine manner to elaborate the local arterial 
microenvironment about Notch expressing cells, which may potentially influence 
adjacent capillary endothelial cells, smooth muscle or mural cells, and hematopoietic 
cells. Indeed, nonautonomous functions for Notch signaling in the endothelium have been 
suggested, including attenuating proliferation of smooth muscle cells (Venkatesh et al. 
2008). Testing of the nonautonomous functions of Notch signaling in the vasculature will 
require determining the roles of Notch-regulated secreted factors in vivo. These 
experiments may include the use of conditional transgenics and knockouts of these 
factors in the endothelia, and determining remodeling and endothelial differentiation 
defects in these models. 
 The transcriptional network controlled by Notch signaling during extraembryonic 
endothelial differentiation is largely unknown. The present data demonstrate a role for 
Notch signaling in the regulation of a number of key genes in the embryonic vasculature 
of the yolk sac, including a variety of secreted factors important for endothelial 
differentiation. These downstream targets suggest a mechanism for Notch regulation of 
vessel diameter size during the remodeling process in the yolk sac vasculature. Further 
work on the in vivo models will help to further define the relationship between the  
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Figure 3.11. Notch Regulates the Expression of Key Genes and the Remodeling of the 
Yolk Sac Vasculature
(A) Proposed model depicts the Notch pathway as a key component in the regulation of 
the remodeling of the vasculature.  In wild type yolk sac Notch acts in concert with VEGF 
and other signaling families to direct the integration of the endothelial cells into both large 
and small caliber vessels.  When Notch is activated this integration is increased leading to 
very large caliber vessels with limited intra-vascular space.  When Notch activity is abro-
gated the integration is limited and the vasculature retains the simple unremodeled appear-
ance of the early vascular plexus. (B) Proposed model of signaling in the endodermal and 
endothelial cells of the early yolk sac.  Signaling from the endoderm and regulation from 
blood flow activates Notch signaling in select endothelial cells.  Notch activates the 
expression of select secreted genes that act in both a paracrine and juxtacrine manner to 
direct endothelial cell migration and integration within the developing vasculature. 
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transcriptional networks regulated by Notch to direct endothelial differentiation, and the 
role of these Notch downstream targets in endothelial migration and vascular remodeling. 
The understanding of these interaction and processes will aid in the development of 
treatments affecting vascular differentiation, including heart disease and tumor 
progression. 
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Chapter 4 
Development of an embryonic stem cell differentiation model for Notch 
functions in vascular development 
4.1 Introduction 
In mouse studies, both loss-of-function and gain-of-function of members of the 
Notch family lead to abnormalities in the vasculature and embryonic lethality (Swiatek et 
al. 1994; Krebs et al. 2000; Uyttendaele et al. 2001; Iso et al. 2003; Krebs et al. 2010). 
These and other data indicate a definite role for Notch signaling in the control of 
endothelial differentiation in the early embryo.  However, the downstream targets of this 
signaling systems and its interaction with other signaling families important for vascular 
remodeling remain largely undefined, particularly during early embryogenesis.  Previous 
work to define Notch downstream targets in cell culture models have identified VEGFR-
3 as a direct target of Notch in 3 human primary endothelial cell lines (Shawber et al. 
2007) and the induced expression of both VEGFR-1 transcripts and protein as a result of 
Notch activation (Funahashi et al. 2010).  Much work remains to establish the correct 
sequence of the signaling cascades involved in vascular differentiation.  
Mouse embryonic stem (ES) cells are derived from the inner cell mass (ICM) of 
E3.5 pre-implantation embryos.  ES cells are pluripotent, capable of dividing and 
remaining in an undifferentiated state for long periods of time, and can be induced to 
differentiate into specialized cells.  Mouse ES cells are amenable to extensive gene 
targeting, allowing for the development of numerous mutant mouse models (Niwa 2010).  
Human and mouse ES cell models have been used to study both Notch signaling and 
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endothelial differentiation in both in vivo and in vitro studies.  ES cell culture systems are 
a useful tool to study the morphological and molecular mechanisms behind ES cell 
differentiation.  ES cells are able to maintain pluripotency in cell culture studies and with 
modified culture conditions or genetic manipulation can be induced to differentiate into 
numerous cells types including neuronal, cardiac, and epithelial (Niwa 2007). Because 
mouse ES cell culture models mimic the pre- and post-implantation development of 
embryonic cells lineages, they are useful in recapitulating in vivo differentiation and for 
the study of the molecular mechanisms that underlie these processes.  
ES cell differentiation models have proven to be useful tools to understand 
endothelial differentiation, leveraging the capacity for genetic manipulation of the ES cell 
model, among other advantages (McCloskey et al. 2006; Ryolva et al. 2008).  Endothelial 
cells (ECs) can be derived through in vitro differentiation of ES cells via a variety of 
methods.  Firstly, via the aggregation of ES cells into embryoid bodies (EBs) by hanging 
drop culture that are then attached to a substratum resulting in a primitive vascular plexus 
similar to that seen in the early mouse yolk sac (Ryolva et al. 2008).  Secondly, mouse ES 
cells can be co-cultured with a layer of OP9 stromal cells in defined media that facilitates 
endothelial and hematopoietic differentiation.  This process limits the environment to two 
cell types instead of the multilineage composition of the EBs.  And thirdly, mouse ES 
cells can be plated on an acellular matrix and supplemented with defined media to 
promote ES cell growth and differentiation, completely limiting the influence from other 
cell types (Noghero et al. 2010). The ability to analyze genetic manipulation in the ES 
cell-derived ECs is proving to be an important tool.  These ECs express many of the same 
markers as in vivo and mimic mutant phenotypes seen in vivo.  Previous work has 
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utilized this model system to investigate the role of Flt-1 isoforms in vessel formation 
(Kappas et al. 2008). 
In this study mouse ES cells were used to study the Notch signaling pathway in 
vitro. A tetracycline-inducible Notch1-ICD transgenic ES cell line was generated to 
activate Notch signaling, while a gamma secretase inhibitor was used for the inhibition of 
Notch signaling.  Molecular analysis of the ES cell lines showed altered gene expression 
of a limited subset of Notch target genes similar to that seen in the in vivo models. These 
results help to expand the molecular hierarchy of Notch signaling in the endothelia, 
however modifications to the system need to be made to recapitulate results seen in the in 
vivo systems analyzed and discussed in chapters 3 and 5 to fully understand the role of 
Notch signaling. 
4.2 Results 
4.2.1 Design and generation of Ainv15-N1-ICD ES cells 
To further understand the role of Notch signaling during endothelial 
differentiation, a tetracycline-inducible Notch1-ICD transgenic ES cell line (Ainv15-N1-
ICD) was generated.  The ploxN1-ICD vector was made by digesting the EGFP gene, 
which acts as a stuffer fragment in PGK-lox-neoEGFP (Kyba et al. 2002), with XbaI and 
XhoI and inserting the XbaI-SalI Notch1-ICD fragment from pBS mNotchIC (Murtaugh 
et al, 2003) to generate ploxNotchICD.  A cell line, Ainv15 (Kyba et al. 2002), which 
consists of the reverse tetracycline transactivator (rtTA) targeted to the Rosa26 locus, and 
a doxycycline-inducible locus targeted to the Hprt locus, was targeted with PALP-
NotchICD and pSALK-Cre by co-electroporation (Figure 4.1A).   
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The resulting ES cell line, Ainv15-N1-ICD, was genotyped to confirm proper 
Cre-mediated integration.  The genotyping confirmed single-copy integration of the N1-
ICD cassette into the dox-inducible locus. The cell line displayed sensitivity to induction 
via dox-supplemented media compared to control (untreated cells). The cell line 
exhibited the expression of the Notch1-ICD in both a time and concentration dependent 
manner with expression 80-fold higher with a 1.0µg/mL dox concentration (Figure 4.1B-
C).   
Importantly, the upregulation of select target genes after dox treatment was seen 
via semi-quantitative RT-PCR, indicating that the Ainv15-N1-ICD ES cells mimic the in 
vivo transgenic models (Figure 4.2).  A whole genome microarray was performed to 
examine the gene defects imposed by the addition of dox, and subsequent activation of 
Notch signaling, in greater detail.  RNA isolated from Ainv15-N1-ICD ES cells treated 
with dox for 0hrs and 20hrs was compared.  Some Notch responsive genes, such as Hes5 
and Nrarp, showed greatly increased expression in dox treated Ainv15-N1-ICD cells, 
while others, including Hey1, Heyl, and Pgf, were either unchanged or not expressed 
(Table 4.1).  As undifferentiated ES cells, the Ainv15-N1-ICD construct is responding to 
treatment as expected and appears to upregulate some Notch target genes identified in 
EC-N1ICD embryos. 
A gamma secretase inhibitor (GSI), which inhibits the cleavage of the Notch-ICD, 
was also employed to inhibit Notch signaling in the ES cells. During Notch signaling, the 
Notch receptor is processed in three separate events.  The final event, following ligand 
binding is cleavage of the receptor within the transmembrane domain by a γ-secretase-
like protease, through to be the Presenilins, which releases the Notch-ICD.  The Notch- 
Figure 4.1. Generation of an Ainv15-N1-ICD ES Cell Line Specifying an Inducible 
Notch1-ICD Transgene
(A) Schematic representation of integrated expression cassettes. Co-electroporation and 
Cre-mediated recombination of the targeting vectors allows for the isolation of transgenic 
cells. The primers used for RT-PCR are indicated. (B) RT-PCR of an Ainv15-N1-ICD ES 
cell clone induced with doxycycline for 0, 4, and 20 hours and at different concentrations.  
The clones showed a strong induction of the N1-ICD at all time points and concentrations. 
(C) Quantitated relative mRNA levels of the concentration gradient. 
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Figure 4.2. Expression Analysis of undifferentiated Ainv15-N1-ICD ES Cells after 
Doxycycline Treatment
RNA was isolated from Ainv15-N1-ICD ES cells treated with dox for 0, 4, and 20 hours 
and RT-PCR was performed to analyze the expression of select markers.  The upregulation 
of sFlt1 and Nrarp at 20 hours is similar to that seen in EC-N1ICD yolk sac.
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ICD translocates to the nucleus where it activates transcription of target genes.  By 
employing a GSI, this cleavage step is inhibited abrogating the translocation of the NICD 
and the activation of downstream targets. 
4.2.2 Endothelial cells differentiated from Ainv15-N1-ICD ES cells 
Two protocols were established to generate endothelial cells from differentiating 
ES cells (Figure 4.3).  Both procedures generated endothelial cells from Ainv15-N1-ICD 
ES cells through the aggregation of the ES cells to form embryoid bodies (EBs) via 
hanging drops, in media lacking LIF and supplemented with a serum lot that enhances 
differentiation (EC media).  Real-time PCR of RNA isolated from EBs after four days of 
growth and from undifferentiated ES cells was performed to analyze the gene expression 
of select ES and endothelial cell markers (Figure 4.4A). The decreased expression of ES 
cell markers (Oct4 and Nanog) and the increased expression of endothelial markers (Flk1 
and Cdh5) indicates that cells within the EBs were trending toward an endothelial-like 
cell state.  The low expression of the endothelial marker CD34 indicates that they are 
more likely an early angioblast-like cell type.   
To differentiate the EBs to endothelial cells, after four days, EBs were collected 
and plated on a collagen Type IV-coated plate.  The growth factors VEGF and FGF2 
were added to the media (ECVF media) to promote endothelial cell differentiation for 4-6 
days.  Marker analysis over the course of this procedure demonstrated substantial 
endothelial differentiation that in many ways recapitulates embryonic development.  The 
decreased expression of Flk1 and the increase of CD34 and Dll4 in the differentiated cells 
compared to ES cells and EBs indicates the plated cells have differentiated into an  
Figure 4.3. Schematic of the Differentiation Process of Ainv15-N1-ICD ES Cells into 
Endothelial Cells
Ainv15-N1-ICD cells are grown feeder free for two passages. Embryoid bodies (EBs) are 
created by allowing cells to aggregate via the hanging drop method in media supple-
mented with serum specified for endothelial cells (EC media).  After growing for four 
days, the EBs are collected and plated on a collagen coated plate or they are embedded 
into collagen. The growth factors VEGF and FGF2 are added to the media at this stage to  
promote endothelial cell differentiation. Cells embedded on collagen are allowed to differ-
entiate to obtain an endothelial-like cell population.  
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endothelial-like cell (Figure 4.4B).  Fluorescence imaging of the collagen-plated EBs 
indicates a number of cells that express the endothelial cell marker CD34 (Figures 4.4C).   
A whole genome microarray was performed to examine the differences in gene 
expression in the differentiated endothelial cells in greater detail.  RNA isolated from 
undifferentiated Ainv15-N1-ICD ES cells and collagen-plated EBs was compared.  
Endothelial markers, such as CD34, Flk1, and Cdh5 exhibited greatly increased 
expression in the differentiated ES cells, while the ES cell markers Nanog and Dppa3 
were decreased (Table 4.2).  This demonstrates that the ES cells were differentiated to a 
variety of cell types, including an endothelial-like cell type.  These data indicate that with 
the addition of a specialized and supplemented media, endothelial-like cells can be 
generated and purified from differentiated mouse ES cells. 
4.2.3 Gene regulation in differentiated Ainv15-N1-ICD ES cells  
Gene expression analysis of the in vivo EC-N1ICD transgenic model has 
identified a set of genes with upregulated expression as a result of activated Notch 
signaling, most interestingly the secreted factors Vegfc, Tgfb2, and Pgf.  To test the 
hypothesis that genes regulated in the endothelia by Notch in vivo are also regulated by 
Notch in the differentiated Ainv15-N1-NICD cell line, collagen plated EBs were allowed 
to differentiate in ECVF media alone, ECVF +dox to activate Notch, or with ECVF +GSI 
to inhibit Notch signaling for 5 days.  RNA was isolated, in triplicate, from the cells and 
gene expression levels were examined in the cells by real-time PCR.  A few genes, 
including Heyl and Hey1 mimic the regulation seen in vivo, with an upregulation of the 
gene in response to dox treatment and a downregulation in response to GSI (Figure 4.5,  
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Figure 4.4. Expression Analysis of Ainv15-N1-ICD Embryoid Bodies and Differenti-
ated Cells
(A) RNA was isolated from embyroid bodies formed from Ainv15-N1-ICD ES cells 
grown in hanging drops in EC media for four days.  Oct4 and Nanog expression levels 
were decreased indicating that the embryoid bodies were losing the ES cell genotype.  The 
upregulation of Flk1 and Cdh5 and the low expression of CD34 indicated that the embry-
oid bodies were tending toward an early angioblast-like cell type. (B) Ainv15-N1-ICD ES 
cells were aggregated into EBs in hanging drops.  EBs were then collected and plated on 
collagen coated plates.  Plated EBs were grown in ECVF media and allowed to differenti-
ate for 5 days.  RNA was isolated and real-time PCR was performed to analyze the expres-
sion of select endothelial markers in differentiated cells compared to ES cells and EBs in 
hanging drops.  The increased expression of CD34 and Dll4 indicated the cells were trend-
ing toward a more endothelial-like cell type. (C) Fluorescence image of differentiated 
Ainv15-N1-ICD ES cells stained with an antibody to the endothelial marker CD34. Scale 
bars are 100µm (C).
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top row).  Other genes, including Dll4, Pgf, and Vegfc, do not appear to be regulated by 
Notch in vitro the same manner they were in vivo (Figure 4.5, bottom row). These data 
indicate that while endothelial cells can be generated from differentiated mouse ES cells 
with the addition of a specialized and supplemented media, gene expression of the 
differentiated cells shows that only a limited number of genes exhibit a similar regulation 
in vitro as they do in vivo, while many others do not.   
4.2.4 Collagen embedded embryoid bodies mimic sprouting 
angiogenesis 
Notch signaling has been shown to play an important role in the process of 
sprouting angiogenesis. Endothelial cells sprout from existing vessels in response to 
VEGF signaling. The leading, or tip, cell receives the signal from VEGF-A which 
activates the expression of Dll4.  This in turn signals through the Notch receptor in the 
base, or stalk, cell, which downregulates the expression of VEGF receptors.  Thus the tip 
cell is free to migrate in search of other sprouts while the stalk cell remains tethered to 
the pre-existing vessel (Siekmann et al. 2008).  In addition to plating on collagen, EBs 
picked from hanging drops after four days were embedded into a 3D microenvironment 
of collagen Type IV, suspending the EBs, and facilitating the formation of sprouts from 
the pre-existing vascular bed (Noghero et al. 2010).  
To study this process, embedded EBs were grown for 6 days in the presence of 
ECVF media.  A time course of embryoid body growth showed that the EBs quickly 
grew greatly in both size and in number of sprouts (Figure 4.6A).  Immunochemistry with 
an antibody to PECAM of an embedded EB at day 5 showed that many of the cells  
Figure 4.5. Expression Analysis of Select Genes  in Differentiated Ainv15-N1-ICD ES 
Cells as Analyzed by Real-time PCR
Collagen plated EBs were allowed to differentiate for 5 days in ECVF media supple-
mented with dox to activate Notch signaling or with GSI to inhibit Notch signaling.  Gene 
expression levels were examined in the cells by real-time PCR. * p < .05,  *** p < .001.
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associated with the sprouts were early endothelial cells (Figure 4.6B).  At day 6, CD34 
immunofluorescence indicated that the sprouts consisted of mature endothelial cells, 
primarily at the base of the sprout.  Cells at the tip of the sprout were likely an earlier 
endothelial-like cell type (Figure 4.6C-D).  To examine the effects of Notch signaling on 
the endothelial sprouts, EBs embedded in collagen were allowed to grow for 6 days in 
collagen supplemented with either ECVF media, ECVF + Dox, or ECVF +GSI.  Based 
on previous data documenting the role of Notch signaling in the formation of sprouts, a 
decrease in migrating tip cells was expected with activated Notch signaling and an 
increase in the number of sprouts was expected with Notch inhibition. These EBs were 
isolated and visualized by staining with an antibody to CD34. The endothelial outgrowth 
of the EBs formed a vascular plexus similar to that seen in the early embryo, however the 
treated EBs did not mimic results seen in the in vivo Notch gain and loss of function. 
Neither addition of Dox to activate Notch signaling, or GSI to inhibit Notch signaling had 
any visible effects on the formation of the endothelial sprouts (Figures 4.6E-G). 
As with the plated EBs, the in vitro model system of embedding the EBs in 
collagen will help to further understand the formation of the early vascular system and 
the process of sprouting angiogenesis.  However, like the plated EBs, the embedded EBs, 
do not exactly mimic the results seen in either of the models presented in Chapter 3 or in 
previously reported studies.   
4.3 Discussion 
Notch signaling has been studied extensively both in vitro and in vivo and has 
been shown to play an important role in the formation of the early vascular system.   
Figure 4.6. Collagen Embedded EBs Mimic Sprouting Angiogenesis but are Unre-
sponsive to Treatment
(A) Time course of embryoid body growth shows that the EBs quickly grew greatly in 
both size and number of sprouts. (B-D) At day 5, an immunochemical PECAM stain was 
done that showed that many of the cells associated with the sprouts were early endothelial 
cells (B).  At day 6, an immunofluorescence stain was done which showed that the sprouts 
are endothelial cells (C-D).  The fluorescent and light overlap image showed that the 
endothelial cells were matured near the base of the sprout and were either an earlier 
endothelial-like cell or a different cell type at the tip (D). (E-G) Fluorescence image of 
collagen embedded EBs stained with an antibody to the endothelial marker CD34.   EBs 
were grown in ECVF alone (E), ECVF supplemented with doxycycline (dox) (F), or 
ECVF supplemented with gamma secretase inhibitors (GSI) (G). Scale bars are 500 µm 
(A-C), 100 µm (D-G).
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Previous work in our lab has demonstrated that both the gain and loss of function of 
Notch signaling in vivo result in vascular differentiation and gene expression defects.  
Gene expression analysis of the in vivo transgenic model has identified a set of genes 
with upregulated expression as a result of activated Notch signaling, most interestingly 
the secreted factors Vegfc, Tgfβ2, and Pgf.  Our analysis employed an in vitro ES cell 
model system to examine whether or not the results seen in vivo were replicated in vitro 
and to further determine the mechanisms of Notch regulated gene expression in vascular 
endothelial cells.  Although some important similarities were noted, the in vitro ES cell 
systems of altered Notch signaling used here did not completely mimic the in vivo 
results.  Steps will need to be taken to modify the ES cells system to better reproduce an 
in vivo like environment. 
 ES cell differentiation models have proven to be useful tools to understand 
endothelial differentiation (McCloskey et al. 2006; Hermant et al. 2007; Ryolva et al. 
2008). The differentiated ES cells in our model, and in others, expressed endothelial 
markers seen in vivo, including CD31, CD34, PECAM, and VE-cadherin, (McCloskey et 
al. 2006; Ryolva et al. 2008) indicating the cells are differentiating from an ES cell to an 
endothelial-like cell population. In depth studies comparing ES cell derived endothelial 
cells to mature mouse aortic endothelial cells (MAEC) showed that while the in vitro 
differentiated cells express endothelial markers they are not as mature as the MAEC 
(McCloskey et al. 2006).  This finding may, in part, explain the differences between the 
in vivo and in vitro Notch models. 
Previous work analyzing genetic manipulations has shown that differentiated  
Flt1-/- mutant ES cells (Kearney et al. 2004) and differentiated ES cells lacking one or 
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both VEGF-A alleles (Bautch et al. 2000) display morphological defects similar to those 
seen in their in vivo counterparts. Although Notch regulation has been examined in 
human endothelial cell lines (Shawber et al. 2007; Funahashi et al. 2010), little has been 
done using mouse endothelial cells in vitro.  Additionally, an extensive genetic analysis 
of any transgenic differentiated ES cell models has yet to be done.  Our work focused on 
both the morphological and molecular analysis of a gain and loss of function Notch 
transgenic ES cell differentiation model.  
 The molecular analysis of differentiated ES cells in our studies indicated that 
some genes are regulated by Notch signaling in a similar manner as in vivo, including 
Hey1 and Heyl; other genes, including Vegfc, Tgfb2, and Pgf were not. The differences in 
Notch targets between the in vivo, ES cell differentiation, and the primary endothelial 
cell models suggest complex, highly regulated, and context-dependent functions for 
Notch signaling in endothelial differentiation.  Importantly, morphological analysis of the 
collagen embedded EBs showed that vessel diameter defects were not observed in the 
altered Notch signaling model, in striking contrast to the in vivo results. The vascular 
plexus formed from the differentiating embedded EBs was unaffected by the addition of 
either dox or GSI.  Modifications will have to be made to this system as well in order to 
fully understand these processes. 
Modifications of the differentiation protocol may help elaborate the basis of these 
differences. In the in vitro ES cell protocols used, the EBs and differentiated endothelial 
cells were grown in or on collagen in media supplemented with growth factors.  In vivo, 
endothelial cells neighbor, and are influenced by, primitive endoderm and are acted upon 
by the shear stress of blood flow. If a protocol was designed in which the EBs were 
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grown with endodermal cells and something to reproduce blood flow, this model system 
might better mimic the in vivo results. Because the EBs from which the ECs differentiate 
consist of many different lineages, purification of the ECs with an endothelial cell 
specific antibody via flow cytometry would also allow for a cleaner analysis of the gene 
expression differences within the EC lineage.  
As for the collagen embedded protocol to study sprouting angiogenesis, a recent 
study also examining the role of Notch signaling in sprouting angiogenesis did result in 
increased sprouting with the addition of the gamma-secretase inhibitor, DAPT.  In this 
model the EBs were grown and embedded following a protocol similar to ours, the only 
differences were in the length of time the embedded EBs were grown and the 
concentration of the γ-secretase inhibitor (Jakobsson et al. 2010).  Simple modifications 
such as these could be implemented in our model to better replicate previous results seen 
in vitro and in vivo. 
The ES cell differentiation model will prove to be useful for certain studies for 
which the early embryo is not amenable, including epigenetic changes associated with 
Notch activity.  It is currently unknown whether the affected genes in the in vivo Notch 
models are direct targets of Notch signaling through RBPJk. Chromatin 
Immunoprecipitation (ChIP) and luciferase assays could be utilized in the ES cell 
differentiation model to find genes that are directly regulated by Notch signaling through 
RBPJ and the chromatin changes associated with Notch activity.    
This in vitro model system, developed in our lab, is a useful tool for the 
differentiation of endothelial cells from ES cells.  It will aid in the determination of the 
mechanisms of Notch regulated gene expression in vascular endothelial cells in at least a 
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subset of the Notch regulated genes observed in vivo.  However, modifications to the 
system need to be made in order to utilize the in vitro model as a companion to the in 
vivo Notch models. With further modification to the system and additional assays this 
model system will further define the role of Notch in the formation of the vascular 
system, specifically the differentiation and migration of the early endothelial cells, and 
the relationship between the various signaling families important for vascular 
differentiation.   These findings will advance treatments for vascular abnormalities, 
including heart disease and cancer. 
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Chapter 5 
Overexpression of placental growth factor in the early embryo disrupts 
vascular differentiation 
5.1 Introduction 
The processes involved in the formation of the early vasculature are tightly 
regulated by a number of signaling cascades, including the angiopoietin/Tie receptor 
pathway, the Notch pathway, the transforming growth factor-β (TGF-β) pathway, and the 
vascular endothelial growth factor (VEGF) pathway, among others (Carmeliet 2000; 
Dumont et al. 1994; Krebs et al. 2000; Suri et al. 1996; Tallquist et al. 1999; 
Yancopoulos et al. 2000). VEGF has been shown to be an endothelial cell-specific 
mitogen, an inducer of angiogenesis, and a mediator of vascular permeability (Park et al. 
1994).  The VEGF family includes VEGF-A (VEGF), VEGF-B, VEGF-C, VEGF-D, and 
placental growth factor (PlGF).  VEGF binds to two transmembrane receptor tyrosine 
kinases, FLT1 (VEGFR-1) (Shibuya et al. 1990) and KDR (VEGFR-2, FLK1) (Quinn et 
al. 1993), both of which are expressed in the endothelia of the developing vessels.  FLT1 
also exists as a truncated, soluble form containing only the extracellular region (Kendall 
and Thomas 1993).  Although VEGF binds with higher affinity to FLT1, the angiogenic 
signal is thought to result from the binding of VEGF-A to KDR (Neufeld et al. 1999; 
Tjwa et al. 2003).   
The VEGF family homolog, PlGF, is also believed to be an inducer of 
angiogenesis.  PlGF binds with high affinity to FLT1 (Park et al. 1994).  PlGF is thought 
to stimulate vascular formation in two ways, by signaling through FLT1 (Neufeld et al. 
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1999) or by acting as a ‘decoy’; limiting VEGF-A binding to FLT1 thereby increasing the 
amount of VEGF-A available to activate KDR (Park et al. 1994).  Previous work has 
revealed a significant increase in the expression of Pgf in the yolk sac of embryos with an 
activated Notch1 intracellular domain (N1ICD) in the endothelia compared to wild type 
(Copeland et al. 2011).  Although PlGF has been shown to play a role in pathological 
angiogenesis in the adult (Carmeliet et al. 2001; Lutton et al. 2002 Odorisio et al. 2002; 
Oura et al. 2003), there has been little analysis of PlGF expression and activity in the 
early embryo.  It is still unclear what the role of PlGF is in the signaling pathways 
controlling vascular differentiation in the embryo, specifically how it interacts with the 
Notch pathway and what downstream genes PlGF affects to initiate cell specification. 
To better understand the activity of PlGF in the formation and remodeling of the 
early vascular system, a gain-of-function conditional PlGF transgenic mouse model was 
generated, and detailed morphological and molecular analyses were performed.  Embryos 
with activated Pgf in the endothelia displayed two distinct phenotypes, which have been 
classified moderate and severe.  Moderate embryos exhibited growth and cardiovascular 
defects, improper remodeling of the yolk sac, increased expression of key genes 
important in vascular differentiation, and subsequent embryonic lethality.  Severe 
embryos had extensive morphological defects and an even greater increase in gene 
expression than the moderate embryos.  Molecular analysis of the yolk sacs of moderate 
embryos indicated increased expression in Notch family members. Our data provides an 
in-depth analysis of PlGF signaling in the early embryo, its effects on vascular 
differentiation and the relative importance of Pgf overexpression in the activated N1ICD 
embryos.  Taken together the upregulation of Pgf expression by Notch signaling 
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(Copeland et al. 2011) and the subsequent upregulation of both Notch ligands and 
receptors by PlGF, indicates a possible feedback loop between the Notch and VEGF 
pathways in the regulation of vascular remodeling in the early embryo. 
5.2 Results 
5.2.1 Design and generation of a transgene to conditionally modulate 
the expression of placental growth factor in the endothelia 
 To expand expression of Pgf, a conditional transgene was generated.  Initially the 
Z/EG expression vector (Novak et al. 2000) was modified via the addition of AscI and 
PacI restriction sites between the BglII and XhoI sites of the Z/EG vector.  Using TOPO 
cloning an AscI site was added to the 5’ end and a PacI site to the 3’ end of the Pgf CDS.  
The Z/EG-Pgf construct was made by digesting the Z/EG vector with AscI and PacI and 
inserting the AscI-PacI Pgf CDS fragment.  The resulting vector was linearized with the 
StuI and ScaI restriction enzymes.  The resulting Z/EG-Pgf transgene contained a β-geo 
cassette flanked by loxP sites under the control of the β-actin promoter, followed by the 
Pgf cDNA and an EGFP cassette. Removal of the β-geo cassette and 3 polyA sequences 
through loxP-mediated recombination, via a CRE expressing transgene, results in the 
expression of Pgf and EGFP (Figure 5.1). The transgene was introduced into E14 
embryonic stem (ES) cells (in the 129P2 genetic background) via electroporation and 
clones that carried the transgene were selected through G418 resistance.  The G418-
resistant clones were screened for a high level of lacZ expression conferred by the β−geo 
fusion gene.  Additionally the clones were lysed for DNA and analyzed via PCR for the 
expression of the transgene.  As a final test, four clones displaying high levels of lacZ and  
Figure 5.1. Conditional Mouse Z/EG-Pgf Transgene Construct
The Z/EG-Pgf construct conists of a β-actin promoter directing expression of the loxP- 
flanked β-geo cassette and 3 polyA sequences which is upstream of the Pgf coding 
sequence, an EGFP coding sequene and a polyA sequence. Upon crossing mice that carry 
the Z/EG-Pgf transgene to a mouse that expresses Cre in the endothelia, recombination 
will remove the neomycin cassette and induce expression of Pgf.  Locations of the primer 
pairs used for genotyping are indicated. 
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genomic expression of the transgene were selected and further screened by karyotyping. 
The B1 clone was used to generate chimeric mice by injection into C57Bl/6 host 
blastocysts.  The resulting male chimeras were bred to wild type C57Bl/6 females, and 
the resulting pups were assessed for germline transmission of the ES cell-derived cells by 
coat color (agouti pups indicated germline transmission).  Agouti pups were genotyped to 
identify those that carried the transgene. The embryonic and adult expression pattern of 
this transgene has been characterized by staining embryos and Z/EG-Pgf adult male 
tissues with X-gal to visualize the level and location of lacZ expression. The results 
demonstrate that this transgene will provide appropriate spatial expression in the early 
embryonic endothelia and will be useful for many analyses in the adult (Figure 5.2).  
5.2.2 Regulated placental growth factor expression is essential for the 
growth and development of the early embryo  
 In studies overexpressing Notch1 in the endothelia, Pgf expression was increased 
approximately 2-fold, specifically in endothelial cells (Figures 3.7B and 3.8).  To 
examine the functions of PlGF activity in the early embryo, female mice heterozygous for 
the Z/EG-Pgf transgene were crossed with male mice hemizygous for the Tie2-Cre 
transgene (Koni et al. 2001), and the resulting embryos were analyzed.  In addition to 
normal wild type embryos, two mutant phenotypes were observed, termed Z/EG-Pgf 
moderate and severe.  The Z/EG-Pgf moderate embryos, when compared to stage-
matched wild type embryos at E9.5, exhibited a reduction in overall size and obvious 
developmental defects (Figure 5.3A-B).  Z/EG-Pgf severe embryos displayed extreme 
developmental defects; embryonic structures were indistinguishable (Figure 5.3C).  The  
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Figure 5.2. LacZ Expression in Embryonic and Adult Tissues in the Z/EG-Pgf Trans-
gene
(A-B) Embryo at E8.5. Note the expression in many tissues, specifically in the endothelial 
cells of the dorsal aorta (A, arrows) and yolk sac (B, arrow). (C) Placenta at E8.5. (D-I) 
lacZ expression in adult male tissues.  Note the expression in the esophagus (D), heart (E), 
testes (F), lung (G), and kidney (H).  No expression was seen in the liver (I). Scale bars are 
50 µm (A, B), 250 µm (C), 1mm (D-I), and 100 µm (D-I, inset).
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intact yolk sac of the moderate and severe embryos was comparable in size to the wild 
type, but had a wrinkled appearance and lacked any discernable blood vessels (Figure 
5.3E-F).  The morphological defects in the Z/EG-Pgf moderate embryos were similar to 
those seen EC-N1ICD embryos, indicating that this model will prove to be very useful to 
define the importance of Pgf overexpression in the phenotypes observed in the EC-
N1ICD embryos, and that the expression level of Pgf must be properly regulated. 
5.2.3 Expression of PlGF via GFP after CRE excision  
 As two distinct phenotypes are seen as a result of a cross with Tie2-Cre, PlGF 
expression in the early embryo and the placenta was localized via the expression of 
EGFP. Immunostaining of E9.5 wild type and Z/EG-Pgf moderate embryos using an anti-
GFP antibody indicated the expression of PlGF in the developing vasculature of the 
Z/EG-Pgf moderate embryo, including the dorsal aortae, cardinal veins, and the 
vasculature surrounding the head and heart (Figure 5.4B, arrows and arrowhead).  As 
expected, the wild type embryo was negative for GFP expression, aside from limited 
autofluorescence of the blood cells (Figure 5.4A).  Immunostaining was also performed 
in the placenta of E9.5 wild type and Z/EG-Pgf moderate and severe embryos using an 
anti-GFP antibody.  Again, the wild type was negative for EGFP expression, however the 
Z/EG-Pgf moderate embryos expressed GFP in the embryo-derived vasculature and very 
slightly in the trophoblast cells (Figure 5.4C-D, arrow).  The Z/EG-Pgf severe embryos 
exhibited a lack of embryo-derived vasculature and a great missexpression of GFP in the 
trophoblast cells of the placenta (Figure 5.4E).  Based on these results, the expression 
level of total Pgf (endogenous and transgenic Pgf) in wild type and Z/EG-Pgf moderate 
and severe yolk sac tissues was compared to the level in wild type placenta via real-time 
PCR. Pgf is normally expressed at low levels in the yolk sac.  The Z/EG-Pgf moderate  
Figure 5.3. Defects in Growth and Vascular Remodeling in Z/EG-Pgf Embryos.
(A-C) Lateral view of E9.5 wild type (A), Z/EG-Pgf moderate (B), and Z/EG-Pgf severe 
(C) embryos.  Z/EG-Pgf moderate embryos were smaller in size than the wild type and 
exhibited cardiovascular defects (B).  Z/EG-Pgf severe embryos displayed extreme 
cardiac distress; embryonic structures were indistinguishable (C).  (D-F) Whole mount 
E9.5 wild type (D), Z/EG-Pgf moderate (E), and Z/EG-Pgf severe (F) embryos with 
surrounding yolk sac.  The Z/EG-Pgf moderate and severe yolk sac were similar in size to 
the wild type, however they had a wrinkled appearance and lacked the large, well-defined 
blood vessels.  (G-I) Immunofluorescence image of E9.5 wild type (G), Z/EG-Pgf moder-
ate (H), and Z/EG-Pgf severe (I) yolk sac visualized with an antibody to PECAM1.  Wild 
type embryos showed a remodeled yolk sac vasculature, with both large and small caliber 
vessels.  The Z/EG-Pgf moderate yolk sac exhibited limited branching; many of the 
vessels were of similar size.  The Z/EG-Pgf severe yolk sac lacked any vascular remodel-
ing. Scale bars are 500µm (A-C), 1mm (D-F), and  200 µm (G-I).
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embryos expressed Pgf in the yolk sac at similar levels to those seen in wild type 
placenta, approximately 40-fold higher than in wild type yolk sac.  The Z/EG-Pgf severe 
embryos expressed Pgf at even higher levels (approximately 130-fold higher) (Figure 
5.4F). These results indicate acceptable levels of expression of Pgf in the vasculature of 
the Z/EG-Pgf moderate embryos, although not in the Z/EG-Pgf severe embryos.  As a 
result of these findings all remaining analyses were done using Z/EG-Pgf moderate 
embryos, except for the analyses of the placenta. 
5.2.4 Vascular defects in Z/EG-Pgf embryos 
 A detailed comparison of the vasculature was performed to define the vascular 
defects in the embryonic and extraembryonic vasculature of the Z/EG-Pgf moderate 
embryos.  Severe defects in the formation of the vasculature were seen in the yolk sac of 
the developing embryo beginning at approximately E9.5.  Immunofluorescence of 
PECAM1 stained E9.5 yolk sac allowed for the visualization of the defects in vascular 
remodeling in greater detail.  In the Z/EG-Pgf moderate embryos, the vasculature had 
begun to remodel into the large and small caliber vessels seen in the stage-matched wild 
type yolk sac, however there was limited branching; many of the vessels were of similar 
size (Figure 5.3G-H).  In contrast, the Z/EG-Pgf severe yolk sac lacked any vascular 
remodeling or any discernable lumenized vessels (Figure 5.3I). 
 Histological sectioning of embryonic and yolk sac tissues was performed to 
visualize the vasculature in cross-section via hematoxylin and eosin staining.  The dorsal 
aortae of the Z/EG-Pgf moderate embryos were approximately twice the cross-sectional 
area of wild type embryos, however they were functional, lumenized, blood-filled vessels 
(Figure 5.5A-B, asterisks).  This enlargement did not affect nearby vessels; the Z/EG-Pgf  
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Figure 5.4. Resulting PlGF Expression in the Early Embryo and Placenta after Tie2-
Cre Mice were Crossed with Z/EG-Pgf Mice
(A-D) Localization of PlGF via expression of GFP in the embryo at E9.5.  Note the 
expression of PlGF in the dorsal aorta, cardinal vein, and veins around the neural tube (B, 
D, arrows) and in the vasculature of the heart (B, arrowhead) of the Z/EG-Pgf moderate.  
The blood cells in both the wild type (A, C) and Z/EG-Pgf moderate (B, D) exhibit auto-
fluorescence. (E-G) Localization of PlGF via expression of GFP in placenta at E9.5.  Note 
the expression of GFP in the embryonic-derived vasculature of the placenta of the Z/EG-
Pgf moderate (F, arrow).  In the Z/EG-Pgf severe there is a lack of embryonic-derived 
vessels and the missexpression of PlGF in the trophoblast (G, brackets). (H) Real time-
PCR analysis of total Pgf expression (Z/EG-Pgf and endogenous Pgf) in wild type yolk 
sac, Z/EG-Pgf moderate and severe yolk sac, and wild type placenta at E9.5.  Pgf expres-
sion in the Z/EG-Pgf moderate yolk sac is comparable to that in wild type placenta. Scale 
bars are 200 µm (A, B), 100 µm (C, D) and 250 µm (E-G). * p < .05.
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moderate embryos contained lumenized cardinal veins (Figure 5.5B, arrow). In the wild 
type yolk sac a distribution of large and small caliber vessels were present and were filled 
with blood cells; in contrast, the Z/EG-Pgf moderate yolk sac contained primarily large 
caliber lumenized vessels that contained blood cells (Figure 5.5C-D, arrows and 
arrowheads). Both wild type and Z/EG-Pgf moderate embryos had a range of yolk sac 
vessel diameter.  However, in wild type yolk sac a greater number of the vessels 
measured consisted of small capillaries compared to Z/EG-Pgf moderate yolk sac in 
which a larger proportion of vessels consisted of a larger cross-sectional area. In Z/EG-
Pgf moderate yolk sac, approximately 24% of vessels measured had an area of 3000µm2 
or greater, while in wild type yolk sac only 2% measured this size.  Conversely, only 9% 
of vessels measured were smaller than 500µm2 in the Z/EG-Pgf moderate yolk sac, while 
in the wild type yolk sac this number was 49% (Figure 5.5E). 
5.2.5 Defects in embryo-derived vasculature and gene expression in 
Z/EG-Pgf transgenic placenta 
Upon examination of PlGF expression in the placenta, it was discovered that in 
the Z/EG-Pgf moderate placenta PlGF was expressed in the embryo-derived vasculature 
and to a small extent the trophoblast cells.  The Z/EG-Pgf severe placenta, however, did 
not have any embryo-derived vasculature and greatly expressed PlGF in the trophoblast 
cells.  To examine these results in greater detail histological sectioning of placental 
tissues was performed with H&E staining. In cross-section the embryo-derived 
vasculature of the placenta of Z/EG-Pgf embryos appeared normal and did invade into 
the labyrinth layer of the placenta, although to a lesser extent than in the wild type 
(Figure 5.6B, arrows and arrowheads). The Z/EG-Pgf severe placenta lacked any 
embryo-derived vasculature or nucleated erythrocytes (Figure 5.6C). To confirm these 
findings, immunostaining of E9.5 wild type, Z/EG-Pgf moderate and Z/EG-Pgf severe  
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Figure 5.5. Defects in Vessel Diameter in Z/EG-Pgf Embryos
(A-D) Histological sections (lateral) of H&E-stained E9.5 embryos (A, B) and yolk sac (C, 
D) at the level of the heart. The dorsal aortae of the Z/EG-Pgf embryos (B, asterisk) were 
approximately twice the area of wild type dorsal aortae (A, asterisk). Both contained 
lumenized cardinal veins (A, B, arrows).  The wild type yolk sac contained an array of 
different caliber vessels, some larger (A, arrows) and some quite small (A, arrowheads). 
The Z/EG-Pgf yolk sacs also contained large and small vessels, however there were 
primarily large caliber vessels (B, arrows). (E) Distribution of vessel area in the yolk sac of 
wild type and Z/EG-Pgf embryos. Both wild type and Z/EG-Pgf embryos had an array of 
differently sized vessels. However, wild type yolk sac had a greater number of vessels with 
an area of 0-500μm2, while Z/EG-Pgf contained more vessels with an area of 3000 μm2 or 
greater. Scale bars are 100 µm (A, B) and 50 µm (C, D).
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placenta was performed using anti-PECAM1 antibody to visualize the vasculature.  As 
expected, the embryo-derived vasculature of the wild type and Z/EG-Pgf moderate 
placenta was positive for PECAM1 staining, and still no vessels were seen in Z/EG-Pgf 
severe placentas (Figure 5.6D-F, arrows).  Interestingly, expression levels of PECAM1 
were elevated slightly in Z/EG-Pgf moderate trophoblast cells and to a greater extent in 
Z/EG-Pgf severe trophoblast cells (Figure 5.6E-F, brackets).  These results indicate 
multiple functions for PlGF activity in the early embryo, including the remodeling of the 
yolk sac vasculature, the regulation of vessel diameter, and formation of the embryo-
derived vasculature of the placenta and its invasion into the labyrinth layer. 
5.2.6 Overexpression of Pgf in the endothelia induces the expression of 
Notch signaling family members 
 Gene expression defects in Z/EG-Pgf moderate yolk sac were examined to 
determine a potential molecular mechanism of how altered PlGF affects vascular 
differentiation and how it interacts with the Notch signaling pathway.  Based on earlier 
results from Notch models, a subset of genes were analyzed in RNA from yolk sacs of 
E9.5 wild type and Z/EG-Pgf embryos via real-time PCR.  Of the genes examined only 
Notch family members and targets exhibited significant increased expression.  The 
endothelial expressed Notch ligands Notch1 and Notch4 were both upregulated in Z/EG-
Pgf moderate yolk sac (approximately 2-fold and 3-fold, respectively), as was the ligand 
Dll4 (approximately 2.5-fold). Interestingly, the Notch ligand Jag1 was unaffected (Table 
5.1). The well characterized members of the Hairy/Enhancer of split-related (HES/HEY) 
family, which are directly regulated by Notch1 signaling via its binding to RBPJ to 
regulatory regions of these loci (Maier and Gessler, 2000), also exhibited increased 
expression in Z/EG-Pgf moderate yolk sac. Real-time PCR revealed that expression of  
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Figure 5.6. Defects in Embryonic-Derived Vasculature and Gene Expression in 
Z/EG-Pgf Moderate and Severe Placentas
(A-C) Histological sections of E9.5 H&E-stained placenta in wild type (A), Z/EG-Pgf 
moderate (B), and Z/EG-Pgf severe (C) embryos. Blood vessels containing nucleated 
erythrocytes were present in wild type (A, arrow) and Z/EG-Pgf moderate placenta (B, 
arrow), and in both the fetal vasculature invaded into the maternal portion of the placenta 
(A, B arrowheads). The Z/EG-Pgf severe placenta (C) lacked any fetal vasculature or 
nucleated erythrocytes. (D-F) Histological sections of E9.5 placenta stained with an 
antibody to PECAM1. The fetal vessels of the wild type and Z/EG-Pgf moderate placenta 
contain PECAM1-positive cells (D, E, arrows), while fetal vessels were undistinguishable 
in Z/EG-Pgf severe placenta.  Expression of PECAM1 was increased slightly in Z/EG-Pgf 
trophoblast cells (E, bracket) and to a much greater degree in Z/EG-Pgf severe trophoblast 
cells (F, bracket). Asterisk (A-C), maternal blood. Scale bars are 100 µm (A-F).
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Hey1 and Heyl was increased 2-fold and 2.5-fold in the Z/EG-Pgf moderate yolk sac 
respectively (Figure 5.7).  The Notch regulated gene Nrarp (Krebs et al. 2001) was also 
upregulated, 1.98-fold in response to PlGF activation.  The expression of members of the 
VEGF family, the endothelial marker Cd34, and Tgfb2 was also examined (Table 5.1). 
Although the expression differences were slight for these genes, specifically Vegfa and 
Tgfb2, the proper level of expression is critical in the development of the embryo.  These 
results, specifically the upregulation of the Notch receptors and ligand, corroborate 
findings that VEGF signaling can act as an upstream component of Notch (Lawson et al. 
2002), and that PlGF plays an important role in this regulation. 
5.3 Discussion 
 The members of the VEGF signaling family have been shown to play specific and 
important roles in the formation of the early vasculature and lymphatic systems and in the 
regulation of pathological angiogenesis.  PlGF in particular has been shown to regulate 
pathological angiogenesis, vascularization, inflammation, and edema formation (Luttun 
et al. 2002; Odorisio et al. 2002; Oura et al. 2003).  To date all studies of PlGF activity 
have been performed in the adult, its role in the early embryo is still largely unknown.  
Previous work in our lab demonstrated that the gain-of-function of Notch signaling 
resulted in the increased gene expression of Pgf, specifically in the endothelia of the early 
embryo (Copeland et al. 2011). Our current analysis employed a similar conditional 
transgenic model to overexpress Pgf in the endothelia under the control of Tie2-Cre, 
allowing for the in depth analysis of PlGF activity in the early embryo.  Our analysis 
concentrated on the morphological and molecular abnormalities associated with this 
increased expression, specifically in the extraembryonic vasculature of the yolk sac and  
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Gene
Symbol
Gene Name Fold Change
Z/EG-Pgf
Jag1
Nrarp
Pgf (endogenous)
Vegfa
Vegfc
Flt1
Kdr
CD34
Tgfb2
jagged 1
Notch-regulated ankyrin repeat protein
placental growth factor
vascular endothelial growth factor A
vascular endothelial growth factor C
FMS-like tyrosine kinase 1
kinase insert domain protein receptor
CD34 antigen
transforming growth factor, beta 2
1.13
1.98 *
0.99
0.82 *
1.56
1.53
1.35
1.61 *
1.68 *
Table 5.1. Expression of Select Genes in Z/EG-Pgf Moderate Yolk Sac Tissues
* p < .05
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placenta.  Substantial defects in the formation of the vasculature in the embryo, yolk sac, 
and placenta were observed, mimicking some of the vascular defects seen in the gain-of-
function Notch model.  Gene expression defects were also seen as a result of increased 
PlGF expression, specifically in Notch family members.  This, taken with data from the 
gain-of-function Notch studies, indicates a potential regulatory loop between the Notch 
and VEGF signaling families to direct the formation and remodeling of the vasculature in 
the developing embryo.  
 Defects in the placenta, both morphological and molecular, were also observed in 
Z/EG-Pgf transgenic embryos.  In the developing placenta the fusion of the allantois to 
the chorion leads to the invasion of embryo-derived vessels into the trophoblast, while 
maternal vessels enter the placenta and are invaded by trophoblast cells. Maternal blood 
bathes the trophoblast cells facilitating the exchange of nutrients and waste with the 
embryo (Coultas et al. 2005; Huppertz and Peeters 2005). Mutations in many signaling 
pathways that have vascular abnormalities in the embryo also exhibit defects in placenta 
development, including the Notch pathway (Gasperowicz and Otto 2008). In our model, 
Z/EG-Pgf moderate embryos exhibited decreased invasion of embryo-derived vessels 
into the labyrinth zone and Z/EG-Pgf severe embryos lack embryo-derived vessels 
entirely, likely due to a failure of allantois-chorion fusion.  PlGF is endogenously 
expressed at its highest level in the trophoblast cells of the placenta, as well as endothelial 
cells (Park et al. 1994).  Our transgene exhibited increased expression of PlGF in the 
trophoblast cells, slightly in Z/EG-Pgf moderate placenta and to a greater extent in Z/EG-
Pgf severe placenta.  This increased expression and the resulting vascular abnormalities 
likely contribute to the morphological defects in the embryo and yolk sac, due to a failure 
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in the maternal-embryonic interaction in the placenta.  At approximately E8.5 the 
allantois makes contact with the chorion.  Blood vessels from the allantois grow into the 
labyrinth of the placenta.  There the embryo-derived vessels facilitate the exchange of 
materials and waste with the maternal blood system.  Cells of the placenta, such as the 
giant and spongiotrophoblast cells, also produce molecules, including VEGF and others, 
that are important for embryonic development.  A failure or defect in this formation leads 
to defects in the growth and development of the embryo. 
 Morphological analysis of Z/EG-Pgf transgenic mice further confirmed that 
VEGF signaling, specifically the regulation of PlGF expression levels, is critical for 
embryonic vascularization.  Similar to the EC-N1ICD model, resulting Z/EG-Pgf 
moderate embryos exhibited growth defects at E9.5 and early lethality, while Z/EG-Pgf 
severe embryos were grossly disfigured. Examination of the vasculature of the early 
embryo revealed abnormalities in the dorsal aortae, yolk sac vasculature, and embryonic-
derived vasculature of the placenta.  These defects were much more severe in the Z/EG-
Pgf severe embryos, which had no apparent remodeling in the yolk sac and no 
embryonic-derived vessels in the placenta, further confirming the need for proper 
regulation of PlGF expression.  Other VEGF models demonstrated defects in vessel 
formation in the early embryo from altered expression of VEGF family members. 
Mutation of Vegfa leads to a decrease in the size and caliber of the blood vessels 
(Carmeliet et al. 1996; Ferrara et al. 1995), Flt1 null mice form abnormal blood vessels 
(Fong et al. 1995) and mice overexpressing Pgf in the skin displayed an increase in blood 
vessel number, branching, and size (Odorisio et al. 2006).  These data stress the 
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importance for VEGF signaling in the formation of the early embryonic vasculature and 
subsequent development of the embryo. 
 Previous studies of Pgf knockout mice indicated that PlGF plays a limited role in 
the development of the vasculature of the early embryo and instead its activity is 
restricted to pathological angiogenesis in the adult (Carmeliet et al. 2001).  However, our 
studies and data from mice overexpressing Pgf in the skin indicates that while PlGF 
activity may not be critical for vascular development, it does act to stimulate it (Odorisio 
et al. 2002).  Likely the limited requirement for PlGF in the early embryo is due to its low 
expression levels, its lower affinity for FLT1, or the increase of VEGF-A as 
compensation (Carmeliet et al. 2001). PlGF may act in a number of ways in our model to 
stimulate vascular formation.  First, PlGF may act directly to activate FLT1, transmitting 
the angiogenic signals (Carmeliet et al. 2001).  Secondly, PlGF may form PlGF/VEGF 
heterodimers, which enhances the angiogenic response (Cao et al. 1996).  And finally, 
PlGF may displace VEGF-A from the FLT1 ‘sink’, making more VEGF-A available to 
signal through KDR (Park et al. 1994) (Figure 5.8A).  Further analysis of the Z/EG-Pgf 
model is needed to determine the correct function of PlGF activity in the early embryo.  
An extensive examination of the gene expression defects in the Z/EG-Pgf moderates 
could be done, via microarray, to identify novel genes regulated by PlGF activity.  
Comparing resulting data with the EC-N1ICD microarray data set could identify possible 
genes involved specifically in this model of Notch/VEGF interaction.  Analysis of the 
level of phosphorylation of the VEGF receptors, via Western blot or 
immunofluorescence, could help identify the function of PlGF in the VEGF signaling 
pathway during the regulation of vascular development. 
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 To further examine PlGFs activity in the early embryo a molecular analysis of the 
Z/EG-Pgf moderate embryo was performed. While no misregulation was apparent in 
many of the genes examined, including members of the VEGF family and Tgfb2, 
members of the Notch signaling pathway showed increased expression in the yolk sac of 
the Z/EG-Pgf moderate embryos.  These included the Notch receptors Notch1 and 
Notch2, the ligand Dll4, and the downstream target genes Hey1 and Heyl.  Interestingly 
the Notch ligand Jag1 was unaffected. It has been demonstrated that a complex hierarchy 
of signaling involving VEGF and Notch is required for the patterning of the vasculature 
in both the early embryo and the adult during neoangiogenesis.  Epistasis experiments in 
zebrafish indicated that Notch signaling is downstream of VEGF signaling in arterial 
specification (Lawson et al. 2002). In vitro it was shown that upregulation of VEGF-A 
can increase expression of Notch members in human arterial endothelial cells (Liu et al. 
2003). This interaction is also seen in the process of sprouting angiogenesis, where the 
interaction between the Notch and VEGF pathways regulates the formation of the 
endothelial sprouts (Siekmann et al. 2008).  This model is a perfect example of the 
feedback loop between Notch and VEGF signaling. Based on these previous studies and 
results from our molecular analysis, PlGF activity may act, in one way or another, to 
regulate Notch signaling in the remodeling of the yolk sac vascular plexus.  PlGF may 
regulate the Notch signaling pathway by displacing VEGF from the FLT1 receptor, 
increasing the amount of VEGF signaling through KDR.  This signaling then induces the 
expression of the Notch ligand Dll4, which interacts with a receptor on a neighboring 
endothelial cell thus activating the Notch signaling pathway and subsequently increasing 
the expression of the target genes Hey1 and Heyl (Figure 5.8B).  PlGF could also act, in a 
FLT-1
(VEGFR-1)
KDR
(VEGFR-2)
FLT-1
(VEGFR-1) KDR
(VEGFR-2)
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32
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X
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angiogenic
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Notch
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Figure 5.8. PlGF modulates the VEGF-response and regulates the expression of 
Notch family members
(A) Schematic model of the role of PlGF, VEGF-A, KDR, and FLT1 in the modulation of 
the angiogenic signal.  1. PlGF activates signaling through FLT1. 2. PlGF forms heterodi-
mers with VEGF to signaling through KDR. 3. PlGF displaces VEGF-A from FLT1, 
increasing its activity through KDR. (B) Proposed model of signaling in the endothelial 
cells of the early yolk sac.  PlGF signaling increases the expression of the Notch ligand 
Dll4 which binds to Notch receptors in adjacent cells.  Notch signaling is activated 
increasing the expression of the target genes, Hey1 and Heyl, among others.
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similar fashion, to increase the expression of the Notch receptors in the endothelial cells, 
also resulting in increased Notch signaling.  
 Interaction between the Notch and VEGF signaling pathways has been examined 
but the specifics are still largely unknown.  The Z/EG-Pgf model further demonstrates a 
role for PlGF in regulating vascular differentiation and in the regulation of Notch family 
members. Notch signaling in the endothelia is also important for vascular remodeling and 
embryonic development, as well as the regulation of key genes. Taken together the data 
expands on the idea of a complex hierarchy of signaling in the regulation of vascular 
differentiation in both the embryo and the adult.  Additional work in these in vivo models 
will help to further define the exact interaction between the pathways and how this 
interaction leads to proper formation of the vasculature. 
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Chapter 6 
General Discussion and Prospectus 
 In this dissertation I focus on the role of Notch signaling in the formation and 
remodeling of the vasculature in the early embryo.  Previous studies found that Notch 
family members are expressed in the endothelia of the early vessels (Uyttendaele et al. 
1996; Villa et al. 2001) and that mutations in Notch family ligands, receptors, and targets 
result in defects in the vasculature and embryonic lethality (Xue et al. 1999; Krebs et al. 
2000; Uyttendaele et al. 2001; Iso et al. 2003; Gale et al. 2004; Krebs et al. 2010). It had 
also been shown that the Notch signaling pathway interacts with the VEGF and TGFβ 
pathways to control this process (Lawson et al. 2002; Lobov et al. 2007; Holderfield and 
Hughes 2008).  However, an in depth analysis of the key genes involved in this complex 
hierarchy was lacking.  To study Notch function in vivo, I employed a gain-of-function 
conditional Notch transgenic system and a tissue-specific loss of RBPJ mutation.  Both 
models exhibited growth retardation and defects in the remodeling of the vasculature, 
particularly in the caliber of the vessels.  Gene expression analysis in the yolk sacs of 
these models indicated defects in a number of genes, specifically the secreted ligands 
Tgfb2, Vegfc and Pgf (Chapter 3).  Furthermore, I employed a doxycycline-inducible 
Notch1-ICD transgenic ES cell line and small molecule inhibitor γ-secretase to study the 
effects of Notch activation and inhibition in vitro.  Molecular analysis showed altered 
gene expression with results differing from results seen in vivo (Chapter 4).  To better 
understand the activity of placental growth factor in the formation of the vasculature and 
its relation to Notch signaling, a gain-of-function PlGF transgenic mouse model was 
generated.  Resulting embryos displayed two distinct phenotypes with defects in growth 
and vascular development and gene expression analysis indicated an increase in the 
expression of Notch family members (Chapter 5).  Taken together, the data help to 
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further define the role of both Notch and VEGF signaling in the regulation of vascular 
development in the early embryo.  Specifically, the in depth molecular analysis 
introduces novel gene and pathway interactions critical for this process. 
6.1 Insights into vascular remodeling 
 The EC-N1ICD, EC-Rbpj-KO, and Z/EG-Pgf models each exhibited defects in 
the formation of the vasculature.  Detailed examination of the yolk sac vasculature, 
dorsal aortae, and fetal vasculature of the placenta revealed an enlarged vessel phenotype 
in the EC-N1ICD, remarkably apparent within the yolk sac, in which the plexus is 
converted to a mass of large diameter vessels. In contrast, small caliber non-remodeled 
vessels are present in the EC-Rbpj-KO yolk sac model. Similar to the EC-N1ICD model, 
the vasculature in the Z/EG-Pgf moderate embryo revealed abnormalities in the dorsal 
aortae, yolk sac vasculature, and embryonic-derived vasculature of the placenta. The 
aortae and vessels of the yolk sac were enlarged.  These vascular defects were much more 
severe in the Z/EG-Pgf severe embryos, which had no apparent remodeling in the yolk 
sac and no embryonic-derived vessels in the placenta.  These data stress the importance 
for Notch and VEGF signaling in the formation and remodeling of the early embryonic 
vasculature. 
 Given that Notch signaling is associated with arterial identity (Uyttendaele et al. 
1996; Villa et al. 2001), the function of Notch signaling to control vessel size may 
represent an aspect of Notch function in the definition of the arteriole. The mechanisms 
of how the Notch, VEGF, and other signaling pathways control vessel size in the various 
regions of the developing embryo are not well defined, and are likely context dependent. 
Some models suggest that directional cell division is important to dictate whether 
endothelial cell proliferation within a patent vessel results in an increase in luminal 
diameter (Zeng et al. 2007). Other models suggest the recruitment of endothelial or 
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angioblast cells into existing vessels as an important mechanism to increase vessel 
diameter (Schmidt et al. 2007). The remodeling process of the yolk sac makes extensive 
use of reallocation of cells during remodeling (discussed below), suggesting complex 
roles for Notch signaling in controlling endothelial cell behavior during remodeling. 
 The yolk sac vasculature represents a genetically tractable model to study 
endothelial differentiation, and the work presented here has made extensive analysis of 
this tissue. Endothelial differentiation within the yolk sac is initiated as groups of cells 
from the proximally situated extraembryonic mesoderm condense into blood islands by 
approximately embryonic day 7.0, which subsequently migrate toward the distal region 
of the yolk sac. The peripheral cells will differentiate to the endothelial cells lining the 
vasculature, whereas the inner cells become blood cells. The endothelial cells expand and 
fuse to form the vascular plexus, which is contiguous with the embryonic vasculature at 
the onset of blood flow (Lucitti et al. 2007). The capillaries are then remodeled into the 
hierarchical vascular network of vitelline artery, capillaries, and vitelline vein. 
Observations of vessel remodeling in the yolk sac, particularly in the chick embryo, 
suggest that the formation of large diameter vessels is from pre-existing capillary-derived 
endothelial cells, via the process of intussusceptive angiogenesis.  This process is readily 
perceived by examination of the avascular space (‘pillars’), in which adjacent pillars 
‘fuse’ during this remodeling process.  This process involves the collapse of some 
capillary microvessels, and the endothelial cells from the capillary are then recruited into 
the nascent vessels to result in a larger diameter vessel (Figure 3.4G, asterisk).  This 
mode of remodeling has been suggested to be an efficient and rapid mode of angiogenesis 
in a variety of sites (Djonov et al. 2000). Although Notch signaling does play a 
significant role in sprouting angiogenesis (Siekmann et al. 2007) in many other contexts, 
the remodeling of the yolk sac in the early embryo may not utilize a sprouting 
angiogenesis method. Based on the current model of endothelial remodeling within the 
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yolk sac plexus, the defects in vessel diameter and the remodeling failure in the Notch 
models used in this study indicate a possible defect in the reallocation of endothelial cells 
from capillaries into arterioles during intussusceptive arborization, suggesting that Notch 
plays a significant role in this migration. The phenotype observed in the EC-N1ICD yolk 
sac vasculature is possibly due to the increased mobilization and disorganized 
recruitment of capillary-derived endothelial cells, resulting in a field of enlarged vessels. 
Conversely the failure of yolk sac remodeling in the EC-Rbpj-KO model is due to the 
abrogation of endothelial cell migration to form the larger caliber vessels.  Indeed, this 
early vascular remodeling is a rather distinct vascular mechanism that is not entirely clear 
and remains to be studied in detail. 
Yolk sac vessel remodeling occurs after the initiation of blood flow, which 
initiates at approximately E8.5 in the mouse (Lucitti et al. 2007), and this flow is essential 
for the remodeling process. It is formally possible that the enlarged luminal diameter of 
the dorsal aorta in the Notch gain-of-function model could give rise to a secondary failure 
of yolk sac remodeling solely due to reduced flow and associated shear stress. However, 
the vessel architecture reported in mouse models with remodeling defects solely due to 
altered blood flow (Lucitti et al. 2007) display very different phenotypes from those 
observed in the N1ICD model. This comparison suggests that the remodeling defects and 
some of the associated gene expression defects in the yolk sac in this Notch1 gain-of-
function model are not secondary to embryonic vessel defects or defects in blood flow. 
The cellular and subsequent molecular response to the shear stress associated with blood 
flow is not completely understood, but may involve complex cell surface signaling 
molecules including VEGFR2, PECAM1, and VE-cadherin (Tzima et al. 2005). Shear 
stress thus initiates a molecular cascade in endothelial cells to direct further 
morphological changes to direct remodeling. An important question is what is the link 
 127 
between blood flow and Notch signaling, both of which are essential for vessel 
remodeling. During remodeling, an arteriole rudiment is first observed at the site of yolk 
sac vasculature contact with the omphalomesentric artery. Early Dll4 expression is 
observed at this arteriole rudiment within the yolk sac (Duarte et al. 2004), indicating it is 
likely the Notch ligand that initiates Notch activity within this restricted region of the 
yolk sac vasculature. It remains to be seen the extent to which fluid dynamics control the 
expression of Notch signaling components and the subsequent remodeling process. 
6.2 Model of role of Notch and VEGF pathways in vascular remodeling 
 Based on data from this dissertation, I propose a model for the role of Notch-
VEGF signaling interactions in the regulation of the development of the vasculature, 
specifically in the remodeling of the vessels in to the large and small caliber vessels via 
the reallocation of endothelial cells.  In the developing yolk sac endothelial cells are acted 
upon by factors from the adjacent endoderm and flow-induced shear stress.  These in turn 
induce activation of the Notch signaling pathway in the endothelial cells.  In particular, in 
my model, VEGF from the endoderm signals through its receptor, KDR, under the 
regulation of the secreted factor PlGF. This in turn induces the expression of the notch 
receptor, which translocates to the cell surface.  Interaction between the Notch receptor 
and a Notch ligand on an adjacent endothelial cell is important for the regulation of select 
secreted factors, including Tgfb2, Vegfc, and Pgf among others.  These molecules then act 
in a paracrine and autocrine manner to elaborate the local arterial microenvironment 
about the cell, including adjacent endothelial cells, smooth muscle cells and 
hematopoietic cells.  Specifically PlGF acts to regulate VEGF signaling through KDR, 
which then activates Notch signaling by inducing the expression of both Notch ligands 
and receptors indicating a positive regulatory loop between the Notch and VEGF 
pathways in vascular development.  This interaction directs endothelial cell migration and 
integration within the developing vasculature (Figure 6.1).   
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Figure 6.1. Model of Role of Notch and VEGF Pathways in Vascular Remodeling 
Proposed model of signaling in the endodermal and endothelial cells of the early yolk sac.  
Signaling from the endoderm and regulation from blood flow activates Notch signaling in 
select endothelial cells.  Notch activates the expression of secreted molecules, including 
PlGF, TGFβ2, and VEGFC, that in turn act in both a paracrine and juxtacrine manner to 
activate the Notch signaling pathway directing endothelial cell migration and integration 
within the developing vasculature. 
cell
protrusion
and interaction
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6.2.1 Implications of model 
 6.2.1.1 Notch/VEGF interaction in embryonic vascular development 
 The data in this dissertation implicate Notch-VEGF signaling interactions as a key 
component in the regulation of vascular development.  Previous work revealed genetic 
interaction between these pathways during arterial endothelial cell differentiation and 
sprouting angiogenesis (Siekmann et al. 2008).  Non-endothelial cell studies indicate 
PTEN as a direct Notch target, resulting in the promotion of VEGF signaling through the 
MAPK pathway leading to arterial differentiation (Whelan et al. 2007).   In mouse 
studies, Notch and VEGF interact to modulate endothelial cell identity during sprouting 
angiogenesis (Lobov et al. 2007).  Recent in vitro studies indicate that Notch may 
function in these processes by directly regulating the expression of the VEGF receptors 
(Harrington et al. 2007; Taylor et al. 2002; Shawber et al. 2007).  Gene expression 
analysis of the gain- and loss-of-function Notch models and the Z/EG-Pgf model showed 
only a little change in the expression of the VEGF receptors; aside from FLT1, which is 
increased approximately 2 fold in EC-N1ICD yolk sac (Table 3.1).  Instead, Notch 
appears to regulate VEGF signaling through the regulation of ligand expression, namely 
PlGF and VEGFC, which in turn could increase the angiogenic signal through VEGF.  
VEGF signaling then acts to regulate expression of Notch ligands and receptors, forming 
a feedback loop between the two pathways similar to that seen in tumor angiogenesis. 
 It is hypothesized that in the early embryo, particularly in the yolk sac, the 
remodeling of the early vascular plexus occurs through the process of intussusceptive 
angiogenesis.  As reviewed in Chapter 1, this process occurs via the insertion of ‘pillars’, 
which form from the protrusion, interaction, and perforation of endothelial cells from 
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opposing walls of a capillary.  Data show that Notch signaling can regulate the 
expression of secreted factors that can then act to influence adjacent cells.  Specifically, 
during the process of intussusceptive angiogenesis, Notch on one endothelial cell could 
act in both a paracrine and autocrine manner, via the secretion of VEGF and TGFβ 
molecules, to induce migration of itself and an endothelial cell on the opposing capillary 
wall, thus creating a ‘pillar’.  Overexpression of Notch, as in the gain-of-function model, 
increases the level of these secreted genes and in ‘pillar’ formation, resulting in a 
decrease in capillaries and vessel enlargement.  A decrease in Notch signaling, like that in 
the loss-of-function model, results in a decrease of ‘pillar’ formation.  The resulting 
vasculature is not remodeled and retains the immature polygon-shaped plexus. 
6.2.1.2 Notch/VEGF interaction in pathological angiogenesis 
As stated previously, Notch and VEGF signaling both play a role in the regulation 
of vascular formation in pathological conditions. Mutations in the Notch3 gene lead to 
cerebral autosomal dominant arteriopathy with subcortical infarct and 
leukoencephalopathy (CADASIL) (Tang et al. 2009). Mutations in Jag1 or in Notch2 
lead to Alagille Syndrome (AGS) (Kamath et al. 2004; Niessen and Karsan 2007).  
VEGF-A induces vascular permeability via activation of KDR and subsequent signaling 
involving Src-kinases (Eliceiri et al. 1999). PlGF has been shown to stimulate vascular 
leakage, likely by attenuating the response to VEGF-A (Park et al. 1994; Luttun et al. 
2002). PlGF has also been shown to regulate inflammation and edema formation in adult 
mice (Oura et al. 2003). 
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Notch signaling and VEGF are both important for tumor angiogenesis, where they 
have been shown to interact.  The ligand Dll4 is strongly expressed in tumor vessels 
(Mailhos et al. 2001).  VEGF-A and KDR are inducers of tumor angiogenesis (Kim et al. 
1993; Carmeliet et al. 2001).  PlGF is upregulated during tumor angiogenesis enhancing 
the angiogenic activity of VEGF-A (Carmeliet et al. 2001).  In Pgf-deficient mice, tumor 
angiogenesis and growth are reduced (Carmeliet et al. 2001), while mice overexpressing 
Pgf in the skin exhibit increased melanoma growth (Marcellini et al. 2006). In tumors 
VEGF-A induces Dll4 expression in sprouting endothelial cells, which in turn signals 
through Notch repressing the activation of VEGF receptors acting as a negative regulator 
of growth.  Inhibition of Dll4/Notch signaling resulted in increased vessel density, but 
decreased vessel function (Noguera-Troise et al. 2006).  
In the Notch1 gain-of-function model, the VEGF genes, Vegfc and Pgf were 
upregulated; while in the PlGF gain-of-function model the Notch genes, Notch1, Notch4, 
and Dll4 had increased expression.  These data further support the interaction between 
the Notch and VEGF signaling pathways observed in the regulation of tumor 
angiogenesis.  However, in sprouting angiogenesis Notch acts to inhibit VEGF signaling 
by regulating VEGF receptors in the stalk cells, while in the proposed model Notch 
stimulates VEGF signaling through regulated expression of the VEGF ligands.  This 
difference highlights contrasting roles for Notch in the regulation of vessel remodeling in 
the early embryonic yolk sac and sprouting angiogenesis in the adult and tumors.  Further 
examination of these processes and development of therapies to regulate this interaction 
in tumor formation could be a successful treatment of cancer. 
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6.3 Future directions 
 Extensive analysis by others and myself has demonstrated an important role for 
both the Notch and VEGF pathways in physiological and pathological vascular 
formation.  These pathways have also been shown to interact in a number of models, 
which has been corroborated in this dissertation in the remodeling of the yolk sac 
vasculature.  However, there is much that remains unknown about this interaction and 
how it acts to regulate these processes.  Although an extensive analysis of the Notch and 
Z/EG-Pgf models revealed significant morphological and molecular anomalies, further 
examination of the models is needed to refine the proposed model.  
 Specifically, the precise role of PlGF and its interaction with VEGF in the early 
embryo remains unknown.  Further examination of its activity in both the Z/EG-Pgf and 
Notch models would add greatly to the current knowledge.  Additionally, in respect to the 
in vitro Notch model, modifications to the system to better replicate in vivo results would 
be beneficial and would allow for additional type of experiments to be performed. A 
number of other, specific, experiments remain which would enhance the current 
knowledge of Notch and VEGF signaling and their role in the formation of the vascular 
system.  These experiments are outlined in the following pages. 
6.3.1 Notch signaling in vascular remodeling 
 Although there has been extensive analysis of the morphological defects resulting 
from mutations of the Notch signaling pathway and our lab has demonstrated altered 
patterns of gene expression in a number of genes in the gain-of-function Notch model, 
questions still remain.  Additional experiments could expand on the exact mechanism of 
 133 
vascular remodeling and the role of Notch in this process.  Defects in the formation of the 
vasculature, particularly in the remodeling, are seen in both the gain-of-function and loss-
of-function Notch models.  Live imaging of the yolk sac in both Notch models used in 
this study would help to elaborate the behavior of the endothelial cells in the remodeling 
process. 
 Additionally, in this dissertation I initially examined gene expression via 
microarray and subsequently confirmed misexpression of only a subset of genes via RT-
PCR.  Numerous other genes were also upregulated and downregulated in these models, 
opening the door to a plethora of genes regulated directly or indirectly by Notch 
signaling, particularly secreted factors.  The use of conditional transgenics and knockouts 
of these factors in the endothelia will be required to determine the roles of these factors in 
vivo in the remodeling process. Gene expression of the VEGF family members Vegfc and 
Pgf was however observed and confirmed in both whole yolk sac and isolated endothelial 
cells.  Although Vegf and Kdr expression was not increased, it would be important to 
examine whether or not VEGF signaling through KDR was increased due to the increase 
in Pgf and/or Vegfc.  Protein from EC-N1ICD yolk sac tissues could be analyzed via 
Western blot with antibodies to the phosphorylated form of KDR and compared to wild 
type tissues.  These experiments could show an increase in the angiogenic signal through 
KDR resulting from the activation of the Notch pathway.  This would be interesting, as it 
would further confirm the role of Notch in the modulation of the VEGF pathway.  
6.3.2 Transgenic ES cell model 
 Our lab successfully generated an inducible ES cell line to examine Notch 
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signaling in vitro and optimized a protocol to differentiate ES cells to an endothelial cell 
type via ES cell aggregation. However, molecular analysis of the collagen-plated cells 
showed only limited similarity to in vivo models. Modifications to the system could help 
utilize the in vitro model as a companion to the in vivo Notch models.  In vivo the 
endothelial cells of the developing vasculature of the yolk sac neighbor primitive 
endodermal cells from which signals arise and can influence the endothelial cells.  These 
cells are also acted upon by the shear stress of blood flow, which is essential for vascular 
remodeling (Lucitti et al. 2007).  If a protocol was established in which the plated EBs 
were co-cultured with an extraembryonic endoderm (XEN) cell line (Kunath et al. 2005) 
or with supplemented growth factors to better replicate those found in vivo and/or the 
flow-induced shear stress was replicated, the gene expression may better mimic the in 
vivo results.  Furthermore, the growth factors present in the culture can influence the 
morphology of the vascular plexus and the expression patterns (Jakobsson et al. 2007).  
Although VEGF and FGF have been established as important growth factors for the 
differentiation of endothelial cells in culture, adjustments could improve the model 
system. Alternatively, this model of ES cell differentiation requires the formation of EBs, 
which consist of many different lineages. Purification of the differentiated ECs with an 
endothelial cell specific antibody, like PECAM1, via flow cytometry would also allow 
for a cleaner analysis of the gene expression differences within the EC lineage. 
 This study also utilized a collagen embedding protocol to study sprouting 
angiogenesis.  Previous work by others following a protocol similar to ours saw an 
increase in sprouting with the addition of a gamma-secretase inhibitor visualized by 
immunofluorescence after treatment with a CD31 antibody (Jakobsson et al. 2010).  
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However, we saw no difference in the formation of the sprouts with either the activation 
or the abrogation of Notch signaling.  The only differences between the two protocols 
were in the concentration of the gamma-secretase inhibitor and the length of time the 
embedded EBs were grown and visualized (6 days in our protocol compared to 10 days).  
Simple modifications to the system such as these could lead to the expected results and 
further elucidate the role of Notch signaling in sprouting angiogenesis. 
6.3.3 Placental growth factor activity in vivo 
 In this dissertation I successfully designed and generated a conditional transgenic 
mouse model to overexpress PlGF in the endothelia.  Although resulting embryos were 
characterized and extensive morphological and molecular analyses were performed, there 
is still much to understand.  Additional experiments to further characterize this model 
could expand on the role of PlGF in vascular remodeling.  Gene expression analysis was 
performed via real time-PCR on a subset of genes known to be critical for vascular 
development.  Additionally, a microarray could be done to compare with genes seen in 
the EC-N1ICD microarray data set to identify novel genes involved in this process. While 
data indicated an increase in Notch family members, the exact role of PlGF in this 
regulation remains unknown.  Since PlGF likely transmits the angiogenic signals through 
FLT1 or KDR (Park et al. 1994; Carmeliet et al. 2001), yolk sac protein could be 
analyzed via Western blot with antibodies to the phosphorylated forms of FLT1 and KDR 
and compared to wild type yolk sac. Because PlGF is a secreted factor, and the yolk sac 
consists of more than one cell type, gene expression could be analyzed in isolated 
endothelial cells as was done in the EC-N1ICD studies. Taken together, data from these 
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studies could provide additional evidence as to the factors involved in the complex 
hierarchy of signals in the regulation of vascular development. 
 I also characterized placental defects with respect to both the formation of the 
embryo-derived vasculature and the gene expression in the trophoblast lineages.  The 
morphological defects could be further analyzed via histological and 
immunofluorescence assays and a molecular analysis of the placenta via real-time PCR 
could be done to examine what other factors are involved in this process. 
6.3.4 Future transgenic studies  
 As a result of activation of Notch signaling a number of secreted factors exhibited 
increased gene expression.  This being an important component of our proposed model of 
the role of Notch pathway in vascular remodeling, I chose to further examine this 
regulation by designing a conditional transgenic system to overexpress PlGF.  Since little 
was known about PlGF activity in the early embryo it seemed an ideal choice.  
Additionally, conditional transgenic mice could be made to examine any of the other 
secreted molecules.  Targeted deletions of members of the TGF-β pathway result in the 
improper formation of the vasculature, indicating the importance for TGF-β signaling 
during vascular development (Goumans and Mummery 2000).  VEGFC is required for 
the formation of the lymphatic system and there are data supporting activities in 
angiogenesis, however there are no vascular defects in Vegfc null mice (Karkkainen et al. 
2004; Cao et al. 1998).  Neither TGFβ2 nor VEGFC activity has been examined in detail 
in the extraembryonic tissue of the early embryo, though the expression of Vegfc and 
Tgfβ2 within the yolk sac suggests a potential function in this tissue.  The development 
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and study of conditional transgenes to overexpress these factors in the endothelia of the 
early embryo could expand on their function in vascular remodeling and their relation to 
the Notch pathway. 
6.4 Concluding remarks 
 In this dissertation I demonstrated the role for Notch and VEGF activity in the 
remodeling of the vasculature and the regulation of key genes in the embryonic 
vasculature.  These pathways must be tightly regulated as unregulated expression leads to 
vascular deformity and embryonic lethality.  The morphological and molecular data 
indicate a mechanism for Notch regulation, in concert with VEGF signaling, of vessel 
calibre in early vasculature remodeling, likely through the regulation of intussusceptive 
angiogenesis. Further work on the in vivo models will help to further define the 
relationship between the transcriptional networks regulated by Notch to direct endothelial 
differentiation, and the role of these Notch downstream targets in endothelial migration 
and vascular remodeling. The understanding of these interactions and processes will aid 
in the development of treatments affecting vascular differentiation, including heart 
disease and tumor progression. 
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Gene 
Symbol
Gene Name Probe Fold 
change
Ankrd1 ankyrin repeat domain 1 1420991_at 11.89
Upk3a uroplakin 3A 1449104_at 11.23
Myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha 1448826_at 6.04
Cyp2f2
cytochrome P450, family 2, subfamily f, 
polypeptide 2
1448792_a_at 6.01
Rgs5 regulator of G-protein signaling 5 1420941_at 5.97
Ntn4 netrin 4 1439794_at 5.76
Actc1 actin, alpha, cardiac 1415927_at 5.48
Heyl
hairy/enhancer-of-split related with YRPW motif-
like
1438886_at 5.45
Ifi202b interferon activated gene 202B 1452349_x_at 5.38
Ly86 lymphocyte antigen 86 1422903_at 5.23
Spib Spi-B transcription factor (Spi-1/PU.1 related) 1460407_at 5.04
Irx5 Iroquois related homeobox 5 (Drosophila) 1421072_at 5.03
Col8a1 collagen, type VIII, alpha 1 1455627_at 4.88
Fabp7 fatty acid binding protein 7, brain 1450779_at 4.8
Tbx18 T-box18 1429974_at 4.77
Ttn titin 1427445_a_at 4.68
Rrad Ras-related associated with diabetes 1422562_at 4.61
Gbp2 guanylate nucleotide binding protein 2 1435906_x_at 4.48
C1qb
complement component 1, q subcomponent, beta 
polypeptide
1417063_at 4.42
Gbp4 guanylate nucleotide binding protein 3 1418392_a_at 4.36
Pscdbp
pleckstrin homology, Sec7 and coiled-coil domains, 
binding protein
1451206_s_at 4.36
Oasl2 2'-5' oligoadenylate synthetase-like 2 1453196_a_at 4.33
Tgtp T-cell specific GTPase 1449009_at 4.32
Myl7 myosin, light polypeptide 7, regulatory 1449071_at 4.23
Microarray data of EC-N1ICD Yolk Sacs*
Appendix I
AI-1 Top 50 Upregulated genes
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Ifit1
interferon-induced protein with tetratricopeptide     
repeats 1
1450783_at 4.16
Crlf1 cytokine receptor-like factor 1 1418476_at 4.04
Vldlr very low density lipoprotein receptor 1434465_x_at 4.04
Nrarp Notch-regulated ankyrin repeat protein 1417985_at 4.02
Olfm3 olfactomedin 3 1425898_x_at 3.97
Cdh2 cadherin 2 1418815_at 3.88
Hoxa9 homeo box A9 1455626_at 3.87
Igfbp3 insulin-like growth factor binding protein 3 1423062_at 3.85
Amacr alpha-methylacyl-CoA racemase 1417208_at 3.82
Ifih1 interferon induced with helicase C domain 1 1426276_at 3.82
Sox11 SRY-box containing gene 11 1436790_a_at 3.8
Jun Jun oncogene 1417409_at 3.79
Foxq1 forkhead box Q1 1438558_x_at 3.78
Emr4
EGF-like module containing, mucin-like, hormone 
receptor-like sequence 4
1451563_at 3.73
Crabp1 cellular retinoic acid binding protein I 1448326_a_at 3.72
Vegfc vascular endothelial growth factor C 1439766_x_at 3.65
Pilra paired immunoglobin-like type 2 receptor alpha 1427327_at 3.61
Sh3bgr SH3-binding domain glutamic acid-rich protein 1422644_at 3.6
Ubap2 ubiquitin-associated protein 2 1442375_at 3.59
Cbx7 chromobox homolog 7 1420039_s_at 3.59
Magel2 melanoma antigen, family L, 2 1417217_at 3.55
Ptk2 PTK2 protein tyrosine kinase 2 1440082_at 3.54
Hey1 hairy/enhancer-of-split related with YRPW motif 1 1415999_at 3.53
Tbx4 T-box 4 1456033_at 3.44
Esm1 endothelial cell-specific molecule 1 1449280_at 3.41
Gucy2c guanylate cyclase 2c 1436370_at 3.38
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Gene 
Symbol
Gene Name Probe Fold 
change
Cxcl7 chemokine (C-X-C motif) ligand 7 1418480_at -7.69
Calml4 calmodulin-like 4 1424713_at -7.34
Mpo myeloperoxidase 1415960_at -5.48
Csf2rb1
colony stimulating factor 2 receptor, beta 1, low-
affinity (granulocyte-macrophage)
1421326_at -5.18
Eif2s1
eukaryotic translation initiation factor 2, subunit 1 
alpha
1420491_at -5.18
Gypa glycophorin A 1423016_a_at -4.48
Cxcl4 chemokine (C-X-C motif) ligand 4 1448995_at -4.22
Rgs18 regulator of G-protein signaling 18 1420398_at -4.07
Prap1 proline-rich acidic protein 1 1455996_x_at -3.97
Fbp2 fructose bisphosphatase 2 1449088_at -3.88
Atp10d ATPase, Class V, type 10D 1436544_at -3.73
Oit3 oncoprotein induced transcript 3 1425125_at -3.7
Abcb1a
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1A
1419758_at -3.69
Map3k7 mitogen-activated protein kinase kinase kinase 7 1433270_at -3.55
Ppargc1a
peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha
1434100_x_at -3.5
Ncf4 neutrophil cytosolic factor 4 1418465_at -3.4
Dscr6 Down syndrome critical region homolog 6 (human) 1420459_at -3.32
Plxnc1 plexin C1 1450905_at -3.3
Hif3a hypoxia inducible factor 3, alpha subunit 1425429_s_at -3.28
Haao 3-hydroxyanthranilate 3,4-dioxygenase 1432492_a_at -3.27
Cited4
Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 4
1425400_a_at -3.19
Eif5b eukaryotic translation initiation factor 5B 1435592_at -3.13
Vat1
vesicle amine transport protein 1 homolog (T 
californica)
1423726_at -3.11
Taok1 TAO kinase 1 1459770_at -3.09
Fcgr3 Fc receptor, IgG, low affinity IIb 1448620_at -3.09
Pi4k2b phophatidylinositol 4-kinase type 2 beta 1420411_a_at -3.02
Pde10a phosphodiesterase 10A 1439618_at -2.99
Cyp2a4
cytochrome P450, family 2, subfamily a, 
polypeptide 4
1422230_s_at -2.99
Spred2
sprouty protein with EVH-1 domain 2, related 
sequence
1436892_at -2.97
Tfrc transferrin receptor 1452661_at -2.95
153
Xdh xanthine dehydrogenase 1451006_at -2.94
Agtrl1 apelin receptor 1438651_a_at -2.93
Asb17 ankyrin repeat and SOCS box-containing protein 17 1420468_at -2.92
Myo7b myosin VIIb 1420426_at -2.92
Hba-a1 hemoglobin alpha, adult chain 1 1417714_x_at -2.83
Itga3 integrin alpha 3 1421997_s_at -2.82
Slc6a19
solute carrier family 6 (neurotransmitter 
transporter), member 19
1428595_at -2.77
Lgals3 lectin, galactose binding, soluble 3 1426808_at -2.77
Timm50
translocase of inner mitochondrial membrane 50 
homolog
1441819_x_at -2.75
Casq2 calsequestrin 2 1454395_at -2.69
Foxh1 forkhead box H1 1422213_s_at -2.65
Ywhaz
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide
1416103_at -2.64
Wdtc1 WD and tetratricopeptide repeats 1 1434560_at -2.64
Pof1b premature ovarian failure 1B 1427492_at -2.64
Ell2 elongation factor RNA polymerase II 2 1450744_at -2.63
Cd36 CD36 antigen 1450884_at -2.6
Epb4.2 erythrocyte protein band 4.2 1417337_at -2.57
Sftpd surfactant associated protein D 1420378_at -2.56
Nudt4
nudix (nucleoside diphosphate linked moiety X)-
type motif 4
1449107_at -2.55
Mscp solute carrier family 25, member 37 1417750_a_at -2.55
* Microarray data was deposited to the Gene Expression Omnibus (GSE22418)
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Gene 
Symbol
Gene Name Probe Fold 
change
Rps9 ribosomal protein S9 1434624_x_at 28.01
Ifi202b interferon activated gene 202B 1457666_s_at 9.68
Kcnj11
potassium inwardly rectifying channel, subfamily 
J, member 11
1455417_at 8.12
Ly86 lymphocyte antigen 86 1422903_at 8.04
Kcne3
potassium voltage-gated channel, Isk-related 
subfamily, gene 3
1418499_a_at 6.14
Dkk1 dickkopf homolog 1 (Xenopus laevis) 1420360_at 6.03
Plcxd1
phosphatidylinositol-specific phospholipase C, X 
domain containing 1
1437842_at 5.96
Ppp1r3c
protein phosphatase 1, regulatory (inhibitor) 
subunit 3C
1433691_at 5.94
Cx3cr1 chemokine (C-X3-C) receptor 1 1450020_at 5.63
Ndrg1 N-myc downstream regulated gene 1 1423413_at 5.33
Spon2 spondin 2, extracellular matrix protein 1417860_a_at 4.96
Fbp1 fructose bisphosphatase 1 1448470_at 4.77
Slc6a20
solute carrier family 6 (neurotransmitter 
transporter), member 20B
1436667_at 4.74
Vtn vitronectin 1420484_a_at 4.73
Adamtsl4 ADAMTS-like 4 1451932_a_at 4.63
Olfm3 olfactomedin 3 1425898_x_at 4.62
Gm1381 family with sequence similarity 47, member E 1455383_at 4.55
Fbxo39 F-box protein 39 1443698_at 4.51
Cd52 CD52 antigen 1460218_at 4.44
Igsf4c cell adhesion molecule 4 1426263_at 4.38
Cfc1 cripto, FRL-1, cryptic family 1 1421524_at 4.37
Ctss cathepsin S 1448591_at 4.28
Lrrc39 leucine rich repeat containing 39 1453592_at 4.26
Ch25h cholesterol 25-hydroxylase 1449227_at 4.20
Lamb3 laminin, beta 3 1417812_a_at 4.19
Kcnj8
potassium inwardly-rectifying channel, 
subfamily J, member 8
1418142_at 4.14
Ddit4 DNA-damage-inducible transcript 4 1428306_at 4.10
Igfbp3 insulin-like growth factor binding protein 3 1423062_at 4.05
Microarray data of EC-Rbpj-KO Yolk Sacs*
Appendix II
AII-1 Top 50 Upregulated genes
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Lst1 leukocyte specific transcript 1 1425548_a_at 4.01
Hspa1a heat shock protein 1A 1452388_at 3.95
Leap2 liver-expressed antimicrobial peptide 2 1427480_at 3.94
Adm adrenomedullin 1447839_x_at 3.91
Ces1 carboxylesterase 1G 1449486_at 3.83
Gadd45b
growth arrest and DNA-damage-inducible 45 
beta
1450971_at 3.81
Lyzs lysozyme 2 1439426_x_at 3.81
Cd200 CD200 antigen 1448788_at 3.72
Ndrl N-myc downstream regulated gene 1 1420760_s_at 3.71
Amdhd1 amidohydrolase domain containing 1 1427370_at 3.69
Gys2 glycogen synthase 2 1424815_at 3.68
B3galt6
UDP-Gal:betaGal beta 1,3-galactosyltransferase, 
polypeptide 6
1435252_at 3.68
D17892 expressed sequence D17892 1447986_at 3.67
Slc22a3
solute carrier family 22 (organic cation 
transporter), member 3
1420444_at 3.66
Rprm
reprimo, TP53 dependent G2 arrest mediator 
candidate
1422552_at 3.63
Ms4a6b
membrane-spanning 4-domains, subfamily A, 
member 6B
1418826_at 3.60
H2-Q8 histocompatibility 2, Q region locus 8 1430802_at 3.54
Esm1 endothelial cell-specific molecule 1 1449280_at 3.51
Gja5 gap junction protein, alpha 5 1429101_at 3.48
Blnk B-cell linker 1451780_at 3.47
Vcam1 vascular cell adhesion molecule 1 1448162_at 3.45
Lzp-s lysozyme 1 1436996_x_at 3.45
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Gene 
Symbol
Gene Name Probe Fold 
change
Prlpe prolactin family 7, subfamily a, member 1 1449529_s_at -32.36
Ctsj cathepsin J 1416413_at -17.92
Plf prolactin family 2, subfamily c, member 2 1427760_s_at -16.32
Mtmr7 myotubularin related protein 7 1447831_s_at -15.36
Csh1 prolactin family 3, subfamily d, member 1 1439002_s_at -11.68
Abcb1b
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1B
1418872_at -10.68
Plekha6 pleckstrin homology domain containing, family A 1427149_at -10.3
Dusp4 dual specificity phosphatase 4 1428834_at -9.6
Csh2 prolactin family 3, subfamily b, member 1 1415835_at -9.27
Slc39a8 solute carrier family 39 (metal ion transporter), 1448482_at -8.43
Prlpa prolactin family 4, subfamily a, member 1 1448572_at -8.02
Prlpk prolactin family 2, subfamily b, member 1 1426730_a_at -7.02
Myo1b myosin IB 1447364_x_at -6.7
Mfap3l microfibrillar-associated protein 3-like 1428804_at -6.68
Pi4k2b phosphatidylinositol 4-kinase type 2 beta 1420411_a_at -5.86
Fgl1 fibrinogen-like protein 1 1424599_at -5.6
Eomes eomesodermin homolog (Xenopus laevis) 1435172_at -5.48
Bach2 BTB and CNC homology 2 1437667_a_at -4.95
Dusp6 dual specificity phosphatase 6 1415834_at -4.83
Ceacam1 carcinoembryonic antigen-related cell adhesion 1425538_x_at -4.78
Tmem27 transmembrane protein 27 1435064_a_at -4.69
Hdc histidine decarboxylase 1454713_s_at -4.68
Abca1 ATP-binding cassette, sub-family A (ABC1), 1421840_at -4.59
Hsf2bp heat shock transcription factor 2 binding protein 1428640_at -4.56
Kndc1
kinase non-catalytic C-lobe domain (KIND) 
containing 1
1428599_at -4.43
Birc1a NLR family, apoptosis inhibitory protein 1 1425298_a_at -4.32
Fcgr3 Fc receptor, IgG, low affinity III 1448620_at -4.26
Spred2 sprouty-related, EVH1 domain containing 2 1434403_at -4.26
Cd59a CD59a antigen 1418710_at -4.09
Rgl1
ral guanine nucleotide dissociation stimulator,          
-like 1
1418535_at -4.04
Coro2a coronin, actin binding protein 2A 1436199_at -3.92
Gm440 RUN domain containing 3B 1434456_at -3.86
Bat2d proline-rich coiled-coil 2C 1429432_at -3.85
Tfrc transferrin receptor 1422967_a_at -3.85
Tulp2 tubby-like protein 2 1417276_at -3.84
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Abcb1a
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1A
1419758_at -3.83
B4galt6
UDP-Gal:betaGlcNAc beta 1,4-
galactosyltransferase, polypeptide 6
1450913_at -3.79
Dnahc8 dynein, axonemal, heavy chain 8 1424936_a_at -3.66
Frmd4b FERM domain containing 4B 1426594_at -3.64
Slc23a1
solute carrier family 23 (nucleobase transporters), 
member 1
1450404_at -3.63
Tipin timeless interacting protein 1459720_x_at -3.62
Tle6
transducin-like enhancer of split 6, homolog of 
Drosophila E(spl)
1448727_at -3.51
Prlpm prolactin family 2, subfamily a, member 1 1449032_at -3.49
Skil SKI-like 1452214_at -3.37
Vwf Von Willebrand factor homolog 1435386_at -3.35
Tmem54 transmembrane protein 54 1417895_a_at -3.35
Myo6 myosin VI 1421120_at -3.35
Sgk serum/glucocorticoid regulated kinase 1 1416041_at -3.29
Rnf125 ring finger protein 125 1429399_at -3.29
Spsb4
splA/ryanodine receptor domain and SOCS box 
containing 4
1451419_at -3.28
* Microarray data was deposited to the Gene Expression Omnibus (GSE22418)
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Gene 
Symbol
Gene Name Probe Fold 
change
Hes5 hairy and enhancer of split 5 (Drosophila) 1456010_x_at 22.84
Pik3cd
phosphatidylinositol 3-kinase catalytic delta 
polypeptide
1453281_at 5.88
Trh thyrotropin releasing hormone 1418756_at 5.82
Fabp7 fatty acid binding protein 7, brain 1450779_at 5.80
Endod1 endonuclease domain containing 1 1426541_a_at 5.29
Nrarp Notch-regulated ankyrin repeat protein 1417985_at 5.09
Spib Spi-B transcription factor (Spi-1/PU.1 related) 1460407_at 4.94
Rhobtb3 Rho-related BTB domain containing 3 1447869_x_at 4.51
D7Ertd715e
DNA segment, Chr 7, ERATO Doi 715, 
expressed
1436964_at 4.42
Cenpe centromere protein E 1439040_at 4.16
Lefty2 Left-right determination factor 2 1436227_at 3.97
Rerg RAS-like, estrogen-regulated, growth-inhibitor 1451236_at 3.89
Has3 hyaluronan synthase 3 1420589_at 3.76
Ramp2 receptor (calcitonin) activity modifying protein 2 1418188_a_at 3.75
Id4 inhibitor of DNA binding 4 1423259_at 3.74
Pax6 paired box gene 6 1452526_a_at 3.58
F5 coagulation factor V 1449269_at 3.58
Msi2h Musashi homolog 2 (Drosophila) 1435521_at 3.50
Kalrn kalirin, RhoGEF kinase 1429796_at 3.40
Nebl nebulette 1438452_at 3.25
Ptges prostaglandin E synthase 1439747_at 3.23
Prpf38b
PRP38 pre-mRNA processing factor 38 (yeast) 
domain containing B
1456506_at 3.14
Fjx1 four jointed box 1 (Drosophila) 1422733_at 3.12
Spsb4
splA/ryanodine receptor domain and SOCS box 
containing 4
1451418_a_at 3.08
Zfhx1b zinc finger homeobox 1b 1422748_at 3.06
Prtg protogenin homolog (Gallus gallus) 1438333_at 3.04
Smc2l1
SMC2 structural maintenance of chromosomes 2-
like 1 (yeast)
1429658_a_at 3.01
Falz fetal Alzheimer antigen 1427311_at 2.95
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Trpm1
transient receptor potential cation channel, 
subfamily M, member 1
1437445_at 2.88
Col13a1 procollagen, type XIII, alpha 1 1422866_at 2.88
Prickle1 prickle like 1 (Drosophila) 1452249_at 2.87
Depdc6 DEP domain containing 6 1419963_at 2.86
Paqr8
progestin and adipoQ receptor family member 
VIII
1444468_at 2.86
Apobec2 apolipoprotein B editing complex 2 1417889_at 2.81
Dnajb14 DnaJ (Hsp40) homolog, subfamily B, member 14 1430561_at 2.79
Tmc7 transmembrane channel-like gene family 7 1456981_at 2.75
Cidea cell death-inducing DNA fragmentation factor, 1417956_at 2.73
Scgb3a1 secretoglobin, family 3A, member 1 1419699_at 2.71
Cpd carboxypeptidase D 1418018_at 2.68
Wfdc2 WAP four-disulfide core domain 2 1424351_at 2.68
Ddx6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 1424598_at 2.65
Spsb1
splA/ryanodine receptor domain and SOCS box 
containing 1
1449752_at 2.65
Fut9 fucosyltransferase 9 1457409_at 2.63
Rian RNA imprinted and accumulated in nucleus 1452899_at 2.60
Stk25 serine/threonine kinase 25 (yeast) 1416770_at 2.60
Alcam activated leukocyte cell adhesion molecule 1426301_at 2.59
Atp6v1h
ATPase, H+ transporting, lysosomal V1 subunit 
H
1457639_at 2.57
Ttyh1 tweety homolog 1 (Drosophila) 1422694_at 2.53
Akap9 A kinase (PRKA) anchor protein (yotiao) 9 1455151_at 2.53
Zbtb16 zinc finger and BTB domain containing 16 1439163_at 2.52
Mia3 melanoma inhibitory activity 3 1459984_at 2.52
Ank3 ankyrin 3, epithelial 1452124_at 2.51
Bub3
budding uninhibited by benzimidazoles 3 
homolog (S. cerevisiae)
1459104_at 2.50
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Gene 
Symbol
Gene Name Probe Fold 
change
Insm1 insulinoma-associated 1 1421399_at -4.61
Dll1 delta-like 1 (Drosophila) 1419204_at -3.96
Lef1 lymphoid enhancer binding factor 1 1421299_a_at -3.93
Lbxcor1
ladybird homeobox 1 homolog (Drosophila) 
corepressor 1
1437880_at -3.88
Ung2 uracil DNA glycosylase 2 1455114_at -3.87
Bnip3 BCL2/adenovirus E1B interacting protein 1, NIP3 1422470_at -3.49
Adm adrenomedullin 1447839_x_at -3.38
Ascl2 achaete-scute complex homolog-like 2 (Drosophila) 1432018_at -3.31
En2 engrailed 2 1418868_at -3.14
Cbfa2t1h CBFA2T1 identified gene homolog (human) 1444615_x_at -3.07
Mlana melan-A 1430635_at -3.01
Cd80 CD80 antigen 1457952_at -2.98
Pou3f1 POU domain, class 3, transcription factor 1 1422068_at -2.94
Neurod1 neurogenic differentiation 1 1426413_at -2.88
Bnipl
BCL2/adenovirus E1B 19kD interacting protein 
like
1420683_at -2.6
Ssty1 spermiogenesis specific transcript on the Y 1 1449467_at -2.54
Foxd3 forkhead box D3 1422210_at -2.51
Samd9l sterile alpha motif domain containing 9-like 1460603_at -2.49
Cyp2s1
cytochrome P450, family 2, subfamily s, 
polypeptide 1
1428283_at -2.49
Mucdhl mucin and cadherin like 1426014_a_at -2.49
Zfp526 zinc finger protein 526 1443585_at -2.48
Trp53 transformation related protein 53 1457623_x_at -2.48
Ptk9l protein tyrosine kinase 9-like (A6-related protein) 1431292_a_at -2.46
Prmt8 protein arginine N-methyltransferase 8 1435204_at -2.45
Plb1 phospholipase B1 1431535_at -2.45
Sorbs2 sorbin and SH3 domain containing 2 1446744_at -2.43
Gpha2 glycoprotein hormone alpha 2 1421497_at -2.43
Grhl2 grainyhead-like 2 (Drosophila) 1429086_at -2.41
Zcchc6 zinc finger, CCHC domain containing 6 1430573_s_at -2.39
Aoc3 amine oxidase, copper containing 3 1449396_at -2.38
Ndrg1 N-myc downstream regulated gene 1 1450976_at -2.37
Aqp8 aquaporin 8 1417828_at -2.36
Plcxd1
phosphatidylinositol-specific phospholipase C, X 
domain containing 1
1437842_at -2.36
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Lrp2bp Lrp2 binding protein 1436538_at -2.36
Fkbp4 FK506 binding protein 4 1458729_at -2.36
Slc5a11
solute carrier family 5 (sodium/glucose 
cotransporter), member 11
1428752_at -2.34
Thap4 THAP domain containing 4 1443311_at -2.33
Hat1 histone aminotransferase 1 1420237_at -2.31
Agxt2l1 alanine-glyoxylate aminotransferase 2-like 1 1452975_at -2.31
Il1r2 interleukin 1 receptor, type II 1419532_at -2.31
Tmem25 transmembrane protein 25 1452962_at -2.3
Camk2b
calcium/calmodulin-dependent protein kinase II, 
beta
1455869_at -2.29
Npc1l1 NPC1-like 1 1438514_at -2.28
Ebna1bp EBNA1 binding protein 2 1437512_x_at -2.28
Xkr4
X Kell blood group precursor related family 
member 4
1456572_x_at -2.27
Bcl11a B-cell CLL/lymphoma 11A (zinc finger protein) 1419406_a_at -2.25
Sbk1 SH3-binding kinase 1 1423978_at -2.25
D7Wsu1 DNA segment, Chr 7, Wayne State University 128, 1456217_at -2.24
Rgs3 regulator of G-protein signaling 3 1454026_a_at -2.24
Hes6 hairy and enhancer of split 6 (Drosophila) 1452021_a_at -2.24
162
Gene 
Symbol
Gene Name Probe Fold 
change
Afp alpha fetoprotein 1416645_a_at 393.11
Cdh11 cadherin 11 1450757_at 233.59
Nr2f1 nuclear receptor subfamily 2, group F, member 1 1418157_at 168.81
Ttr transthyretin 1454608_x_at 167.13
Hand2
heart and neural crest derivatives expressed 
transcript 2
1436041_at 165
Hbb-y hemoglobin Y, beta-like embryonic chain 1436823_x_at 141.59
Col3a1 collagen, type III, alpha 1 1427884_at 141.24
Rgs5 regulator of G-protein signaling 5 1420941_at 136.24
Hbb-bh1 hemoglobin Z, beta-like embryonic chain 1437990_x_at 112.41
Asb4 ankyrin repeat and SOCS box-containing 4 1433919_at 108.43
Dkk1 dickkopf homolog 1 (Xenopus laevis) 1420360_at 107.91
Dnm3os dynamin 3, opposite strand 1452382_at 99.89
Igfbp5 insulin-like growth factor binding protein 5 1452114_s_at 89.57
Tbx2 T-box 2 1422545_at 84.14
Hba-a1 hemoglobin alpha, adult chain 1 1452757_s_at 80.61
Ptn pleiotrophin 1416211_a_at 79.87
Lum lumican 1423607_at 76.96
Nrp1 neuropilin 1 1448943_at 74.97
Frzb frizzled-related protein 1448424_at 73.44
Tcf21 transcription factor 21 1417447_at 70.8
Isl1 ISL1 transcription factor, LIM/homeodomain 1450723_at 65.59
Prrx1 paired related homeobox 1 1425528_at 64.87
Igf2 insulin-like growth factor 2 1415931_at 63.34
Rbms3
RNA binding motif, single stranded interacting 
protein
1436938_at 60.41
Fli1 Friend leukemia integration 1 1433512_at 57.36
Rkhd3 mex3 homolog B (C. elegans) 1437152_at 56.4
Agtrl1 apelin receptor 1438651_a_at 54.44
Postn periostin, osteoblast specific factor 1423606_at 54.16
Emcn endomucin 1425582_a_at 53.35
Pdgfra
platelet derived growth factor receptor, alpha 
polypeptide
1421917_at 52.75
Flrt2 fibronectin leucine rich transmembrane protein 2 1455096_at 52.53
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Tshz2 teashirt zinc finger family member 2 1435385_at 51.34
Capn6 calpain 6 1421952_at 49.86
Adam12
a disintegrin and metallopeptidase domain 12 
(meltrin alpha)
1421171_at 47.36
Ptprd protein tyrosine phosphatase, receptor type, D 1429052_at 46.8
Col9a1 collagen, type IX, alpha 1 1428571_at 46.27
Nr2f2 nuclear receptor subfamily 2, group F, member 2 1416158_at 45.62
Edg3 sphingosine-1-phosphate receptor 3 1438658_a_at 44.9
Islr
immunoglobulin superfamily containing leucine-
rich repeat
1418450_at 44.63
Dlk1 delta-like 1 homolog (Drosophila) 1449939_s_at 44.17
Fbn2 fibrillin 2 1422831_at 43.81
Pcdh7 protocadherin 7 1449249_at 43.58
Fat4 FAT tumor suppressor homolog 4 (Drosophila) 1460574_at 43.29
Sema6d
sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6D
1453055_at 42.75
Plagl1 pleiomorphic adenoma gene-like 1 1426208_x_at 42.08
Tgfbi transforming growth factor, beta induced 1448123_s_at 41.94
Tshz1 teashirt zinc finger family member 1 1427233_at 40.84
Unc5c unc-5 homolog C (C. elegans) 1419592_at 39.76
Hoxd10 homeobox D10 1418606_at 38.15
Ctla2a Ctla2a 1448471_a_at 37.86
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Gene 
Symbol
Gene Name Probe Fold 
change
Tdgf1 teratocarcinoma-derived growth factor 1 1450989_at -36.66
Sycp3 synaptonemal complex protein 3 1449534_at -35.26
Aass aminoadipate-semialdehyde synthase 1423523_at -33.58
Fgf4 fibroblast growth factor 4 1420085_at -29.8
Gad1 glutamic acid decarboxylase 1 1416561_at -26.29
Eras ES cell-expressed Ras 1456511_x_at -25.74
Klf9 Kruppel-like factor 9 1436763_a_at -23.04
Neurod1 neurogenic differentiation 1 1426412_at -21.88
Ndg2
coiled-coil-helix-coiled-coil-helix domain 
containing 10
1433720_s_at -20.64
Dpys dihydropyrimidinase 1436291_a_at -19.81
Lefty1 left right determination factor 1 1417638_at -19.55
Pou5f1 POU domain, class 5, transcription factor 1 1417945_at -19.22
Dnahc8 dynein, axonemal, heavy chain 8 1424936_a_at -19.14
Dmrt1 doublesex and mab-3 related transcription factor 1 1423582_at -19.05
Slc27a2
solute carrier family 27 (fatty acid transporter), 
member 2
1416316_at -18.44
Gm397 zinc finger and SCAN domain containing 4C 1457033_at -17.86
Ddx4 DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 1427242_at -17.64
Clca6 chloride channel calcium activated 6 1443256_at -17.48
Pla2g1b phospholipase A2, group IB, pancreas 1437015_x_at -17.45
Esrrb phospholipase A2, group IB, pancreas 1436926_at -17.35
Mael maelstrom homolog (Drosophila) 1436837_at -16.62
Prmt8 protein arginine N-methyltransferase 8 1435204_at -16.01
Nanog Nanog homeobox 1429388_at -15.93
Atp1a3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 1427481_a_at -15.67
Psma8
proteasome (prosome, macropain) subunit, alpha 
type, 8
1427170_at -15.6
Hck hemopoietic cell kinase 1449455_at -15.21
Fut9 fucosyltransferase 9 1435308_at -15.04
Morc1 microrchidia 1 1419418_a_at -14.79
Prdm14 PR domain containing 14 1444390_at -14.56
Jam2 junction adhesion molecule 2 1431417_at -14.55
Dnmt3l DNA (cytosine-5-)-methyltransferase 3-like 1425035_s_at -14.37
Hook1 hook homolog 1 (Drosophila) 1439173_at -13.58
Nefh neurofilament, heavy polypeptide 1424847_at -13.4
Zfp42 zinc finger protein 42 1418362_at -13.38
Lrrc2 leucine rich repeat containing 2 1453628_s_at -13.2
165
Rex2 reduced expression 2 1438237_at -12.79
Nr0b1 nuclear receptor subfamily 0, group B, member 1 1417760_at -12.7
Pycard PYD and CARD domain containing 1417346_at -12.4
Ina
internexin neuronal intermediate filament protein, 
alpha
1448991_a_at -12.3
Rasd2 RASD family, member 2 1427344_s_at -12.24
Cobl cordon-bleu 1434917_at -12.19
Gbx2 gastrulation brain homeobox 2 1420337_at -12.1
Gng3
guanine nucleotide binding protein (G protein), 
gamma 3
1417428_at -12.02
Tcfcp2l1 transcription factor CP2-like 1 1418091_at -12.02
Lrrc34 leucine rich repeat containing 34 1429366_at -11.98
Fbxo15 F-box protein 15 1427238_at -11.59
Syt9 synaptotagmin IX 1423258_at -11.5
Hsf2bp heat shock transcription factor 2 binding protein 1428640_at -11.33
Dppa2 developmental pluripotency associated 2 1429654_at -11.26
Pipox pipecolic acid oxidase 1449374_at -11.03
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